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Stroke is the 2nd leading cause of death in the UK and worldwide.  150,000 
people have a stroke each year in the UK (ischaemic stroke being the most 
common) and a significant proportion of NHS resources go towards the 
treatment of these individuals (~£2.8 billion).  Twin and family history 
studies have shown that having affected relatives makes you between 30 and 
76% more likely to suffer a stroke, suggesting that there is a genetic 
component to the disease.  So far, no genes have been convincingly 
associated with stroke.  Intermediate traits may be useful tools for 
identifying genetic factors in complex disease.  For stroke, two commonly 
used intermediate traits are carotid intima-media thickness (CIMT) and 
white matter hyperintensities (WMHs), which both show high heritabilities.  
These traits have both been studied widely for associations with many 
candidate gene polymorphisms.   
 
In this thesis I systematically reviewed the literature for all genetic 
association studies of these two traits.  Where particular associations have 
been studied in large numbers I meta-analysed the available data, 
developing novel methods for meta-analysis of genetic association data.  I 
found there was substantial heterogeneity and small study bias in the 
literature and most polymorphisms have still been studied in too small 
numbers to make accurate conclusions.  Apolipoprotein E (APOE) ε is the 
only polymorphism which shows a consistent association with CIMT, even 
when only the largest studies are analysed (MD 8µm (95% CI 6 to 11) 
between E4 and E3, and E3 and E2).  No polymorphism has shown a 
convincing association with WMHs and interestingly APOE appears unlikely 
 
ii 
to be associated with this trait.  This is consistent with previous work that 
shows that APOE is associated with large artery but not small artery stroke.   
 
Taking this hypothesis I attempted to investigate the association of APOE 
comparing patients who have had a large artery stroke with those who have 
had a small artery stroke in the Edinburgh Stroke Study cohort.  However, 
genotyping of this polymorphism failed and I present investigatory analyses 
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This thesis is organised into two main sections (A and B).  Section A comprises 
two large-scale systematic reviews, one of the commonly studied genes for an 
association with carotid intima-media thickness, and the other of the commonly 
studied genes for an association with white matter hyperintensities.  From 
section A I devised a hypothesis to test in the Edinburgh Stroke Study (ESS).  I 
planned to genotype Apolipoprotein E and test for an association between this 
genotype and stroke subtypes. 
 
The results and interpretation of the attempted APOE genotyping study in the 
ESS are presented in section B.  Unfortunately, problems were encountered 
during the genotyping and so I could not carry out the planned association.  
Instead, I present a thorough investigation of the potential causes of genotyping 






In this chapter I introduce the topics that are combined in this thesis.  I first 
define stroke and the various types and subtypes of the disease and discuss 
the public health impact, as well as the risk factors (including heritability).  I 
then introduce the reader to methods used in genetic epidemiology to 
identify genes that influence disease (including the use of intermediate traits) 
and discuss the attempts to identify genes for stroke.  I then present the 
history and methodology for systematic review and meta-analysis.   Finally, I 
outline the aims of this thesis, to use systematic review and meta-analysis 
techniques to identify genetic polymorphisms that influence intermediate 
traits for stroke and then to attempt to test any hypotheses arising from this 
in a cohort of stroke patients collected in Edinburgh. 




A stroke is the sudden death of a portion of the brain due to lack of oxygen. 
This occurs when blood flow to the brain is interrupted, by blockage or 
rupture of an artery.  The most common symptom is numbness and/or 
weakness of the face, arm or leg, normally on one side of the body.  Other 
symptoms include difficulty speaking or swallowing, dizziness, confusion 
and - occasionally - unconsciousness.  The symptoms vary according to the 
area of the brain that is affected and the severity of the symptoms tends to be 
associated with the size of the area of damaged brain tissue. 
 
The World Health Organisation defines a stroke as: 
‚a clinical syndrome characterized by rapidly developing clinical 
symptoms and/or signs of focal, and at times global (applied to patients 
in deep coma and those with subarachnoid haemorrhage), loss of 
cerebral function, with symptoms lasting more than 24h or leading to 
death, with no apparent cause other than that of vascular origin‛ 
[Hatano, 1976] 
 
1.1.2 Main Pathological Types 
Stroke is heterogeneous in its pathology.  There are three main pathological 





Chapter 1 - Introduction 
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1.1.2.1 Ischaemic stroke 
This accounts for 80% of all strokes and is caused by an occluded blood 
vessel. 
1.1.2.2 Primary intracerebral haemorrhage 
This accounts for 10% of all strokes and is caused by rupture of a blood 
vessel with leaking of blood into the brain tissue. 
1.1.2.3 Subarachnoid haemorrhage 
This accounts for 5% of all strokes and is caused by rupture of a blood vessel 
with leaking of blood into the subarachnoid space (within the skull, but 
outside the brain tissue). 
 
 Ischaemic stroke          Haemorrhagic stroke 
 
Figure 1.1 Diagram of ischaemic (occluded artery) and haemorrhagic (ruptured 
artery) stroke.  Illustration by Nucleus Communications, Inc. 
Chapter 1 - Introduction 
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1.1.2.4 Other 
In community / population-based studies around 5% of strokes are of 
undetermined type, because of lack of appropriately timed brain scan or 
autopsy to distinguish reliably between the different pathologies.   
In this thesis I will focus specifically on ischaemic stroke. 
 
1.1.3 Ischaemic Stroke Subtypes 
Ischaemic stroke can also be classified into subtypes.  There are several 
methods of classifying and diagnosing ischaemic stroke subtypes.  Two 
common methods are TOAST (Trial of Org 10172 in Acute Stroke Treatment) 
and OCSP (Oxfordshire Community Stroke Project).  The OCSP uses clinical 
symptoms and signs to assign the patient to one of four categories that 
predicts the site, size and likely pathophysiological mechanism(s) of the 
ischaemic stroke: TACI – total anterior circulation infarct; PACI – partial 
anterior circulation infarct; POCI – posterior circulation infarct; LACI – 
lacunar infarct [Bamford et al., 1991].  The TOAST classification is based 
directly on the presumed pathophysiological mechanisms and so is 
considered more suitable for investigating the relationship of risk factors to 
specific pathophysiological processes leading to ischaemic stroke [Adams, Jr. 
et al., 1993].  One disadvantage is the requirement for a series of (often high-
tech) investigations and so it is not suitable for a quick diagnosis or for use in 
less equipped clinics.  The TOAST classification also leaves quite a large 
proportion of ischaemic strokes unclassified due to incomplete investigations 
or multiple possible mechanisms [Jackson & Sudlow, 2005].  It classifies 
ischaemic stroke into the following four subtypes: 
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1. Large-artery atherosclerosis 
Clinical and imaging findings show evidence of stenosis or occlusion of a 
major brain artery.  There is evidence of atherosclerosis and the infarct on 
imaging is more than 1.5cm in diameter.  This diagnosis is made after 
excluding sources of cardioembolism.  See figure 1.2. 
 
2. Small-vessel occlusion 
Dysfunction of the small perforating arteries results in a typical lacunar 
syndrome.  Imaging shows a deep infarct of no more than 1.5cm.  This 
diagnosis is made after sources of cardioembolism and >50% stenosis of an 
ipsilateral artery are excluded.  See figure 1.3. 
 
 
Figure 1.2 Diagram of large artery ischaemic stroke.  Image taken from 
http://uwmedicine.washington.edu 
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3. Cardioembolism 
Patients in this category have an occluded artery with a presumed cardiac 
source of embolism.  Clinical and imaging findings are similar to that for 
large-artery atherosclerosis, but large artery atherosclerosis sources of 
thrombosis or embolism are excluded. 
 
4. Other 
This includes patients with rare causes of disease such as nonatherosclerotic 
vasculopathies, hypercoagulable states or haematological disorders.  In 
addition to clinical and imaging findings, blood tests or arteriography help to 
diagnose these rarer causes. 
 
1.1.4 Public Health Impact of Stroke 
According to the World Health Organisation, cardiovascular disease 
(ischaemic heart disease and stroke combined) is the leading cause of death 
 
Figure 1.3 Diagram of small-vessel ischaemic stroke.  Image taken from 
http://uwmedicine.washington.edu 
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and burden of disease worldwide, accounting for 32% of the deaths in 
women and 29% of the deaths in men in 2004 [World Health Organisation, 
2004].  On its own stroke is second only to ischaemic heart disease, with 5.7 
million deaths worldwide in 2004.  In the UK stroke is also second only to 
ischaemic heart disease, with around 55,000 deaths caused by stroke in 2006 
[Allender et al., 2008].  In low-income countries stroke drops to the fifth 
leading cause of death [World Health Organisation, 2004].  There were 9 
million new cases of stroke worldwide in 2004 (2 million in Europe).  Clearly, 
stroke is of major public health importance.  As well as accounting for a huge 
number of deaths, stroke is an important cause of disability worldwide, since 
a large number of people who have a stroke live with the disabling effects for 
many years.  In 2004 there were an estimated 30 million stroke survivors in 
the world, 12 million of whom were described as having moderate or severe 
disability [World Health Organisation, 2004].  Stroke is described as the 
single biggest cause of major disability in the UK [Mackay & Mensah, 2004]. 
 
Stroke has a vast health care and economic burden.  With stroke patients 
occupying 20% of all acute hospital beds and 25% of long-term beds, the 
direct cost of stroke to the NHS is thought to be around £2.8 billion per year 
[Department of Health, 2005]. 
 
It is thought that the burden of stroke will increase by the year 2030, mainly 
due to an increasingly ageing population [World Health Organisation, 2004]. 
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1.1.5 Traditional Risk Factors 
Traditional risk factors for stroke include non-modifiable factors such as age, 
sex, and ethnicity; and potentially modifiable factors such as hypertension, 
smoking, diabetes and atrial fibrillation [Goldstein et al., 2006].   
 
Age - Stroke risk has been found to double for each successive decade after 
age 55. 
Sex - There is a higher incidence of stroke in men than in women (age-
adjusted). 
Ethnicity - There is a higher incidence of stroke in African Americans and 
East Asian individuals.  This could possibly be due to the 
higher incidences of hypertension, obesity and diabetes in these 
populations 
Hypertension -  This is probably the most established modifiable risk 
factor for stroke.  Individuals with higher blood pressure 
have increased risk of stroke.  Antihypertensive 
treatment is associated with approximately 40% 
reduction in risk of stroke. 
Smoking - Smoking doubles the risk of ischaemic stroke and is 
associated with a 3-fold increased risk of haemorrhagic 
stroke. 
Diabetes - Diabetes is associated with an increased ischaemic stroke 
relative risk of between 1.8 and 6. 
Atrial Fibrillation - AF is associated with a 3 to 4 fold increased risk 
of stroke.  Stroke in patients with AF tend to be 
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larger and more disabling, and AF is associated 
with increased mortality. 
Hyperlipidaemia -  Increased cholesterol levels are associated with 
increased risk of ischaemic stroke. 
Carotid stenosis - Ischaemic stroke is more frequent in patients with 
severe (>75%) carotid stenosis. 
 
There are many other potential risk factors for stroke including diet, 
physical activity, hormone therapy, obesity, alcohol and drug abuse, and 
oral contraceptive use. 
 
Some risk factors may be of particular importance to specific subtypes of 
stroke.  For example, while diabetes has been shown to be a risk factor for 
ischaemic but not haemorrhagic stroke [Abbott et al., 1987], hypertension has 
been associated with both haemorrhagic and ischaemic stroke [Sacco et al., 
1997].  Also, risk factor profiles may differ between specific subtypes of 
ischaemic stroke. However, as many risk factors are included in the 
definitions of specific subtypes, this is difficult to test without bias.  In a 
systematic review, Jackson et al. [Jackson & Sudlow, 2005] found that both 
hypertension and diabetes were more common in lacunar than other 
subtypes of ischaemic stroke, but when risk factors were excluded from the 
stroke subtype definitions, this was only true for hypertension and the excess 
in lacunar ischaemic stroke was very small.  They also found that atrial 
fibrillation and carotid stenosis were more common in non-lacunar stroke. 
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1.1.6 Heritability 
Although stroke is not thought of as a genetic disease in the traditional sense, 
a family history of stroke has long been regarded as an important risk factor 
for the disease.  Many studies have attempted to estimate how heritable 
stroke is using twin and family history studies.  Flossmann et al. [2004] 
systematically reviewed the evidence for heritability of stroke.  They 
identified 3 twin studies, 33 case control family history studies and 17 cohort 
family history studies, published between 1966 and 2003.  They concluded 
that monozygotic twins had a 65% increased odds of being concordant for 
stroke compared with dizygotic twins.  The case control studies showed that 
having a family history of stroke increased the odds of stroke by 76%.  The 
cohort studies showed that a family history of stroke increased the odds by 
30%.  These estimates may be biased by various factors, including an 
unmeasured environmental contribution that may explain some of the 
supposed ‘heritability’.  In addition, many studies did not distinguish 
between haemorrhagic and ischaemic stroke.  However, the twin studies 
(which are considered the most reliable and less influenced by confounding 
environmental factors) present a convincing case for at least a small genetic 
influence on the risk of stroke. 
 
It has been shown that a family history of stroke is a stronger predictor of 
stroke when the affected relatives were younger [Flossmann et al., 2004]. 
 
Few studies have assessed the influence family history has on odds of stroke 
stratified by stroke subtype, but those that have, have found that a family 
history of stroke is less frequent in cardioembolic stroke compared to large 
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and small artery stroke [Flossmann et al., 2004; Schulz et al., 2004], and is 
more frequent in large artery stroke than small artery stroke [Jerrard-Dunne 
et al., 2003a].  This latter study also found that family history of MI was more 
common in patients with large artery stroke, than other subtypes. 
 
Traditional risk factors for stroke (such as hypertension, diabetes, 
hyperlipidaemia) are known to have genetic components and could account 
for some of the heritability.  Although adjusting for traditional risk factors 
diminished the association between family history and stroke, this still 
remained significant in a number of studies [Flossmann et al., 2004], 
suggesting there are other genetic influences for stroke, beyond that expected 
for known risk factors. 
 
1.2 Genetics 
1.2.1 State of the Art 
Studies that attempt to identify genetic variants that influence disease or 
phenotypic traits can be divided into two categories; linkage analysis studies, 
and association studies.  Association studies can be candidate studies with a 
priori expectations, or genome-wide studies with no a priori expectations of 
the genes involved.  Statistical methods and laboratory techniques have 
advanced to allow sophisticated analysis of genetic data. 
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1.2.1.1 Linkage studies 
Linkage studies rely on the co-segregation of loci in pedigrees.  
Recombination between markers during meiosis occurs at a rate related to 
the distance between them.  Therefore a disease/trait allele will be inherited 
in families along with a background section of the genome.  By studying 
which genomic sections are commonly co-inherited with the disease/trait of 
interest in a family, the location of the variant of interest can be later refined 
*Dawn & Barrett, 2005+.  Linkage analysis is generally ‘genome-wide’ or 
‘chromosome-wide’ and only identifies large regions of linkage, not specific 
genes or mutations.  This method is most useful for variants that have a large 
effect (which are often rare).  Linkage studies also have their limitations for 
late-onset conditions such as stroke, since it is not necessarily appropriate to 
assign young people as unaffected, when they may go on to develop the 
disease in the future. 
 
1.2.1.2 Association studies 
Association studies, by contrast, are more useful for variants that are 
common, but have small effects [Risch & Merikangas, 1996].  This method 
looks for an association between the disease/trait and genetic variants in the 
population [Cordell & Clayton, 2005].  However, linkage disequilibrium (LD) 
between close markers means that the associated variant is not necessarily 
the causal variant. 
 
Association studies can be either of candidate genes or genome-wide.  
Candidate gene studies require background knowledge to inform the choice 
of genes to be studied.  This decision may be based on prior evidence of 
Chapter 1 - Introduction 
13 
association or linkage in the region, but are often selected with only tentative 
biological reasoning.  Often little is known about the mechanistic pathways 
leading to a trait or disease and so selecting candidate genes this way can be 
difficult.  Given the number of genes in the genome (~20,000), it is extremely 
unlikely a priori that disease risk genes will be selected for such studies, and 
so important genes are likely to be missed with this approach.   
 
1.2.1.3 Genome-wide association studies 
Genome-wide studies require no a priori expectation on which genes are 
associated with the disease or trait of interest.  They usually involve 
genotyping of single nucleotide polymorphisms (SNPs) from across the 
entire genome.  Associations with each SNP are then tested for.  This can 
result in novel genes being identified as associated with the diseases/trait of 
interest.  Genome-wide SNP chips have been developed that are either gene-
centric; include large numbers of randomly selected SNPs from across the 
genome; or include ‘tagging’ SNPs that represent each LD block in the 
genome (thereby capturing as much of the variation as possible) [Li et al., 
2008].  SNP chips can now screen more than 1 million SNPs and the cost of 
genotyping has been rapidly decreasing, making genome-wide studies more 
affordable.  However SNP chips do not capture all genomic variation and so 
this approach may miss some important genetic associations, demonstrating 
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1.2.2 Complex Disease Genetics 
1.2.2.1 Problems 
Figure 1.4 shows the number of genes identified for Mendelian and complex 
traits up to 2002.  The identification of the genes that cause Mendelian 
diseases has been straightforward and successful (see figure 1.4, pink 
squares).  However, these diseases are relatively rare and hence of limited 
public health importance.  Attentions have now turned to more common 
diseases that affect vast numbers of people and do not appear to be inherited 
in a Mendelian fashion, e.g. cancer, heart disease, schizophrenia, asthma and 
stroke etc.  These are likely to be determined by a number of genetic and 
environmental factors.  As most of these factors are likely to have modest 
effects, identifying them is difficult and, on the whole, attempts have been 
disappointing (see figure 1.4, blue triangles). 
 
Figure 1.4 Cumulative numbers of identification of genes underlying human 
Mendelian traits and genetically complex traits in humans and other species. [Glazier et 
al., 2002] 
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Figure 1.5 shows a schematic diagram of a possible pattern of causality for a 
complex disease.  It is likely that there are many genetic factors that influence 
(to differing amounts) various protein levels and/or functions and 
intermediate phenotypes, which in turn, influence other intermediate 
phenotypes, ultimately resulting in the manifestation of disease.  Alongside 
the genetic influences, there are also environmental contributions, which 
may have more of an effect at the higher (and later) levels (figure 1.5). 
 
As the individual effect that a single variant will have on the occurrence of 
disease is likely to be very small, studies will require extremely large 
numbers of subjects to be statistically powered to detect them.  Also, 
different genes will cause the same disease in different people (genetic 
heterogeneity) and not everyone with a particular ‘causal’ variant will 
 
Figure 1.5 Schematic diagram of the relationship of genes and their products to 
intermediate phenotypes as well as the more overt clinical
 
manifestations of a disease. 
The thickness of the arrows denotes
 
the strength of the contribution of a lower-level factor 
to a
 
higher-level factor. The inverted triangle on the left-hand side
 
of the figure represents 
the (likely) diminishing effect of environmental
 
conditions on factors integrated at lower 
and lower levels of
 
a biochemical and physiological hierarchy. P=protein; LL=lower-level 
factor; INT=intermediate trait; HL=higher-level factor [Schork, 1997]. 
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develop the disease (phenotypic heterogeneity), further complicating the 
identification of genes of importance.  There may also be interactions 
between genes and/or environmental factors.  All of these are likely reasons 
why the contribution of a gene to disease may be obscured and may explain 
why studies of genes influencing common complex disease have been 
conflicting [Schork, 1997].  
 
 
Figure 1.6 Schematic diagram of the relationship of a gene and its product to a 
single pathway that, when disrupted or dysfunctional,
 
may contribute to disease. The 
thickness of the arrows between
 
elements at different levels characterizes the strength of 
the
 
contribution of a lower-level factor to a higher-level factor.
 
The percentages next to an 
arrow give the hypothetical percentage
 
of variation explained by the lower-level factor for 
the higher-level
 
factor that they influence. The symbols on the right-hand side
 
of the figure 
characterize the potential for diagnosis and therapeutic
 
intervention at each level, with the 
size of the figures corresponding
 
to the most realistic points for diagnosis or intervention 
[Schork, 1997]. 
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1.2.2.2 Use of intermediate quantitative traits 
One possible way to overcome the problems of identifying genetic factors for 
complex disease is to study the upstream intermediate traits [Majumder & 
Ghosh, 2005; Pan et al., 2006].  Intermediate quantitative traits are often 
highly heritable and have a simpler genetic architecture than the disease end-
point, as they are closer to the gene in the pathway (see figure 1.6).   
Therefore, it may be easier to identify the genetic polymorphisms that 
influence the intermediate trait. 
 
Another advantage of intermediate traits is that they can be measured in the 
general population, usually with high accuracy.  This is in contrast with the 
disease end-point, which is often late-onset and diagnosing somebody as a 
‘control’, rather than a ‘pre-case’ may be difficult.  Intermediate traits also 
tend to be quantitative (instead of binary), which increases the power of 
statistical analyses.   
 
1.2.3 Identification of Genes that Cause Stroke 
Many studies have assessed the genetic component of stroke.  For example, 
HuGENavigator (http://hugenavigator.net), a database of human genetic 
epidemiology data which screens PubMed for relevant publications, lists 90 
genes that have been studied for association with cerebral infarction.  
However, these attempts to identify genetic risk factors for stroke have been 
disappointing.  Many studies have been conflicting and no single gene with a 
large effect has been identified.  A meta-analysis of the 13 most commonly 
studied genes found only small associations for four genes (Factor V, 
MTHFR, prothrombin and ACE) [Casas et al., 2004].   
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The deCODE group in Iceland has identified two potentially important genes 
for stroke using linkage analysis.  A significant region of linkage was 
observed on chromosome 5q for ischaemic stroke [Gretarsdottir et al., 2002].  
A subsequent case control association study on a denser set of markers 
within this region identified PDE4D as the associated gene [Gretarsdottir et 
al., 2003].  The association appeared to be specific to large artery and 
cardioembolic stroke, rather than small artery stroke.  Another linkage study 
by the same group identified a significant region of linkage on chromosome 
13q for stroke and MI.  The subsequent case control association analysis 
identified ALOX5AP as the gene of interest [Helgadottir et al., 2004].  This 
gene appeared to be associated with both haemorrhagic and ischaemic 
stroke.  However, subsequent association studies of these two genes in other 
populations have been conflicting [Dichgans, 2007] and a meta-analysis of 
the association between genetic variants in the PDE4D gene and stroke 
reported no clear evidence of overall association [Bevan et al., 2008]. 
 
Certain genes may predispose to all subtypes of stroke, whilst others may 
only predispose to specific subtypes [Dichgans & Markus, 2005].  Therefore 
studies which carefully classify stroke subtypes and analyse according to 
these, are important.  Genes may also influence conventional risk factors (e.g. 
hypertension and diabetes) or may impact more directly on disease of the 
blood vessels or on neuronal susceptibility to an ischaemic or haemorrhagic 
insult.  Other genes may not predispose to the disease itself but may 
influence the ability to recover from a stroke. 
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1.2.3.1 Quantitative traits for stroke 
As described earlier, quantitative traits can provide greater statistical power 
for identifying genetic associations than the end-point of disease itself.  For 
stroke two commonly used quantitative traits are carotid intima-media 
thickness (CIMT) and white matter hyperintensities on a brain scan (WMHs) 
[Dichgans & Markus, 2005].  These both have a strong genetic component.  
CIMT is a marker of subclinical atherosclerosis [Lorenz et al., 2007], is a 
strong predictor of future myocardial infarction and stroke [Dijk et al., 2006], 
and is associated more with large artery than small artery stroke. It is 
therefore a suitable quantitative trait for large artery stroke.  WMHs are 
associated with a history of, and later progression to, small artery infarcts 
and clinical stroke [Leys et al., 1999], and have been shown to be more 
prevalent in small artery compared to large artery stroke [Wiszniewska et al., 
2000]. They are therefore a suitable quantitative trait for small artery stroke. 
 
Large numbers of studies have tested for associations between these traits 
and variation in many genes.  However, these have produced conflicting 
results.  Humphries & Morgan [2004] have published a narrative review on 
some of the genes which have been studied for an association with CIMT and 
report that the conflicting and under-powered studies make it difficult to 
determine the effects of these genes on CIMT.  No review has been published 
on the association of genetic variants with WMH. 
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1.3 Systematic Review and Meta-Analysis 
A meta-analysis is a statistical technique to calculate an overall summary 
outcome measure from the results from two or more studies.  This may 
include some or all of the data available on a particular topic.   
 
A systematic review is a review of all of the available evidence on a topic, 
which may or may not include a formal statistical meta-analysis. 
 
A systematic review containing a meta-analysis provides a summary 
estimate calculated from all of the available data on a topic.  This provides a 
(potentially) unbiased overall estimate with increased statistical power and 
so precision of the result.  
 
1.3.1 History 
The first documented combination of data from several studies was carried 
out by Karl Pearson in 1904 [Pearson, 1904]. He combined evidence from 11 
datasets on the use of vaccines for typhoid.  He estimated the overall 
correlation between typhoid inoculation and mortality, and concluded that 
this was weak.  He also made observations analogous to what we now call 
‘heterogeneity’ and ‘statistical significance’.  
 
Glass coined the term ‘meta-analysis’ in 1976 *Glass, 1976+, and the technique 
became popular in the 1980s.  In recent years, an explosion in the number of 
original studies published has led to a correspnding explosion in meta-
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analyses, with a rise from approximately 250 meta-analyses published in 
1990, to 2250 published in 2006 [Sutton & Higgins, 2008]. 
 
Systematic reviews and meta-analyses have been increasingly widely used to 
summarise the results of clinical trials, at least in part due to the 
establishment of the Cochrane Collaboration.  This organization aims to: 
‚Improve healthcare decision-making globally, through systematic 
reviews of the effects of healthcare interventions, published in The 
Cochrane Library.‛ 
 
As well as being a valuable resource for those searching for systematic 
reviews on a particular topic, the organisation also provides guidelines, 
assistance and software for investigators carrying out such reviews.  Of 
particular relevance here is the Cochrane RevMan software[The Cochrane 
Collaboration, 2006], in which an entire review can be produced.  It provides 
a step-by-step approach for preparing the text, tables, references, and for 
data input, and enables the user to perform meta-analysis and produce 
relevant graphs.  Although the software has been designed for reviews of 
randomised trials of interventions, it can also be used for observational 
studies (albeit with limitations which I discuss in chapter 2). 
 
The common use of systematic review and meta-analysis for observational 
epidemiological studies is more recent, and does not yet have the supportive 
infrastructure that the Cochrane Collaboration provides for randomised 
trials [Dickersin, 2002].  However, the HuGENet (Human Genome 
Epidemiology Network) collaboration has been recently formed to provide 
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similar guidelines and infrastructure for reviews of genetic epidemiology 
[Seminara et al., 2007].  
 
1.3.2 Systematic Review Methodology 
A review is ‘systematic’ if it attempts to collate all evidence on a particular 
topic.  To achieve this, firstly, the research question must be properly 
defined.  For example ‘is gene A associated with stroke?’ is often insufficient.  
The reviewer must consider the types of studies to include (case-control, 
cohort, family studies), as well as the specific population of interest (e.g. 
early onset, elderly).  Once a specific research question has been devised, a 
thorough search strategy can be built around this. 
 
1.3.2.1 Database searching 
Online databases such Medline and Embase aim to collate all health and 
medical journal articles and index them according to study details, including 
authors, title, journal and keywords, to allow these to be searched easily and 
the results downloaded into reference software such as Reference Manager. 
 
The appropriate databases to search will depend on the field of study.  For 
medical and health related journals, Medline and Embase provide good 
coverage.  BIOSIS may be of more relevance for topics in general life sciences.  
Medline and Embase both index approximately 5000 journals, with 
approximately 3000 journals that are indexed in both (table 1.1).  Depending 
on the subject, Embase or Medline may be more appropriate, but a 
comprehensive search of medical articles should generally include both. 
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Once the database/s have been selected, the next stage is to develop the 
search strategy.  Different search strategies will be needed for each database, 
as the indexing terms they use may differ.  As well as searching the citations 
for specific words or phrases, Medical Subject Headings (MeSH), which have 
been used to index the citations, can be used to identify relevant articles.  
Boolean terms, along with other syntax for specific queries can be 
incorporated to devise a sophisticated search strategy that matches the user’s 
requirements.  For a systematic review, the search strategy should be 
designed for maximum sensitivity whilst maintaining appropriate 
specificity.  Table 1.2 shows an example of a multi-stage search strategy used 
to search the Medline database. 
 
1.3.2.2 Selecting articles 
Often a systematic search of the literature gives thousands of articles, many 
of which will be irrelevant.  After searching, the investigators can then use 
their exact study criteria to select which citations are relevant, and which are 
not. 
 
A systematic review may merely present all of the relevant papers, along 
with their results and stop there.  However, if possible and appropriate it is 
likely that a review will go on to carry out a meta-analysis to summarise the 
data in a meaningful way. 
Table 1.1 Numbers of citations indexed in Medline and Embase databases. Data 
from Ovid 




Number of citations 
added each year 
Medline 1966 - present ~5250 ~11.8 million ~520,000 
Embase 1980 - present ~4550 ~7.7 million ~500,000 
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1.3.3 Meta-Analysis Methods 
The method for combining the individual results to obtain an overall 
estimate of the results (summary statistic), depends on the research question 
and the type of data available.  For dichotomous data common summary 
statistics are odds ratios (ORs), risk ratios and hazard ratios.  For continuous 
data, mean differences (MDs) or standardised mean differences are 
commonly used as summary statistics.  The first stage is to obtain study-
Table 1.2 Demonstration search strategy for MEDLINE (Ovid format), for the topic 























randomized controlled trial.pt. 







1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
animals.sh. not (humans.sh. and animals.sh.) 
 9 not 10 
exp Breast Neoplasms/ 
(breast adj6 cancer$).mp. 
(breast adj6 neoplasm$).mp. 
(breast adj6 carcinoma$).mp. 
(breast adj6 tumour$).mp. 
(breast adj6 tumor$).mp. 
12 or 13 or 14 or 15 or 16 or 17 
exp Tamoxifen/ 
tamoxifen.mp. 
19 or 20 
11 and 18 and 21 
The ‘adj6’ operator indicates within six words; ‘$’ indicates truncation; .mp. indicates a 
search of title, original title, abstract, name of substance word and subject heading word; 
.pt. indicates publication type; .ab. indicates a search of the abstract; .fs. indicates 
qualifiers for MeSH terms; .sh. indicates MeSH terms; exp …. / indicates a MeSH term 
and all of its subsidiary terms. 
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specific estimates and then a weighted average of these across all studies is 
calculated to give the summary statistic together with its p value and 95% 
confidence interval.  Below I will describe two methods for study summary 
statistics; one for dichotomous data (ORs) and one for continuous data 
(MDs). I will then show the weighting methods used to obtain the pooled 
estimates. 
 
1.3.3.1 Odds Ratio 
Table 1.3  Notation used for odds ratio calculation. i refers to the ith study. 
Risk Factor Affected Unaffected 
Present ai bi 
Absent ci di 
 














where OR = Odds ratio, SE=standard deviation 
 
1.3.3.2 Mean difference 
Table 1.4 Notation for mean difference calculation 
Risk Factor Mean of trait Standard 
deviation 
Sample size 
Present m1i SD1i n1i 
Absent m2i SD2i n2i 
 
Table 1.4 shows the notation used in the following calculations: 
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where MD= mean difference 
 
1.3.3.3 Estimating pooled summary statistic 









where θ denotes the summary statistic and w denotes the study weight. 
 
The weights applied to each study depend on either a fixed- or a random-
effects model.  Next, I will describe these two models. 
 
1.3.3.4 Fixed/Random effects model 
A fixed effects model assumes that the true summary statistic from each 
study is the same.  It will therefore weight the studies based on the standard 
error of each study.  A random effects model assumes that studies estimate 
effects vary around a central estimate (following a normal distribution).  The 
model incorporates an estimate of ‘between study variation’ into the 
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calculation of the pooled summary statistic.  There are several methods for 
carrying out a fixed or random effects meta-analysis e.g.: 
 
For fixed effects, dichotomous outcomes:  








For fixed effects, continuous outcomes:  








For random effects, for both continuous and dichotomous outcomes: 







where τ2 is the variance between study estimates, and so takes into account 
the heterogeneity of studies. 
 
These popular meta-analysis methods have been developed for the 
comparison of two groups.  In studies where there are more than two 
groups, as is common in genetic association studies, these methods are 
limiting and so need to be expanded [Attia et al., 2003; Salanti et al., 2005].  
This topic will be the focus of chapter 2 of this thesis.  
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1.4 Aims of Thesis 
In this thesis I present the results from two systematic reviews and meta-
analyses on the association between two quantitative stroke-related traits 
(CIMT and WMH) and commonly studied genes.  I discuss the development 
of meta-analysis methods for genetic studies where there are generally three 
groups and a genetic model must be selected and use these methods where 
appropriate in my reviews.  Following on from these reviews, I also report 
the results of a study attempting to test the association of the apolipoprotein 
E genotype with large artery compared with small artery stroke in a large 







2 Development of Genotype-Quantitative Trait 
Association Meta-Analysis Method 
 
(Development of meta-analysis method) 
 
In this chapter I discuss the limitations and problems with existing meta-
analytical methods and I attempt to overcome these with a novel three-step 
approach.  I devised and present three possible methods for determining the 
genetic model (step 2) and using test datasets discuss the merits and 
weaknesses of each.  I finally present the chosen method to be used in 
chapter 3. 
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2.1 Introduction 
Most traditional meta-analyses compare outcomes between two groups of 
patients (e.g. treatment and control arms of a randomized controlled trial) 
and so the most widely available statistical methods and software packages 
(e.g. RevMan [The Cochrane Collaboration, 2006]) have been designed to 
deal with this data structure.  However, genetic association studies (along 
with some other observational studies) usually have more than two 
comparison groups.  For the simplest genetic mutation (a to A) each 
individual will have one of 3 genotypes (aa, aA or AA).  Therefore, 
traditional meta-analysis statistical methods and software packages that 
compare two groups are insufficient.  As my PhD involves meta-analyses of 
intermediate phenotypes for stroke I will focus on the methods that allow 
meta-analysis of a continuous outcome where there are three genotypes (the 
‘trait increasing’ allele denoted A). 
 
2.2 Existing Methods  
The problem of how to deal with genetic data when carrying out a meta-
analysis has been addressed in the literature with a variety of methods.  Most 
collapse the data into two groups and use the traditional methods and 
software.  Methods particular to genetic meta-analysis have also been 
developed recently which analyse the data as three separate groups.  
 
2.2.1 Methods Which Collapse Data into Two Groups 
Method (i) Assume a dominant or recessive genetic model.  Collapse the 
three genetic groups into two, based on an assumed genetic 
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model.  The heterozygote Aa individuals are grouped with the 
AA or aa individuals depending on which model is adopted, 
e.g. [Juo et al., 1999]. 
 
Dominant: AA and Aa compared to   aa 
Recessive: AA  compared to  Aa and aa  
 
Method (ii) Compare the two extreme genotypes (AA and aa).  This may be 
done when the underlying genetic model is thought to be co-
dominant and so method (i) would be inappropriate, e.g.  
[Sayed-Tabatabaei et al., 2003] 
 
Method (iii) Often, if the genetic model is not known, multiple comparisons 
are made.  Either the data are analysed according to multiple 
models (both recessive and dominant), or several comparisons 
between the individual genotypes are made (e.g. AA versus Aa 
and AA versus aa), e.g.  [Rantala et al., 2000] 
 
A systematic review of all meta-analyses of genetic association studies up to 
August 2000 [Attia et al., 2003] found that five out of the seven continuous 
outcome meta-analyses used multiple comparisons (method (iii)) to analyse 
the association and most failed to account for this multiple testing.  The other 
two studies assumed a genetic model (method (i)).  One gave explicit 
biological reasons for using the assumed model and the other gave no 
reason.   
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Adopting a certain genetic model is only appropriate if there is sufficient 
evidence to show that the correct one has been chosen.  Using biological 
evidence is sensible if the evidence relates to the trait being studied.  If there 
is evidence that a mutation works in a recessive way on one trait, this does 
not necessarily mean its influence on another trait is recessive.  Often, when 
carrying out a meta-analysis one is constrained to using a particular genetic 
model, because many of the papers have presented their data according to 
this model and selecting this model generates the largest and most complete 
dataset possible.  Providing the individual papers have chosen this genetic 
model sensibly, this model should be the most appropriate. 
 
Comparing the two extremes (method (ii)) may show the largest difference, 
but removing the Aa genotype group (which is often much larger than the 
AA group) will reduce statistical power to detect an association. 
 
2.2.2 Methods Which Analyse as Three Groups 
Some methods have been developed that analyse the data as three groups.  
These either use a per-allele (co-dominant model), or attempt to analyse the 
data without assuming a particular genetic model.  The methods are as 
follows: 
 
Method (iv) Use a per-allele method, which assumes a co-dominant model.  
Ye et al. [2006] estimate a per-allele odds ratio using logistic 
regression.  This method could be adapted to analyse 
continuous data and report the average mean difference 
between genotypes AA and Aa, and genotypes Aa and aa. 
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Method (v) A Bayesian model-free approach has been described for 
dichotomous outcomes [Minelli et al., 2005].  This method is 
based around odds ratios but could be extended to analyse an 
association for a continuous outcome.  It works on the basis 
that in a simple bi-allelic situation there are two odds ratios to 
be estimated; Aa compared with aa (ORAa) and AA compared 
with aa (ORAA).  The relationship between these two odds ratios 
is dependent on the genetic model.  The method treats the log 
odds ratio of Aa versus aa (logORAa) as an unknown proportion 




AaORlogλ   and thus ORAa =[ORAA]λ 
 
λ values of 0, 0.5 and 1 correspond to recessive, co-dominant 
and dominant respectively, but λ is allowed to take any value 
between 0 and 1.  The study-specific log ORAA is modelled as a 
normally distributed random effects parameter and λ is 
modelled as a fixed parameter.  The study specific log ORAa is 
equal to the product of λ and the study-specific log ORAA.  By 
estimating the log ORs and λ, this approach provides 
information of the genetic magnitude of the effect as well as the 
mode of inheritance.  But, its results can be difficult to interpret 
as they depend on priors and the methods are inaccessible to 
those unfamiliar with Bayesian analysis.  
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Method (vi) A frequentist genetic model-free approach is described by 
Thakkinstian et al. [2005].  In this method, analysis of variance 
(ANOVA) is used to test for an overall association between a 
gene and a trait, but no estimation of λ or size of effect is made.  
The genetic-model-free ANOVA approach above is useful as it 
tests for an association without making any assumptions about 
the underlying genetic model.  However, once an overall 
association has been found, it is still necessary to investigate the 
association further.  The ANOVA result does not tell you which 
of the genotypes is associated with an increase or decrease in 
the trait or the size of any effect.  After establishing an overall 
association a method is still required to determine which 
genetic model is appropriate, so that the data can then be 
analysed according to that model to determine the effect size. 
 
2.3 Aim 
I aimed to devise a new, easy to use method that deals with three 
comparison groups in a meta-analysis of the association with a continuous 
trait.  By using the relationship between two mean differences to estimate λ 
(similar to that described in method (v)) the best genetic model (recessive, 
dominant or co-dominant) can be chosen.  There are many ways λ can be 
estimated.  I have devised and investigated three different methods of 
calculating λ and used real data to test these methods.  However, as I will 
show, estimating λ is meaningless and often misleading if there is no 
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underlying association and so ANOVA provides a useful tool for 
establishing if there is any association to begin with. 
 
First, I describe the ANOVA method, then I describe three different λ 
estimation methods, and then the meta-analysis mean difference method for 
the three genetic models.  Finally I examine the three different λ estimation 
methods using a dataset that gives conflicting results between methods, 
discuss the methods and choose the most appropriate λ estimation method 
for my novel, simple, three-step approach for estimating the pooled 
association between a genetic polymorphism and a continuous trait. 
 
To test these methods I used seven of the datasets collected for my carotid 
intima-media thickness (CIMT) meta-analyses (chapter 3).  These datasets are 
shown in table 2.1.  The number of studies in each dataset varies between 3 
and 34.  I carried out all analyses in Stata (version 7.0, [StataCorp., 2001]) and 
so provide instructions and code for this software package.   
 
2.4 Methods Tested 
2.4.1 Meta-ANOVA 
Meta-ANOVA can be used to test for an overall association between 
genotype and a trait.  By modelling ‘genotype’ and ‘study’ as independent 
categorical variables the between study differences can be accounted for and 
‘genotype’ can be tested to see if it is a significant determinant of ‘trait’.  The 
ANOVA is weighted using (1/[standard error of the trait mean]2), allowing 
larger and more precise studies to be weighted more heavily than small  
Chapter 2 – Development of Meta-Analysis Method 
37 
Table 2.1  7 meta-analysis test datasets, studying the association between a gene and a 
trait.  Each study reported 3 genotypes: sample size (n), mean value of the trait (mean) and 
standard deviation (SD).  Data were taken from the CIMT datasets collected (chapter 3). 
  genotype 1 genotype 2 genotype 3 
Gene study n mean SD n mean SD n mean SD 
A 1 158 1.24 0.44 179 1.27 0.52 38 1.29 0.36 
 2 262 0.90 0.23 215 0.92 0.24 42 0.91 0.18 
 3 244 0.92 0.21 220 0.96 0.31 41 0.88 0.17 
 4 43 0.37 0.07 57 0.35 0.08 18 0.45 0.13 
 5 73 0.70 0.43 46 0.92 0.47 8 1.10 0.51 
 6 89 0.53 0.38 72 0.55 0.34 6 0.60 0.42 
 7 59 0.98 0.10 56 1.07 0.23 16 1.16 0.36 
 8 1218 0.79 0.35 1013 0.79 0.32 217 0.81 0.29 
B 1 23 0.75 0.19 88 0.68 0.19 76 0.74 0.17 
 2 23 1.02 0.20 124 1.06 0.30 93 1.05 0.40 
 3 18 1.14 0.40 47 0.94 0.28 36 0.81 0.28 
 4 103 0.81 0.18 264 0.80 0.15 148 0.83 0.19 
 5 16 0.7 0.08 70 0.76 0.08 46 0.78 0.07 
 6 87 0.63 0.16 116 0.63 0.17 32 0.64 0.17 
 7 147 0.99 0.36 149 1.06 0.54 60 1.20 0.59 
 8 88 0.72 0.15 256 0.73 0.16 151 0.73 0.15 
 9 31 0.62 0.15 55 0.63 0.18 62 0.63 0.13 
 10 57 0.54 0.10 165 0.54 0.13 118 0.55 0.11 
 11 33 0.52 0.04 80 0.54 0.06 37 0.53 0.04 
 12 70 0.63 0.12 150 0.62 0.1 135 0.64 0.12 
 13 42 1.04 0.23 100 1.08 0.33 77 1.01 0.19 
 14 228 0.71 0.14 535 0.71 0.14 343 0.71 0.15 
 15 7 0.71 0.05 22 0.76 0.09 22 0.8 0.10 
 16 8 0.72 0.13 25 0.71 0.12 14 0.75 0.16 
 17 65 0.74 0.27 69 0.76 0.307 41 0.88 0.35 
 18 19 1.01 0.29 46 1.10 0.25 33 1.06 0.26 
 19 1540 0.87 0.28 1640 0.87 0.29 477 0.87 0.26 
 20 83 0.79 0.12 95 0.80 0.14 27 0.81 0.14 
 21 116 0.56 0.16 180 0.59 0.23 84 0.58 0.17 
 22 29 0.94 0.20 86 0.97 0.20 69 0.98 0.21 
 23 29 0.73 0.54 62 0.77 0.55 36 0.91 0.48 
 24 29 0.53 0.32 84 0.56 0.37 44 0.61 0.33 
 25 30 0.58 0.12 27 0.67 0.11 45 0.79 0.18 
 26 18 0.49 0.10 25 0.48 0.10 15 0.46 0.10 
 27 35 0.55 0.10 57 0.53 0.10 28 0.57 0.11 
 28 38 0.82 0.21 62 0.80 0.19 30 0.81 0.21 
 29 1418 0.79 0.15 3264 0.80 0.16 1806 0.80 0.16 
 30 10 0.42 0.06 21 0.43 0.07 17 0.40 0.08 
 31 16 0.42 0.07 31 0.43 0.09 9 0.48 0.06 
 32 8 1.32 0.29 28 1.29 0.33 28 1.29 0.30 
 33 39 0.60 0.08 106 0.59 0.10 79 0.57 0.08 
 34 25 0.64 0.06 34 0.72 0.05 29 0.78 0.06 
C 1 130 0.74 0.23 36 0.67 0.18 7 0.74 0.08 
 2 213 0.55 0.16 142 0.57 0.18 25 0.61 0.18 
 3 3170 0.77 0.36 1668 0.78 0.44 245 0.76 0.37 
D 1 33 0.85 0.23 155 0.97 0.25 66 1.00 0.24 
 2 32 1.80 0.10 177 1.84 0.15 45 1.95 0.45 
 3 26 0.99 0.50 261 1.04 0.49 62 1.10 0.48 
 4 22 0.62 0.17 176 0.63 0.17 33 0.64 0.15 
 5 24 0.52 0.05 90 0.54 0.05 30 0.52 0.04 
 6 4 1.20 0.60 38 1.10 0.30 10 1.50 0.50 
     
Chapter 2 – Development of Meta-Analysis Method 
38 
Gene study n mean SD n mean SD n mean SD 
D cont. 7 33 0.59 0.13 200 0.63 0.38 28 0.75 0.35 
 8 38 0.54 0.13 208 0.53 0.12 66 0.55 0.11 
 9 10 0.72 0.25 77 0.70 0.25 25 0.80 0.25 
 10 20 0.95 0.12 109 1.05 0.17 60 1.03 0.16 
 11 750 0.75 0.14 3122 0.77 0.14 1392 0.77 0.18 
 12 27 0.79 0.12 137 0.79 0.13 38 0.83 0.16 
 13 10 0.61 0.15 65 0.64 0.14 20 0.76 0.17 
 14 12 0.89 0.18 160 0.9 0.19 86 0.98 0.26 
 15 13 0.78 0.15 150 0.93 0.21 90 0.93 0.23 
 16 22 0.91 0.37 109 0.99 0.52 31 0.93 0.42 
 17 146 0.69 0.13 650 0.72 0.15 283 0.70 0.13 
 18 10 0.81 0.17 64 0.88 0.16 18 1.02 0.19 
 19 34 0.62 0.12 161 0.68 0.17 58 0.89 0.15 
 20 11 0.59 0.11 75 0.60 0.13 20 0.71 0.14 
 21 373 0.73 0.16 1782 0.74 0.18 568 0.74 0.20 
 22 18 0.76 0.17 158 0.81 0.21 49 0.83 0.23 
 23 12 0.60 0.20 92 0.70 0.40 14 0.70 0.50 
 24 17 0.86 0.23 89 0.78 0.16 21 0.88 0.30 
 25 23 0.89 0.16 120 0.93 0.16 39 0.88 0.16 
 26 717 0.71 0.11 3923 0.71 0.13 1124 0.72 0.13 
 27 10 0.60 0.15 122 0.65 0.16 31 0.69 0.19 
 28 634 0.72 0.13 1427 0.73 0.11 1126 0.75 0.13 
 29 1459 0.72 0.12 5534 0.73 0.15 2311 0.74 0.14 
 30 4 0.79 0.06 40 0.89 0.14 24 0.99 0.19 
 31 4 0.90 0.00 22 0.96 0.17 7 0.87 0.08 
 32 59 0.72 0.12 242 0.79 0.21 144 0.74 0.21 
E 1 19 1.30 0.42 38 1.09 0.25 35 1.17 0.24 
 2 47 0.85 0.17 19 0.78 0.21 5 0.72 0.15 
 3 381 0.69 0.15 557 0.70 0.12 171 0.70 0.17 
 4 320 0.77 0.14 500 0.77 0.14 180 0.79 0.16 
 5 265 0.98 0.29 422 0.98 0.26 136 1.10 0.26 
F 1 89 1.31 0.31 94 1.35 0.35 39 1.58 0.54 
 2 35 0.83 0.19 38 0.86 0.19 22 0.88 0.20 
 3 87 0.79 0.13 54 0.85 0.15 10 0.93 0.07 
 4 28 0.98 0.21 72 1.03 0.17 20 1.23 0.18 
 5 59 0.64 0.23 111 0.69 0.21 36 0.79 0.30 
 6 47 0.86 0.29 55 0.93 0.22 22 0.89 0.22 
 7 325 0.73 0.15 304 0.72 0.13 62 0.68 0.11 
 8 1197 0.85 0.11 1542 0.86 0.10 508 0.86 0.11 
 9 110 0.74 0.18 120 0.73 0.17 30 0.79 0.24 
 10 171 0.67 0.13 84 0.67 0.12 20 0.67 0.15 
 11 198 0.69 0.17 72 0.69 0.16 13 0.79 0.20 
 12 312 1.02 0.16 378 1.02 0.17 125 1.03 0.16 
 13 60 0.64 0.14 117 0.67 0.15 24 0.59 0.10 
 14 346 0.76 0.20 316 0.75 0.18 52 0.74 0.18 
 15 290 0.75 0.23 220 0.75 0.16 31 0.77 0.18 
G 1 14 0.89 0.38 63 0.72 0.17 62 0.74 0.18 
 2 88 0.76 0.15 91 0.76 0.13 17 0.78 0.18 
 3 165 0.51 0.05 169 0.51 0.05 28 0.49 0.03 
 4 140 1.14 0.22 111 1.13 0.21 35 1.12 0.23 
 5 30 0.65 0.27 77 0.83 0.27 45 1.05 0.32 
 6 262 0.88 0.19 198 0.88 0.18 36 0.90 0.17 
 7 273 0.87 0.17 198 0.87 0.19 32 0.86 0.23 
 8 110 0.88 0.19 146 0.85 0.16 29 0.90 0.17 
 9 55 0.51 0.07 66 0.52 0.08 12 0.54 0.09 
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studies and trait estimates with large variances (method derived from 
Thakkinstian et al. [2005]). 
 
Table 2.2 shows a section of the example data for gene D, as entered into 
Stata.  Study number is coded (1-32), there are 3 genotypes per study (coded 
as 1, 2 and 3) and each genotype has sample size (n), mean value of trait 
(mean) and standard deviation (SD) (from which the standard error (SE) was 
derived, from SD/√n). 
 
Stata code: 
xi: regress mean i.genotype i.study [aweight=1/se^2] 
testparm _Igenotype* 
 
Table 2.2  Section of data entered into Stata for the meta-ANOVA between gene D and a 
continuous trait.  The data have been rearranged from table 2.1 so that each genotype 
from each study represents a single observation in the meta-ANOVA and the standard 
error (SE) has been derived from the data.  
 
study genotype n mean sd se 
1 1 33 0.85 0.23 0.04 
1 2 155 0.97 0.25 0.02 
1 3 66 1.00 0.24 0.03 
2 1 32 1.80 0.10 0.02 
2 2 177 1.84 0.15 0.01 
2 3 45 1.95 0.45 0.07 
3 1 26 0.99 0.50 0.10 
3 2 261 1.04 0.49 0.03 
3 3 62 1.10 0.48 0.06 
.      
.      
.      
.      
32 3 144 0.74 0.21 0.02 
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Table 2.3 shows the results obtained using the seven example datasets.  
Using this meta-ANOVA approach, three of the example datasets show a 
significant association (at p<0.05) between the trait and genotype (B, D and 
F).  However, the results do not explain the nature of these associations.  For 
these analyses to be biologically informative, we need to know which of the 
genotypes/alleles are causing an increase in the trait and by how much.  So, 
carrying out a mean difference meta-analysis is still necessary, but we need a 
method for choosing the most appropriate genetic model.   
 
Thakkinstian et al. [2005], who described this meta-ANOVA first stage 
approach, chose the most appropriate genetic model by calculating pooled 
mean differences between each pair of genotypes (between groups AA and 
aa [D1], Aa and aa [D2], and groups AA and Aa [D3]).  They then used the 
following rules to choose the most appropriate genetic model: 
 
‚ (a) If D1 = D3 ≠ 0 and D2 = 0, then a recessive model is suggested. 
(b) If D1 = D2 ≠ 0 and D3 = 0, then a dominant model is suggested. 
(c) If D2 = -D3 ≠ 0 and D1 = 0, then a complete over-dominant model is 
suggested. 
(d) If D1 > D2  > 0 and D1 > D3  > 0 (or D1 < D2  < 0 and D1 < D3  < 0, then a 
co-dominant  model is suggested.‚ 
Table 2.3  meta-ANOVA results for the seven example datasets.  p-value for the test of 
‘genotype’ as a significant variable in the model. 
 
Gene number of studies p-value for association between genotype and trait 
A 10 p=0.26 
B 34 p=0.01 
C 3 p=0.71 
D 32 p<0.001 
E 5 p=0.37 
F 15 p=0.02 
G 9 p=0.58 
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(NB. a complete over-dominant model occurs when the two homozygotes 
have equal values and the heterozygotes have a different value) 
 
This method is limited as it is extremely unlikely that two mean differences 
would be exactly equal to each other, even if in the underlying model they 
were.  There is no measurement of the error in this method of simply 
comparing mean differences and it requires a subjective judgement to be 
made on which model is most appropriate.   
 
Typical post-hoc tests for ANOVA (e.g. Newman-Keuls, Tukey and Scheffe 
tests) may identify differences between the two extreme groups, but might 
not resolve what should be done with the intermediate group, and so are not 
useful when trying to deduce the genetic model.  So, I investigated several 
alternative methods for choosing a genetic model. 
 
2.4.2 Choosing a Genetic Model 








MD1 = the mean trait difference between Aa and aa, and 
MD2 = the mean trait difference between AA and aa 
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i.e. MD1 is the effect of having one ‘trait increasing’ allele and MD2 is the 
effect of having two ‘trait increasing’ alleles.  The ratio between these two 
relates to the genetic model. 
 
λ takes theoretical values depending on the underlying genetic model:  
0=recessive; 1=dominant; 0.5=co-dominant.  All methods are based on this 
relationship but there are several different ways λ can be estimated.  Here I 
describe and test three different methods. 
 
2.4.2.1 Method 1 
Calculate pooled MD1 and MD2 using traditional meta-analysis methods.  I 
used both random and fixed effects analyses in STATA.  The random effects 
analysis uses the DerSimonian & Laird method and the fixed effects analysis 
uses the Mantel-Haenszel method. 
 
Stata code for random effects: 
pooled MD1: 
metan nAa xAa sdAa naa xaa sdaa, random nostandard 
pooled MD2:  
metan nAA xAA sdAA naa xaa sdaa, random nostandard 
 
Stata code for fixed effects: 
pooled MD1:  
metan nAa xAa sdAa naa xaa sdaa, fixed nostandard 
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pooled MD2:  
metan nAA xAA sdAA naa xaa sdaa, fixed nostandard 
 
An overall estimate of λ can then be calculated: 
 
λ = (pooled MD1) / (pooled MD2) 
 
Table 2.4 shows the estimation of both random effects and fixed effects 
pooled MD1 and MD2 for gene D.  These pooled mean differences are then 
used to estimate λ: 
 
‘random effects’ λ = 0.025 / 0.050 = 0.50 
‘fixed effects’ λ = 0.013 / 0.021 = 0.62 
 
which both suggest a co-dominant genetic model.  The estimates of λ are 
both close to 0.5, but there is no estimation of the error. 
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2.4.2.2 Method 2 
Calculate λ for each study (using MD1/MD2) and weight each study to 
obtain an overall estimate of λ across all studies.   
 
The SEs for the two mean differences in a single study were averaged to 
obtain a study estimate of SE.  Weighting of the studies was then done using 
inverse variance (1/SE2).   















1 0.120 0.032 to 0.208 1.04 0.22 0.150 0.052 to 0.248 2.05 0.25 
2 0.040 -0.001 to 0.081 3.63 0.98 0.150 0.014 to 0.286 1.21 0.13 
3 0.050 -0.149 to 0.249 0.22 0.04 0.103 -0.122 to 0.328 0.49 0.05 
4 0.007 -0.069 to 0.083 1.34 0.29 0.016 -0.072 to 0.104 2.37 0.30 
5 0.020 -0.003 to 0.043 7.12 3.27 0.000 -0.025 to 0.025 6.58 3.87 
6 -0.100 -0.696 to 0.496 0.02 0.00 0.300 -0.365 to 0.965 0.06 0.01 
7 0.040 0.040 to -0.029 1.60 0.35 0.160 0.023 to 0.297 1.20 0.12 
8 -0.003 -0.048 to 0.042 3.15 0.81 0.009 -0.041 to 0.059 4.51 0.95 
9 -0.020 -0.185 to 0.145 0.31 0.06 0.080 -0.103 to 0.263 0.72 0.07 
10 0.100 0.038 to 0.162 1.94 0.44 0.080 0.014 to 0.146 3.39 0.53 
11 0.020 0.009 to 0.031 10.32 13.32 0.020 0.006 to 0.034 7.33 12.32 
12 0.000 -0.050 to 0.050 2.70 0.66 0.040 -0.028 to 0.108 3.29 0.50 
13 0.030 -0.069 to 0.129 0.83 0.17 0.150 0.031 to 0.269 1.51 0.16 
14 0.010 -0.096 to 0.116 0.73 0.15 0.090 -0.026 to 0.206 1.58 0.17 
15 0.150 0.062 to 0.238 1.03 0.21 0.150 0.056 to 0.244 2.15 0.26 
16 0.080 -0.103 to 0.263 0.26 0.05 0.020 -0.194 to 0.234 0.54 0.05 
17 0.030 0.006 to 0.054 6.73 2.87 0.010 -0.016 to 0.036 6.47 3.47 
18 0.070 -0.042 to 0.182 0.66 0.13 0.210 0.073 to 0.347 1.19 0.12 
19 0.060 0.012 to 0.108 2.88 0.72 0.270 0.214 to 0.326 4.05 0.75 
20 0.010 -0.061 to 0.081 1.51 0.33 0.120 0.031 to 0.209 2.32 0.29 
21 0.010 -0.008 to 0.028 8.28 4.97 0.010 -0.013 to 0.033 6.70 4.38 
22 0.050 -0.035 to 0.135 1.10 0.23 0.070 -0.032 to 0.172 1.93 0.23 
23 0.100 -0.040 to 0.240 0.43 0.09 0.100 -0.185 to 0.385 0.31 0.03 
24 -0.080 -0.194 to 0.034 0.64 0.13 0.020 -0.149 to 0.189 0.83 0.08 
25 0.042 -0.029 to 0.113 1.51 0.33 -0.015 -0.097 to 0.067 2.60 0.34 
26 -0.001 -0.010 to 0.008 10.94 21.64 0.009 -0.002 to 0.020 7.48 19.78 
27 0.050 -0.047 to 0.147 0.86 0.18 0.090 -0.025 to 0.205 1.60 0.18 
28 0.012 0.001 to 0.023 10.25 12.70 0.024 0.011 to 0.307 7.40 14.85 
29 0.010 0.003 to 0.017 11.31 33.02 0.020 0.012 to 0.028 7.59 33.75 
30 0.099 0.024 to 0.174 1.39 0.30 0.198 0.100 to 0.296 2.04 0.24 
31 0.060 -0.010 to 0.130 1.55 0.34 -0.033 -0.094 to 0.028 3.73 0.63 
32 0.070 0.030 to 0.110 3.71 1.01 0.020 -0.026 to 0.066 4.79 1.11 
pooled 
random 
0.025 0.015 to 0.034   0.050 0.033 to 0.066   
pooled 
fixed 
0.013 0.009 to 0.017   0.021 0.016 to 0.026   
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Pooled λ = 0.54, suggesting a co-dominant genetic model.  But, there is no 
estimation of the error. 
 
2.4.2.3 Method 3 
This final method aims to provide an estimate of λ and also provide a 
measurement of its precision.  Weighted linear regression is used to estimate 
Table 2.5  Results of λ estimation for example dataset, D.  λ is calculated for each study 
and weighted by 1/(the mean standard error of the two mean differences)
2
, to obtain the 
pooled estimate. 
 
 MD1 MD2 λ (MD1/MD2) weight weight (%) 
1 0.120 0.150 0.80 591 0.3 
2 0.040 0.150 0.27 473 0.2 
3 0.050 0.103 0.49 152 0.1 
4 0.007 0.016 0.44 869 0.4 
5 0.020 0.000 - - - 
6 -0.100 0.300 -0.33 21 0.0 
7 0.040 0.160 0.25 364 0.2 
8 -0.003 0.009 -0.33 2560 1.2 
9 -0.020 0.080 -0.25 210 0.1 
10 0.100 0.080 1.25 1208 0.5 
11 0.020 0.020 1.00 30416 13.8 
12 0.000 0.040 0.00 1341 0.6 
13 0.030 0.150 0.20 472 0.2 
14 0.010 0.090 0.11 742 0.3 
15 0.150 0.150 1.00 895 0.4 
16 0.080 0.020 4.00 114 0.1 
17 0.030 0.010 3.00 7899 3.6 
18 0.070 0.210 0.33 353 0.2 
19 0.060 0.270 0.22 1639 0.7 
20 0.010 0.120 0.08 789 0.4 
21 0.010 0.010 1.00 10914 4.9 
22 0.050 0.070 0.71 654 0.3 
23 0.100 0.100 1.00 90 0.0 
24 -0.080 0.020 -4.00 255 0.1 
25 0.042 -0.015 -2.80 881 0.4 
26 -0.001 0.009 -0.11 50045 22.7 
27 0.050 0.090 0.56 618 0.3 
28 0.012 0.024 0.50 30390 13.8 
29 0.010 0.020 0.50 72503 32.9 
30 0.099 0.198 0.80 548 0.2 
31 0.060 -0.033 0.27 601 0.3 
32 0.070 0.020 0.49 2092 0.9 
pooled   0.54   
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λ with MD1 (from each study) as the dependent variable and MD2 (from 
each study) as the independent variable, restricted to pass through (0,0) and 
with each study weighted by 1/(SE)2  (where the study SE is estimated as in 
method 2 – the mean of the SEs from the two MDs).  
The slope of the linear regression line represents λ and a 95% confidence 
interval (CI) of this estimate can be calculated. 
 
As can be seen from figure 2.1 the theoretical λ values of 0, 0.5 and 1 
correspond to three lines on the graph.  So as well as estimating λ and 
obtaining a 95% CI, the graph provides a useful visual representation of the 
data.  By plotting MD1 against MD2 and sizing the points according to the 






0.1 0.2 0.3 
1 = dominant 
0.5 = co-dominant 
0 = recessive 
MD1 
MD2  
Figure 2.1  Plot of MD1 against MD2.  A gradient of 0 represents a recessive genetic model, 
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After MD1 and MD2 for each study have been calculated the gradient of the 
regression line can be calculated. 
 
Stata code: 
regress MD1 MD2 [aweight=1/se^2], noconstant 
 
Figure 2.2 shows the example of gene D.  The estimated gradient of the 
regression line is 0.42 with a 95% CI of 0.27 to 0.57, suggesting that a co-
dominant model is appropriate.   
 
2.4.3 Mean Difference Meta-Analysis using Chosen Genetic Model 
Once the most appropriate genetic model has been selected the 
corresponding pooled mean difference can be estimated.  If a dominant or 
recessive model is selected then two of the three genotypes are combined and 
compared to the third genotype, using traditional meta-analysis methods for 
comparing two groups.  If a co-dominant model is selected then the three 
genotypes are compared and the average per-allele mean difference is 
calculated. 
 
Co-dominant: average of AA – Aa and Aa – aa 
 Dominant: AA,Aa – aa 
 Recessive: AA – Aa,aa 
 
The analyses were carried out in Stata using the ‘gametan’ command 
designed by Julian Higgins [J Higgins, personal communication, Nov,2006]. 
 







Figure 2.2 (A) Plot of MD1 against MD2 for example dataset D.  The bubbles represent 
each study, with size proportional to weight. (B) Plot showing λ. The red line is the weighted 
regression line, with a gradient (λ) of 0.42.  The black lines represent the 95% confidence 

























gametan AAn AAx AAsd Aan Aax Aasd aan aax aasd, codominant 
Dominant:  
gametan AAn AAx AAsd Aan Aax Aasd aan aax aasd, dominant 
Recessive:  
gametan AAn AAx AAsd Aan Aax Aasd aan aax aasd, recessive 
 
The recessive and dominant analyses essentially collapse the data into two 
groups and carry out standard ‘metan’ analyses . 
 
The co-dominant (per-allele) mean difference for gene D was 0.025 (95% CI 
0.017 to 0.033) using random effects meta-analysis.  Each step change (from 
aa to Aa, and from Aa to AA) corresponds to an increase in the trait of 0.025 
units. 
 
2.5 Results Using Test Data 
Table 2.6 shows the results of all methods described in this chapter for all 
seven test datasets.  Only genes B, D and F showed a significant association 
with the trait on ANOVA.  The genes that did not show a significant 
association with the trait in the ANOVA analysis often had conflicting λ 
estimates using the three methods and a large confidence interval for method 
3.   
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2.5.1 Genes B&D 
All λ estimation methods suggest that co-dominant genetic models are the 
most appropriate for both B and D genes and the 95% CIs for method 3 only 
span one genetic model (0.5, co-dominant).  Both genes showed a significant 
association with the trait in the meta-ANOVA analyses (p=0.01 and <0.001 
respectively), suggesting that there is an association between genotype and 
trait for both of these genes.  Using the most appropriate genetic model, co-
dominant, the per-allele pooled mean difference was estimated to be 0.014 
(95% CI, 0.005 to 0.022) for gene B and 0.025 (95% CI, 0.017 to 0.033) for gene 
D. 
 
2.5.2 Genes A, C, E & G 
The three methods for genotype model estimation for genes A, C, E and G 
gave conflicting and often nonsensical results (e.g. -2.05 for gene C, method 
Table 2.6  Results of the meta-ANOVA method, three λ estimation methods and the mean difference 
method for the 7 example datasets. *denotes the ANOVA results that showed a significant 
association between genotype and trait (p<0.05), **gene is associated but λ estimation methods give 

























difference (95% CI) 
A 8 0.26 0.79 0.31 -0.08 0.23 
(-0.15 to 0.61) 
no association - 
B 34 0.01* 0.46 0.67 0.70 0.52 
(0.41 to 0.62) 
co-dominant 0.014 
(0.005 to 0.022) 
C 3 0.71 0.08 0.75 -2.05 0.31 
(-2.26 to 2.87) 
no association - 
D 32 <0.001* 0.50 0.62 0.54 0.42 
(0.27 to 0.57) 
co-dominant 0.025 
(0.017 to 0.033) 
E 5 0.37 0.00 0.13 0.47 0.22 
(-0.35 to 0.79) 
no association - 
F 15 0.02* 0.10 0.63 0.79 0.23 
(0.08 to 0.39) 
** - 
G 9 0.58 0.03 0.00 0.01 0.38 
(0.14 to 0.62) 
no association - 
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2) and the 95% CIs for method 3 were very large, spanning multiple genetic 
models (e.g. -0.35 to 0.79 for gene E) .  However, none of these genes showed 
a significant association with trait in the meta-ANOVA analyses (p=0.26, 0.71, 
0.37, 0.58, respectively), and therefore estimating λ is essentially a 
meaningless task. 
 
2.5.3 Gene F 
Gene F was a significant variable in the meta-ANOVA analysis (p=0.02), 
suggesting an association between genotype and the trait.  Despite this, the 
three λ estimation methods gave different results.  Method 1 using random 
effects (λ=0.10) suggests a recessive genetic model, method 1 with fixed 
effects (λ=0.63) suggests a co-dominant genetic model, method 2 (λ=0.79) 
suggests a dominant model and the 95% CI for method 3 does not span any 
genetic model (0.08 to 0.39).  In the next section I use this gene to compare the 
different λ estimation methods and explain why they give different results, 
as well as choosing which method to use in my later analyses (chapter 3). 
 
2.6 Which Genetic Model Method to Use 
As gene F gave conflicting results for the various genetic model estimation 
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2.6.1 Results for gene F 
2.6.1.1 Method 1 
Table 2.7 shows the results for gene F. 
random effects analysis λ = 0.004 / 0.039 = 0.10 
fixed effects analysis λ = 0.005 / 0.008 = 0.63 
 
This method is essentially the same as that by Thakkinstian et al. [2005] 
described in section 2.4.1, except here I go further than just calculating the 
MDs and observing similarities and differences.  I actually calculate a ratio of 
these mean differences. 
 
Table 2.7  Results of MD1 and MD2 meta-analyses for example dataset F. 
 









1 0.040 -0.056 to 0.136 0.81 0.45 0.270 0.089 to 0.451 2.52 0.26 
2 0.029 -0.058 to 0.116 0.98 0.54 0.042 -0.061 to 0.145 5.19 0.81 
3 0.060 0.012 to 0.108 3.04 1.75 0.140 0.089 to 0.191 8.33 3.25 
4 0.050 -0.037 to 0.137 0.97 0.54 0.250 0.139 to 0.361 4.80 0.70 
5 0.050 -0.021 to 0.121 1.47 0.82 0.150 0.036 to 0.264 4.64 0.66 
6 0.070 -0.031 to 0.171 0.72 0.40 0.030 -0.094 to 0.154 4.23 0.56 
7 -0.012 -0.034 to 0.010 11.93 8.14 -0.050 -0.082 to -0.018 9.47 8.12 
8 0.007 0.005 to 0.009 39.03 62.01 0.006 0.003 to 0.009 10.30 66.68 
9 -0.017 -0.064 to 0.029 3.30 1.90 0.043 -0.050 to 0.136 5.70 0.98 
10 -0.006 0.038 to 0.026 6.54 4.01 -0.008 -0.079 to 0.062 7.08 1.73 
11 -0.004 0.047 to 0.039 3.78 2.20 0.091 -0.022 to 0.203 4.73 0.68 
12 0.000 0.025 to 0.025 10.22 6.73 0.010 -0.023 to 0.043 9.43 7.76 
13 0.024 -0.021 to 0.069 3.50 2.03 -0.055 -0.108 to -0.002 8.19 2.99 
14 -0.010 -0.039 to 0.019 7.79 4.89 -0.020 -0.073 to 0.033 8.20 3.01 








0.005 -0.001 to 0.011   0.008 -0.001 to 0.017   
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This method gives an estimate of λ but does not provide a measure of error 
for λ.  As the MD1 and MD2 estimates both include aa individuals, but one 
also includes Aa individuals, while the other also includes AA individuals, 
typical properties of variance cannot be applied to estimate a 95% CI for λ.  It 
is extremely unlikely that λ would be estimated to be exactly 0, 0.5, or 1 and 
so the nearest of these is the best guess, but with no measure of error we 
cannot tell how accurate the estimates are.  However, from simply observing 
the very wide 95% CIs of MD1 and MD2 for both random and fixed analyses, 
it is clear that the error around the estimate of λ would be very large.   
 
I used both random and fixed effects for this method as it is unclear which is 
the most appropriate.  Although one would expect λ to be a ‘fixed’ parameter 
(i.e. the genetic model will be the same in all populations), the MDs may be 
either fixed or random (i.e. the effect size of the genotype on the trait may 
differ between populations).  The random and fixed effects analyses gave 
very different results.  The random effects analysis λ estimation is closest to a 
recessive genetic model (λ=0.10) and the fixed effects analysis λ estimation is 
closest to a co-dominant model (λ=0.63).  This discrepancy arises because the 
two analyses weight the studies differently.  The fixed effects analysis gives 
much larger weighting to study 8 (which has a much smaller MD2 compared 
to the other studies), due to the much smaller variance in this study, whilst 
the random effects analysis weights studies with smaller variances less, and 
so is more influenced by (larger) MD2 estimates from other studies. 
 
There is a problem with both of these analyses, and this problem explains the 
discrepancy between the random and fixed effects analyses.  When MD1 and 
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MD2 are pooled separately across studies, the within-study comparisons are 
broken, and imbalances in the data (such as differing sizes of MDs between 
studies) results in bias.  This is similar to Simpson’s paradox, which shows 
that something true of each subgroup, need not be true of the whole 
population [Altman & Deeks, 2002].  MD1 and MD2 being pooled separately 
results in studies being given different weights for the two MDs.  For 
example, in study 8, in the random effects analysis, the weight for MD1 is 
39% and the weight for MD2 is 10%.  This study has particularly small MDs 
for both comparisons.  So by weighting the MDs differently MD2 becomes 
falsely inflated compared to MD1, resulting in a low estimation of λ.  This 
outcome is particularly enhanced in the random effects analysis compared to 
the fixed effects, as the fixed effects analysis appears to weight the studies 
more evenly.  Even so, it is clear that calculating pooled MDs separately and 
then calculating λ is inherently flawed and other methods that maintain the 
within-study comparison would be more appropriate. 
 
2.6.1.2 Method 2 
Here I estimate λ for each study and weight across studies.  This method was 
the simplest I could think of to maintain the within-study comparison of the 
data whilst estimating an overall estimate of λ. 
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The results for gene F using this method are shown in table 2.8.  This method 
suggests a dominant model (λ=0.79).  The between study estimates vary 
quite considerably (from -0.44 to 2.33).  The extreme estimates tend to come 
from small studies that have large standard errors of trait means and so are 
weighted less than larger studies. 
 
This method weights study 8 much more than any other (weight = 61% for 
this study), resulting in the estimate of λ being close to 1.   
 
Again, this method does not provide any measurement of precision for the 
estimate of λ.   
 
Table 2.8  Results of λ estimation for example dataset, F.  λ is calculated for each study 
and weighted by 1/(the average standard error of the two mean differences)
2
, to obtain 
the pooled estimate. 
 
 MD1 MD2 λ (MD1/MD2) weight weight (%) 
1 0.040 0.270 0.15 249 0.34 
2 0.029 0.042 0.69 443 0.60 
3 0.060 0.140 0.43 1989 2.69 
4 0.050 0.250 0.20 446 0.60 
5 0.050 0.150 0.33 509 0.69 
6 0.070 0.030 2.33 314 0.42 
7 -0.012 -0.050 0.24 6349 8.57 
8 0.007 0.006 1.17 44936 60.67 
9 -0.017 0.043 -0.40 1110 1.50 
10 -0.006 -0.008 0.74 3034 4.10 
11 -0.004 0.091 -0.05 1933 2.61 
12 0.000 0.010 0.00 5147 6.95 
13 0.024 -0.055 -0.44 1694 2.29 
14 -0.010 -0.020 0.50 3488 4.71 
15 0.000 0.020 0.00 2427 3.28 
pooled   0.79   
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2.6.1.3 Method 3 
Figure 2.3 shows the example of gene F.  The estimated gradient of the 
regression line (and hence the estimation of λ) is 0.23 with a 95% CI of 0.08 to 
0.39.  For this particular example the 95% CI does not include any of the three 
models, suggesting that none of recessive, dominant or co-dominant are 
appropriate.  However, as the estimate is closer to 0 than 0.5 or 1, I chose to 
perform meta-analysis for this gene using a recessive genetic model. 
 
Method 3 gives a different result to method 2 because a regression method 
will be more influenced by studies with a large MD1, MD2 or both, even 
though the two methods use the same weights.  Method 2 is heavily 
influenced by study 8, which has very small MD1 and MD2.  The MDs for 
study 8 are MD1=0.007 and MD2=0.006.  Method 2 would have given the 
same result if the MDs were of a greater magnitude (e.g. 0.7 and 0.6 -more 
convincing evidence for a λ of 1.2), but for method 3 the study would have 
had more influence if the MDs had been 0.7 and 0.6.  A study having more 
influence if it shows larger differences seems more appropriate.  Observing 
figure 2.3A it seems that a linear regression line λ=0 is more sensible than 
λ=1.  In addition, method 3 provides an estimate of the 95% CI surrounding 
the estimation of λ, which is useful in determining how precise it is. 
 





Figure 2.3 (A) Plot of MD1 against MD2 for example dataset F.  The bubbles represent each 
study, with size proportional to weight. (B) Plot showing λ. The red line is the weighted 
regression line, with a gradient (λ) of 0.23.  The black lines represent the 95% confidence 
limit for λ (0.08 to 0.39).  
0.1 
0.2 
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Carrying out a recessive meta-analysis, the mean difference was 0.031 (95% 
CI 0.000 to 0.061, p=0.051), which is (just) not significant, despite the meta-
ANOVA showing a significant association (p=0.02).  Carrying out the meta-
analysis using other genetic models did not give a significant result either.  
The mean difference may not reach formal significance because the genetic 
model used is inaccurate (λ=0.23, not 0) and/or because the overall 
association was of marginal significance, and statistical significance is lost in 
the collapsing of two groups.  If the two extreme genotypes are compared, 




Current methods used in meta-analysis of the association between 
continuous traits and genotypes are inadequate and often biased.  Most 
studies make multiple comparisons and do not account for this multiple 
testing.  I have investigated three methods of estimating which genetic model 
is the most appropriate, so that one meta-analysis can be carried out using 
this selected model. 
 
Of the three methods that estimate λ, method 3, the linear regression 
method, seems to be the most appropriate and useful.  Method 1 disrupts the 
within study comparison and hence introduces bias and method 2 heavily 
weights studies with small SE, regardless of the magnitude of the MDs, 
which may give counter-intuitive results.  Methods 1 and 2 provide no 
measurement of error of the estimate of λ.  Method 3 provides not only a 95% 
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CI, but also a graphical representation of how well the genetic model fits the 
data. 
 
Before the genetic model is estimated, meta-ANOVA is required to test for an 
overall association.  This is necessary as trying to choose the best genetic 
model when there is no association is meaningless and gives spurious and 
imprecise results as I have shown (genes A, C, E and G).  The 95% CI of λ in 
some cases spanned all three genetic models. 
 
Estimating λ using a linear regression method is more sophisticated than 
simply carrying out two or three meta-analyses and then comparing the 
results to choose the best model, as the estimate of λ along with its CI shows 
how strong the evidence is for choosing a particular genetic model.  It also 
means there is no issue of multiple testing. 
 
The method I describe here also allows the data to be analysed as using a co-
dominant (per-allele) model, should that be appropriate.  Many software 
packages for meta-analysis (such as RevMan [The Cochrane Collaboration, 
2006]) cannot do this.  
 
For genes B and D, significant p-values in the meta-ANOVA suggest an 
association and the linear regression estimates λ to be close to 0.5, suggesting 
a co-dominant model.  Using a co-dominant model to analyse these 
associations shows the mean differences are small but significant.  For gene 
F, although a significant p-value was obtained in the meta-ANOVA there 
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was no association when analysing the data using the chosen genetic model.  
λ was estimated to be 0.23 (95% CI 0.08 to 0.39) which does not include any 
of the three assumed models, so the closest model was chosen: recessive.  As 
theoretically a genetic model where λ is 0.23 is possible, this highlights that 
genetic studies that assume a model to be recessive, dominant or co-
dominant have limitations.  Comparing AA with aa for this gene there is a 
significant difference and so in specific cases of marginal significance, a 
meta-ANOVA may show association, whilst the mean difference meta-
analysis does not. 
 
Eliminating genes from the mean difference meta-analysis that showed no 
overall association on meta-ANOVA does mean that results for genes which 
have not quite reached significance in the first stage are not plotted out on a 
forest plot.  It is sometimes of interest to view a forest plot of the mean 
differences even if there is no statistically significant association.  It may be 
that the association between the gene and trait has not reached significance 
because it has not been studied in large enough numbers yet or that a 
significant association is only found in a subgroup of the studies (e.g. in 
those individuals of a particular ethnicity).  However, as a forest plot 
compares two groups and there is no unbiased way of selecting which two 
groups to compare for these genes, a forest plot is inappropriate.  If it is still 
desirable to view a display of this data the three means and SDs for each 
study could be plotted. 
 
The method I devised is simple and quick to use and is an improvement on 
most current methods used to analyse genetic meta-analyses.   
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2.8 Method Used in Future Chapters 
For the meta-analyses in chapter (3) of this thesis, I use a three-step meta-
analysis approach: 
i. Use the meta-ANOVA method (described in section 2.4.1) to test 
for an overall association between a polymorphism and a trait,  
ii. For those that show a significant association, investigate the 
genetic model using a novel linear regression method (as described 
in section 2.4.2.3) 
iii. Use the most appropriate genetic model from ii) to carry out a 
traditional two group comparison or per-allele mean difference 
meta-analysis (as described in section 2.4.3). 
 
The Stata (version 7.0, [StataCorp., 2001]) step by step code I devised is 





3 CIMT Systematic Review and Meta-Analysis 
 
This chapter comprises a systematic review and meta-analyses of the most 
commonly studied genetic polymorphisms in association with carotid 
intima-media thickness. 
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3.1 Introduction 
3.1.1 Carotid Intima-Media Thickness 
Carotid intima-media thickness (CIMT) is an atherosclerotic trait, measured 
non-invasively by B-mode ultrasonography (figure 3.1).  The carotid artery is 
the main artery supplying oxygenated blood to the head.  There is one 
carotid artery on each side of the neck.  CIMT has been commonly 
investigated and typical mean CIMT values reported in population-based 
studies were between 0.63 and 0.80mm [Lorenz et al., 2007].  The standard 
deviations of the means from these studies were consistently 0.15 or 0.16.   
 
CIMT is a marker of atherosclerosis and a surrogate of vascular disease 
[Greenland et al., 2000] and is a strong predictor of future myocardial 
infarction and stroke [Lorenz et al., 2007].  CIMT has been shown to be 
 
Figure 3.1  Carotid artery ultrasound scan procedure. Illustration from A.D.A.M. Inc. 
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greater in patients with large artery, compared to those with small artery 
ischaemic stroke, with a mean difference between the two groups of 0.16mm 
(95% CI 0.09 to 0.23) [Pruissen et al., 2007]. 
 
CIMT is a commonly used intermediate phenotype for early atherosclerosis 
and large artery stroke [Dichgans & Markus, 2005].  Studying CIMT may be a 
powerful way to determine which genes influence risk of large artery stroke. 
 
3.1.2 Measurement Methods 
CIMT can be measured using B-mode real-time imaging, with a transducer 
being placed against the neck close to the carotid artery.  An image is 
normally returned to a screen and image-analysing software can give 
estimates of CIMT at various positions.  There are many different sites of the 
carotid artery that can be measured and many different ways in which the 
thickness can be reported.   
 
There are different sections to the carotid artery:  the common carotid artery 
(CCA) – the first part of this arterial group that branches from the 
brachiocephalic artery on the right and the aortic arch on the left side; the 
internal carotid artery (ICA) – one of the two branches from the CCA which 
supplies blood to the brain; the external carotid artery (ECA) – the other 
branch from the CCA, supplying blood to the anterior parts of the neck and 
the face; and the place where these three arteries join - the bifurcation (BIF).  
Measurements can be made in any of these segments.  The ECA thickness is 
not important as a predictor of stroke, while ICA is harder to measure than 
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the CCA, which is more reproducible [O'Leary et al., 1991].  Figure 3.2, taken 
from Lorenz [2007] shows the different definitions that several large clinical 
studies have used for the sections of CIMT measurement.  Studies use very 
different definitions for the CCA, some of which do not even overlap, 
illustrating the considerable heterogeneity in carotid measurement methods 
across studies. 
 
Some studies measure both the near and far walls.  Van Bortel [2005] 
suggests that measuring only the far wall may be more precise, because near 
wall measurements are performed at the trailing edge of the ultrasound 
pulse and variability is higher for this wall [Wendelhag et al., 1991]; 
[Wikstrand & Wiklund, 1992].  Some studies report a maximum CIMT, 
whilst others report a mean across several measurements.   
 
The inconsistencies in CIMT measurement have been well documented and 
 
 
Figure 3.2  Definitions of the carotid segments in several large scale clinical studies.  
Illustration from [Lorenz et al., 2007]. 
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have led to the Mannheim Intima-Media Thickness consensus [Touboul et al., 
2004], which aims to persuade future studies to use standardised definitions 
and measurement methods, to enable more meaningful comparisons of 
results across studies.  They propose that standard measurements should be 
of a plaque free region of the far wall of the CCA, ICA or BIF. 
 
A study has shown that inter- and intra-observer variability of CIMT 
measurements is small [O'Leary et al., 1991]. 
 
3.1.3 Heritability 
The first estimate of the heritability of CIMT was extremely high – 0.92 
[Duggirala et al., 1996].  This study used 46 sibships from Mexico City, and 
probably overestimated the heritability, as it was very small and did not 
account for shared environmental factors.  Subsequent studies have 
produced more moderate heritability estimates.  The Northern Manhattan 
Family Study report an age- and sex-adjusted CCA CIMT heritability of 0.39 
using 440 subjects from 77 community based families [Juo et al., 2004].  The 
Framingham Heart Study, which studied data from 1886 subjects from 586 
families reported an age- and sex-adjusted CCA CIMT heritability of 0.44 
[Fox et al., 2003].  A further study among 565 subjects from 154 families with 
a parent affected with carotid artery atherosclerosis found a higher 
heritability of 0.61, adjusted for age, sex hypertension, diabetes mellitus and 
lipoprotein (a) [Moskau et al., 2005].  A study of 252 diabetic subjects 
estimated the age- sex- and race-adjusted heritability as 0.32 [Lange et al., 
2002].  Despite the wide-ranging estimates, it seems that CIMT has at least a 
moderate heritability. 
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3.1.4 Genetic Associations 
Hundreds of studies have attempted to identify the genes that are 
responsible for this genetic influence on CIMT.  More than 90 candidate 
genes have been studied for an association with CIMT [Manolio et al., 2004; 
Pollex & Hegele, 2006].  However, these have been conflicting and generally 
only included small numbers of subjects, preventing firm conclusions from 
being made.  Although some reviews have attempted to provide an overview 




I aimed to identify all studies that have analysed the association between 
CIMT and any gene.  For the most commonly studied genes I systematically 
sought every relevant paper and carried out meta-analyses to provide a 
summary estimate of the association using all available data.  I also aimed to 
identify sources of heterogeneity between studies 
 
3.2 Methods 
3.2.1 Initial Search Strategy 
I sought all papers describing the association between any gene and CIMT, 
using comprehensive, electronic search strategies in Medline (1966 to end 
2007) and Embase (1980 to end 2007).  I combined MeSH terms and 
textwords to ensure a highly sensitive search strategy.  Table 3.1 shows the 
search strategy for Medline; a similar search was used in Embase. 
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3.2.2 Genes Selected for Meta-Analysis 
I read the titles of all studies identified from the search and excluded any 
papers that were obviously not relevant.  I then read the abstracts (or full 
papers where no abstract was available) of all remaining studies and retained  
all potentially relevant studies (any original study of the association between 
any gene and CIMT).  I listed all genes that had been studied in association 
with CIMT and calculated the approximate number of studies and subjects 
for each gene. 
 
Table 3.1  Medline search strategy for all genetic CIMT studies. 
Stage 1 Medline search strategy* 
1     exp carotid artery diseases/ge 
2     exp carotid arteries/ 
3    (carotid adj8 (atherosclero$ or stenos$ or plaque$ or imt or cimt or arteriosclero$ or 
intima media$ or intimal media$ or ultrasound or sclero$ or atheroma$ or wall or 
thick$)).tw. 
4     2 or 3 
5    exp genetics/ or exp genotype/ or exp inheritance patterns/ or exp "linkage (genetics)"/ 
or exp phenotype/ or exp "variation (genetics)"/ or chromosomes/ or exp genes/ or 
exp genome/ 
6     (polymorphi$ or genotyp$ or gene or genes or genetic$ or allel$ or mutat$).tw. 
7     5 or 6 
8     4 and 7 
9     1 or 8 
10     limit 9 to humans 
* I used a similar, appropriately adapted strategy for Embase 
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I selected, for my systematic review and meta-analysis, any gene that had 
been studied in an estimated total of >7000 subjects.  I also selected any gene 
studied in an estimated total of >3000 subjects if the largest study had >3000 
subjects.  These cut-offs were chosen to restrict the detailed analysis to those 
polymorphisms for which results were likely to be the most precise and 
reliable, avoiding meta-analyses of multiple small studies of less extensively  
studied polymorphisms which would be likely to yield largely 
uninformative - or even potentially misleading - results.  The precise cut-off 
chosen was based on feasibility. 
 
Table 3.2  Medline search strategy for MTHFR CIMT studies. 
Stage 2 Medline search strategy for MTHFR* 
1     exp carotid artery diseases/ge 
2     exp carotid arteries/ 
3    (carotid adj8 (atherosclero$ or stenos$ or plaque$ or imt or cimt or arteriosclero$ or  
intima            media$ or intimal media$ or ultrasound or sclero$ or atheroma$ or wall or 
thick$)).tw. 
4     1 or 2 or 3 
5     exp "Methylenetetrahydrofolate Reductase (NADPH2)"/ge [Genetics] 
6     (MTHFR or methylenetetrahydrofolate or c677t or nadph2).tw. 
7     methylene tetrahydrofolate.tw. 
8     5 or 6 or 7 
9     4 and 8 
* I used a similar, appropriately adapted strategy for Embase.  The specific terms used in 
the other gene-specific searches are shown in appendix 2. 
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3.2.3 Gene Specific Searches and Study Selection 
To ensure that all potentially relevant papers had been identified, I carried 
out a series of supplementary searches for the selected genes in Medline and 
Embase, replacing the general genetics terms with gene-specific terms (see 
table 3.2 and appendix 2).  Again, I read all the titles or abstracts and retained 
all relevant studies.  A second person (one of: Nahara Martinez-Gonzalez, 
Rebecca Charleton, Mabel Chung) independently read all the titles or 
abstracts and selected the papers they felt to be relevant.  Comparing these, I 
compiled a final list of relevant studies. 
 
I obtained the full articles of these potentially relevant studies.  Studies in all 
languages were included, and I obtained translations where necessary.  I 
checked the reference lists of all relevant articles for further relevant studies 
that may have been missed by the electronic searches. 
 
Studies were included if they had assessed the association between variation 
in one of the selected genes and a measure of the thickness of the intima-
media of the carotid artery.  I excluded studies of IMT of other arteries, 
studies of frank atheroma and plaque, and studies that had only measured a 
change or rate of change in CIMT.  To avoid double counting, where two or 
more studies used overlapping subjects, I used only the largest available 
published dataset and excluded the other study/ies. 
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3.2.4 Data Extraction 
I extracted the following information from the papers and entered it into pre-
designed spreadsheets: first author and year of publication; total number of 
subjects studied; country in which the study was conducted; ethnicity of the 
subjects; types of subjects studied (e.g. healthy volunteers, general 
population sample, subjects with hypertension, subjects with diabetes); mean 
age and gender distribution of subjects; candidate gene(s) and 
polymorphism(s) studied; number of subjects with each genotype; whether 
the genotypes of subjects conformed to Hardy-Weinberg equilibrium; 
method of CIMT measurement; mean CIMT (and standard deviation) of 
subjects with each genotype.  
 
Where studies had presented data separately for subjects defined by different 
criteria (such as ethnicity, or presence/absence of specific medical condition), 
I extracted data for each group separately, and analysed these as separate 
sub-studies (e.g. i, ii, iii). 
 
A second person (one of Nahara Martinez-Gonzalez, Rebecca Charleton or 
Mabel Chung) independently reviewed study eligibility and extracted the 
information and data from each study.  We resolved differences by 
discussion and mutual consensus, and if necessary discussed with Steff 
Lewis or Cathie Sudlow, to reach consensus. 
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3.2.5 Data Manipulation 
Where papers did not present data in the required format I had to carry out 
transformations of the data.  The common transformations are shown below, 
with examples presented in appendix 3.  Other transformations that were 
particular to certain studies are also presented in appendix 3. 
 
 Combining groups of subjects within a paper.  For some studies I 
had to combine means from two or more groups to obtain the data of 
interest, for example: to combine the mean (and SD) CIMT for men 
and women, where they were presented separately; to determine the 
CIMT results per APOE group (E2,E3,E4) where results for all 
genotypes were presented separately; and in many cases to estimate 
the mean age across all subjects within a study.   
 
 I used the following formula to obtain the overall mean when 







where ni represents the sample size of the ith group, and µi 
represents the mean of the ith group. 
 
I used the following formula to obtain the overall variance when 
 combining two groups: 



















where σ2i  represents the variance of the ith group 
 
 I expanded these formulae to include more than two groups  where 
necessary. 
 
An example of this data transformation is presented in appendix 3.1 
and an example of combining measurements within individuals 
(which is different) is presented in appendix 3.2. 
 
 Converting standard errors to standard deviations. Where studies 
had only reported the former I used the following formula: 
nerrorstandarddeviation standard  
 where n is the size of the sample for which the standard error refers. 
 
 Converting confidence intervals to standard deviations. Where 




deviation standard  
where ‘upper’ and ‘lower’ are the limits of the 95% CI. 
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 Estimating numbers of subjects.  In some papers, only genotype 
proportions were reported, not actual numbers for each genotype.  In 
these cases, I used the total number of subjects and the genotype 
frequencies to estimate the number of subjects per genotype, but often 
several actual values were possible and so I had to make a best guess. 
 An example of this data transformation is presented in appendix 3.3. 
 
 Other transformations 
 There was a small number of papers that required specific 
transformations, such as estimating numbers from a graph, or 
transforming the CIMT data from sums to means.  These specific cases 
are presented in appendix 3.4 to 3.10. 
 
3.2.6 Attempts to Acquire Missing Data 
Where papers did not present the required data, and it could not be 
calculated, I contacted the corresponding authors of the papers.  I designed a 
standardised data collection form and emailed this along with a letter to each 
author (see appendix 4).   
 
3.2.7 Statistical Analysis 
I used the three-step meta-analysis method described in chapter 2 to 
investigate the association with CIMT of each genetic polymorphism. 
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The method is briefly as follows: 
1. Determine whether there is an overall association between each 
genotype and CIMT, by carrying out a meta-analysis of variance 
(meta-ANOVA) of CIMT, with study and genotype as categorical 
variables, weighting studies by the inverse of the square of the 
standard error of the mean CIMT. 
2. Where I found a statistically significant overall association (p<0.05) 
in step 1, I went on to determine the most appropriate genetic 
model (λ), using a linear regression method to estimate λ (where 
0=recessive, 0.5=co-dominant, 1=dominant).   
3. Using the most appropriate genetic model from step 2, I calculated 
pooled mean CIMT differences between genotype groups 
(combining two genotype groups for recessive and dominant 
models and calculating a per-allele mean difference for co-
dominant models). 
 
Most polymorphisms are single mutations, resulting in two alleles and 
therefore three genotypes.  Apolipoprotein E (APOE) has three alleles (ε2, ε3, 
ε4), making six genotypes.  Conventionally the rare ε2ε4 genotype is 
commonly disregarded and the remaining genotypes are grouped into three 
groups: E2 (ε2ε2, ε2ε3); E3 (ε3ε3); E4 (ε3ε4, ε4ε4).  I analysed APOE using 
these three groups and so the genetic models refer to these groupings and 
not the individual genotypes. For example the ‘co-dominant model’ does not 
represent a per-allele difference, but the (equal) difference between E4 and 
E3 genotypes , and E3 and E2 genotypes.  
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Where there was only one study for a particular polymorphism I carried out 
ANOVA (instead of meta-ANOVA), and I based the genetic model selection 
on the single study (λ = MD1/MD2).  Where MD1 is the mean CIMT 
difference Aa and aa genotypes, and MD2 is the mean CIMT difference 
between AA and aa genotypes. 
 
Where full genotype data needed for meta-ANOVA and genetic model 
selection were unavailable but the relevant studies had consistently reported 
and analysed data according to a particular genetic model, I used that model 
for the meta-analysis of that polymorphism. 
 
I assessed the extent of heterogeneity between studies using the I2 statistic. I2 
is an estimate of the percentage of variation between studies that cannot be 
attributed to chance [Higgins et al., 2003].  
 
Before carrying out the meta-analyses, I pre-specified several subgroup 
analyses.  These were: study size (splitting into large and small, where large 
studies are those larger than the mean number of subjects across all eligible 
studies or sub-studies for that polymorphism); ethnicity (White, East Asian, 
South Asian, Black); vascular risk status (high – subjects with a history of 
vascular disease or with vascular risk factors such as diabetes or 
hypertension, low – healthy subjects or from a general population).  I carried 
out these sub-group analyses for all polymorphisms that showed a 
significant overall effect and had been studied in sufficient number of studies 
to allow this analysis.  The within subgroup I2 statistics are reported and I 
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tested for significant heterogeneity between subgroups using the Q-test, as 
suggested by Deeks et al. [2001]. 
 
I carried out all analyses in Stata (version 7.0 [StataCorp., 2001]) – code for 
the three-step meta-analysis method is shown in appendix 1.  Random effects 
mean differences were calculated in the primary analyses.  Fixed effects 
mean differences were also calculated in secondary analyses. 
 
I could not include in the formal meta-analyses any study for which the 
necessary data were unavailable (even after contacting authors).  I quantified 
the proportion of these unavailable data and in an attempt to minimise the 
impact of bias due to missing data, I extracted qualitative statements on the 
presence or absence of an association from the papers (where available) and 
informally assessed how the inclusion of this data may have affected the 
conclusions. 
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3.3 Results 
3.3.1 Genes Commonly Studied 
The first stage of the search strategy yielded 2319 papers, 384 of which 
appeared to be potentially relevant from reading the titles and abstracts.  
Appendix 5 shows the full table of the estimated numbers of all genes.  The 
top part of the table is shown in table 3.3.  I carried out formal systematic  
Table 3.3  Most studied for CIMT genes (top section of full table – appendix 5).  Grey 
shaded genes are those selected for systematic review and meta-analysis. 





Apolipoprotein E 37493 47 12491 
Angiotensin converting enzyme 23935 51 5321 
Methylenetetrahydrofolate reductase 14205 33 3247 
Nitric oxide synthase 3 9434 19 2448 
Paraoxonase 1 8921 27 1786 
Adducin 1 8535 5 6471 
Angiotensinogen 7515 19 737 
Interleukin 6 7190 10 2421 
C-reactive protein 6603 3 4641 
CD14 molecule 5943 7 1110 
Factor V 5828 5 3750 
Toll-like receptor 4 5638 6 2955 
Apolipoprotein A1/C3 5363 8 2265 
Hemachromatosis 5288 4 2932 
Adrenergic beta-2 receptor 5249 1 5249 
Angiotensin II receptor, type 1 5117 14 737 
Cholesteryl ester transfer protein 4387 7 2632 
Fibrinogen gamma/alpha 4274 1 4274 
Insulin-like growth factor 1 4239 2 3769 
Lipoprotein lipase 4178 10 2445 
Adiponectin 4035 4 1745 
Apolipoprotein B 3386 7 326 
Hepatic lipase 3181 4 2268 
Toll-like receptor 2 3000 2 2955 
peroxisome proliferator-activated 
receptor alpha 2991 2 2301 
peroxisome proliferator-activated 
receptor gamma 2963 2 1379 
Tumor necrosis factor 1 2737 1 2737 
Maxtix metallopeptidase 3 2531 5 1111 
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Table 3.4  Function and estimated and final numbers of relevant studies and subjects for the 
13 selected polymorphisms. 
Gene (polymorphism) Function of              
protein product 
Estimated 
number of studies 
(subjects) 
Final number of studies 
fulfilling inclusion criteria 
(subjects) 
APOE (ε2, ε3, ε4) Lipid metabolism 47 (37493) 30 (32995) 
ACE (I/D) Renin-angiotensin system 
(BP/fluid balance) 
51 (23935) 39 (20105) 
MTHFR (677 C/T) Homocysteine 
metabolism 
33 (14205) 20 (10487) 
NOS3 (Glu298Asp) Vascular smooth muscle 
+ endothelial function 
19 (9434) 12 (7475) 
ADD1 (Gly460Trp) Endoskeletal protein 
involved in BP regulation 
5 (8535) 4 (6056) 
PON1 (Gln192Arg) LDL modification 27 (8921) 14 (4651) 
IL6 (-174 G/C) Cytokine involved in acute 
phase response 
10 (7190) 7 (4595) 
IGF1 (192bp allele) Interacts with insulin to 
control carbohydrate 
metabolism 
2 (4239) 1 (5132) 
ADRB2 (Gln27Glu) Intracellular signal 
transduction 
1 (5249) 1 (5173) 
CRP  
(5 SNPs -790 A/T, 
1919 A/T, 2667 G/C, 
3872 G/A, 5237 A/G) 
Inflammation 3 (6603) 1 (4641) 
FGG/FGA  
(7 SNP haplotype) 
Coagulation factor 1 (4274) 1 (4274) 
AGT (Met235Thr) Renin-angiotensin system 
(BP/fluid balance) 
19 (7515) 11 (3528) 
FV (Leiden) Activation of thrombin 5 (5828) 3 (3525) 
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reviews for all genes with an estimated total of >7000 subjects (APOE, ACE, 
MTHFR, PON1, NOS3, ADD1, AGT, IL6) and any additional gene which had 
been studied in a total of >3000 subjects where the largest individual study 
included >3000 subjects (ADRB2, FGG/FGA, CRP, IGF1, FV).   
 
3.3.2 Study Selection for Meta-Analyses 
I identified 122 studies (103,804 individual subjects – 112,713 when ‘multi-
counting’ subjects for whom multiple genes were analysed in individual 
studies) that had analysed the association between CIMT and one of the 13 
genes of interest.  
 
The final numbers of relevant papers and subjects for each genetic 
polymorphism after carrying out supplementary searches and excluding any 
overlapping or irrelevant papers are shown in table 3.4.  The final numbers of 
relevant studies for each gene were often substantially smaller than the 
estimated numbers from stage 1.   This was because the gene-specific 
searches added only a few papers, but papers were excluded where they did 
not fulfill the inclusion criteria after careful consideration, or contained 
overlapping or identical groups of subjects. 
 
3.3.3 Collection of Missing Data 
Of the 122 studies of interest, 38 (including 21,794 subjects) did not have the 
necessary full data available in the published papers. 19% of data was 
initially missing.  I contacted authors of these studies and 13 authors 
responded with the necessary missing data [Altamura et al., 2007; Asakimori 
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et al., 2003; de Maat et al., 2003; Fortunato et al., 2003; Junyent et al., 2006; 
Karvonen et al., 2002b; Karvonen et al., 2004; Kelemen et al., 2004; Lembo et 
al., 2001; Mayosi et al., 2005; McDonald et al., 2005; Varda et al., 2005; Visvikis 
et al., 2000].  I therefore managed to retrieve 26% (5596/21794 subjects) of the 
‚missing‛ data and reduced the overall proportion of ‚missing‛ data to 14%.  
Table 3.5 shows, for each genetic polymorphism, the number of papers with 
(i) full data available from the published paper, (ii) full data made available 
from the authors, (iii) full data not available, despite contacting authors.  The 
papers that still had ‘missing data’ after this data collection stage are shaded 
grey in the study characteristics table (table 3.6). 
 
3.3.4 Study Characteristics 
Table 3.6 shows the summary characteristics extracted from all relevant sub-
studies for the 13 genes.  Sample sizes ranged from 47 to 9304 (mean=708).  
White subjects from Europe, Australia and the US made up the majority of 
the subjects. Several studies were carried out in Eastern Asian subjects from 
China, Japan and Taiwan (one recruited subjects from Canada with Eastern 
Asian heritage).  One study recruited subjects from Canada with Southern 
Asian heritage.  Four studies were carried out in Black Americans. 
 
Subjects were mostly middle-aged to elderly.  Most were from general 
population samples or healthy volunteers, but some were of selected subjects 
at high vascular risk.  Genotypes were mostly in Hardy-Weinberg 
equilibrium (81% of studies), and where they were not (6%), the subjects 
were generally selected patient groups, for whom Hardy-Weinberg 




Table 3.5  Number of studies (and subjects) with and without sufficient data for meta-analysis, both from the publications and from correspondence with the 
authors for the 13 genes. 
Gene  Number of studies with 
sufficient data for analysis 
in publication 
Number of studies where 
authors provided me with 
necessary data  
Papers which provided me with necessary data Number of studies with 
unavailable data. 
APOE  23 (31316) 4 (937) Karvonen 2002; Asakimori 2003;Junyent 2006; Altamura 
2007 
3 (742) 
ACE 29 (16934) 1 (104) Varda 2005 9 (3067) 
MTHFR  10 (6235) 3 (1710) DeMaat 2003; Kelemen 2004; McDonald 2005 7 (2542) 
NOS3  5 (4015) 1 (375) Lembo 2001 6 (3085) 
ADD1 3 (5636) -  1 (420) 
PON1 5 (905) 3 (1647) Visvikis 2000; Fortunato 2003; Karvonen 2004 6 (2099) 
IL6 4 (2272) 1 (823) Mayosi 2005 2 (1500) 
IGF1 1 (5132) -  - 
ADRB2 1 (1573)† -  - 
CRP  1 (4641) -  - 
FGG/FGA  1 (4274)† -  - 
AGT  6 (1255) -  5 (2273) 




Table 3.6 Characteristics of studies included for each of the 13 selected genes 
         CIMT measurement method 




Country Ethnicity of 
subjects 
Type of subjects Mean age ± SD % male Vascular 
risk status 





APOE             
[Terry et al., 1996] 254 US White Coronary angiography referrals 59±9 50 High  CCA Both Both Mean of max of 4 sites 
[Cattin et al., 1997] 254 Italy White Population sample 53±7 46 Low  CCA Both Both Mean of right and left 
[Kogawa et al., 1997]i 349 Japan E.Asian NIDDM patients 60±11 58 High  CCA/BIF * * Mean of 3 sites 
[Kogawa et al., 1997]ii 231 Japan E.Asian Non-diabetic subjects 51±11 37 Low  CCA/BIF * * Mean of 3 sites 
[Olmer et al., 1997]
†
 66 France White Haemodialysis patients 50±15 50 High  CCA Far Both Mean of 3 each side 
[Vauhkonen et al., 1997]i
‡
 83 Finland White NIDDM patients 56±7 52 High  CCA/BIF Far Both Mean of max of 4 sites 
[Vauhkonen et al., 1997]ii
‡
  123 Finland White Population sample 54±5 46 Low  CCA/BIF Far Both Mean of max of 4 sites 
[Sass et al., 1998] 144 France White Population sample 41±4 52 Low * CCA * Both Mean of 2 each side 
[Zhang et al., 1998] 52 China E.Asian CHD patients 57±8 100 High  CCA/BIF/ICA Far Both Mean of 8 sites 
[Guz et al., 2000] 261 Turkey White Haemodialysis patients 46±15 57 High  CCA * Both Mean of 3 each side 
[Hanon et al., 2000] 312 France White Patients with vascular risk factors/disease 49±12 53 High * CCA Far Right One measurement 
[Horejsi et al., 2000] 112 Czech Republic White Lipoprotein disorder patients 53±* 45 High * CCA Far * Mean of max of 3 sites 
[Ilveskoski et al., 2000] 189 Finland White Population sample 54±3 100 Low  CCA Both Both Max of 4 sites 
[Slooter et al., 2001] 5264 Netherlands White Population sample 69±9 41 Low  CCA Far Both Mean of left and right 
[Tabara et al., 2001] 202 Japan E.Asian Population sample 70±9 32 Low  CCA Far  Right Mean of 3 sites 
[Haraki et al., 2002] 95 Japan E.Asian Healthy subjects 50±8 100 Low  CCA Far Right Mean of 9 sites 
[Karvonen et al., 2002b]i 258 Finland White Hypertensive patients 51±6 100 High  CCA/BIF/ICA Far Both Mean of 20 sites 
[Karvonen et al., 2002b]ii 253 Finland White Population sample 51±6 100 Low  CCA/BIF/ICA Far Both Mean of 10 sites 
[Asakimori et al., 2003] 162 Japan E.Asian Haemodialysis patients 55±11 52 High  CCA Far Both Maximum 
[Beilby et al., 2003] 1079 Australia White Population sample 53±13 50 Low  CCA Far Both Mean of 3 each side 
[Li et al., 2003] 92 China E.Asian Hypertensive patients 64±11 55 High  CCA * * * 
[Xiang et al., 2003]i 253 China E.Asian NIDDM patients * * High  CCA/BIF/ICA Far Both Mean of 3 each side 
[Xiang et al., 2003]ii 106 China E.Asian Healthy controls * * Low  CCA/BIF/ICA Far Both Mean of 3 each side 
[Elosua et al., 2004] 2723 US White Population sample 59±10 48 Low  CCA Both Both Mean of max each side 
[Fernandez et al., 2004] 225 Spain White CHD patients 61±8 85 High * CCA Far Both Mean of 3 each side 
[Kahraman et al., 2004] 118 Turkey White Renal transplant recipients 40±8 68 High * CCA * Both Mean of left and right 
[Bednarska et al., 2005] 127 Poland White Alcoholics 49±6 100 High  CCA Far  Both Mean of 3 each side 
[Bleil et al., 2006] 182 US White Hypertensive patients 56±9 100 High  CCA/BIF/ICA Both Both Mean of all sites 
[Brenner et al., 2006]
†
 470 France White Ischaemic stroke patients range 18-85 * High * CCA Far Both Mean of right and left 
[Debette et al., 2006] 5764 France White Population sample 74±5 40 Low  CCA Far Both Mean of right and left 
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Type of subjects Mean age ± SD % male Vascular 
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[Junyent et al., 2006] 163 Spain White Familial hypercholesterolaemia patients 47±* * High  CCA Far Both Mean of right and left 
[Volcik et al., 2006]i 3187 US Black Population sample range 45-64** * Low  CCA/BIF/ICA * Both Mean of 6 sites 
[Volcik et al., 2006]ii 9304 US White Population sample range 45-64** * Low  CCA/BIF/ICA * Both Mean of 6 sites 
[Altamura et al., 2007]i 68 Italy White Alzheimer disease patients 75±8 31 High * CCA * Both Mean of right and left 
[Altamura et al., 2007]ii 33 Italy White Vascular dementia patients 77±8 51 High * CCA * Both Mean of right and left 
[Wohlin et al., 2007] 437 Sweden White Population sample all 75 100 Low  CCA Far Both Mean of 3 each side 
ACE             
[Castellano et al., 1995] 187 Italy White Population sample 58±3 52 Low  CCA/BIF/ICA  Both Mean of all sites 
[Dessi-Fulgheri et al., 1995] 240 Italy White Outpatients without vascular risk factors 53±7 57 Low  CCA/BIF/ICA Both Both Mean 
[Markus et al., 1995] 101 UK White Ischaemic CVD patients 65±9 68 High  CCA Far * Maximum 
[Kauma et al., 1996] 515 Finland White Hypertensive patients 51±6 49 High  CCA Far Both Mean of max at each site 
[Pujia et al., 1996] 132 Italy White NIDDM patients 50±10 100 High  CCA Far Both Mean of 6 sites 
[Kogawa et al., 1997]i 356 Japan E.Asian NIDDM patients 60±11 58 High  CCA/BIF * * Mean of 3 sites 
[Kogawa et al., 1997]ii 235 Japan E.Asian Non-diabetic subjects 51±11 37 Low  CCA/BIF * * Mean of 3 sites 
[Watanabe et al., 1997]
‡
 169 Japan E.Asian Healthy volunteers 59±6 51 Low  CCA/BIF/ICA Both Both Mean 
[Arnett et al., 1998] 495 US White Population sample 59±6 42 Low  CCA/BIF/ICA Far Both Mean of 6 sites 
[Frost et al., 1998] 148 Germany White IDDM patients 30±7 38 High  CCA Far Both Maximum 
[Girerd et al., 1998] 340 France White Patients with vascular risk factors/disease 49±12 53 High  CCA Far Right One measurement 
[Sass et al., 1998] 150 France White Population sample 41±4 52 Low  CCA Far Both Mean of all 
[Ferrieres et al., 1999] 355 France White Population sample 54±7 100 Low  CCA Far Both Mean of 12 sites 
[Huang et al., 1999] 219 Finland White Population sample 54±3 100 Low  CCA Far Both Maximum 
[Hung et al., 1999] 1106 Australia White Population sample 53±12 50 Low  CCA Far Both Mean of 6 sites 
[Nergizoglu et al., 1999] 51 Turkey White Hemodialysis patients 36±9 69 High  CCA Far Both Mean of 6 sites 
[Pit'ha et al., 1999] 47 Czech Republic White Hypertensive patients  62±3 100 High  CCA Far Both Mean of 10 sites 
[Jeng, 2000] 175 China E.Asian Hypertensive patients 57±10 52 High X CCA Far Both Mean of right and left 
[Pontremoli et al., 2000]
†
 215 Italy White Hypertensive patients 48±9 62 High  CCA Far Both Mean of 3 sites 
[Taute et al., 2000] 98 Germany White PAD patients 61±9 79 High  CCA Far Both Maximum 
[Mannami et al., 2001] 3657 Japan E.Asian Population sample 60±12 46 Low  CCA Both Both Mean of 4 sites 
[Markus et al., 2001]
†
 287 UK White Population sample 61±8 100 Low  CCA Far Both Mean  
[Tabara et al., 2001] 205 Japan E.Asian Healthy population sample 70±9 32 Low  CCA Far Right Mean 
[Balkestein et al., 2002] 380 Belgium White Population sample 40±16 50 Low  CCA Far Right Mean of 3 sites 
[Diamantopoulos et al., 
2002] 
184 Greece White NIDDM patients 62±8 41 High  CCA Far Both Max of mean from each side 




184 Japan E.Asian In-patients being evaluated for possible 
atherosclerosis 
67±14 47 High  CCA Far Both Mean of right and left 
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[Piao et al., 2002]
‡
 262 Japan E.Asian NIDDM patients 58±10 66 High * CCA/BIF/ICA * Both Mean of 6 sites 
[Czarnecka et al., 2004]i 127 Poland White Population sample – parents 51±5 40 Low  CCA Both Both * 
[Czarnecka et al., 2004]ii 157 Poland White Population sample – offspring 24±5 50 Low  CCA Both Both * 
[Li et al., 2004] 102 China E.Asian Hypertensive patients 54±9 * High X CCA Both Both Mean of 12 sites 
[Pall et al., 2004]i 120 Hungary White Hypertensive students 16±1 53 High  CCA * * Mean of 3 sites 
[Pall et al., 2004]ii 58 Hungary White Non-hypertensive students * * Low  CCA * * Mean of 3 sites 
[Bednarska et al., 2005] 130 Poland White Alcoholics 48±6 100 High  CCA Far Both Mean of each side 
[Sleegers et al., 2005] 6488 Netherlands White Population sample 69±9 41 Low  CCA Both Both * 
[Varda et al., 2005]i 56 Slovenia White Offspring of CVD patients 18±6 52 High  CCA/ICA * Both Mean of 4 sites 
[Varda et al., 2005]ii 48 Slovenia White Subjects without parental history of CVD 18±6 52 Low  CCA/ICA * Both Mean of 4 sites 
[Bilici et al., 2006] 64 Turkey White Memory impaired patients 57±13 83 High  CCA Far Both Mean of right and left 
[Brenner et al., 2006]
†
 470 France White Ischaemic stroke patients range 18-85 * High * CCA Far Both Mean of right and left 
[Burdon et al., 2006]
†
 737 US White NIDDM patients & their siblings 61±10 43 High  CCA Both Both Mean of 20 sites 
[Islam et al., 2006] 224 Finland White Population sample 34±2 54 Low  CCA Far Left Mean of 4 sites 
[Yamasaki et al., 2006]
†
 690 Japan E.Asian NIDDM patients 63±7 52 High * CCA/BIF/ICA * Both Mean of max 
[Bartoli et al., 2007]
‡
 53 Italy White Systemic sclerosis patients 60±11 11 High  CCA Far Both Mean of right and left 
[Tanriverdi et al., 2007] 88 Japan E.Asian Coronary angiography patients 55±11 55 High X CCA * Both Mean of 8 sites 
MTHFR             
[Arai et al., 1997] 222 Japan E.Asian NIDDM patients 60±8 73 High  BIF Both Both Maximum  
[Demuth et al., 1998]
†
 144 France White Patients with vascular risk factors/disease 48±13 46 High  CCA Far Right * 
[Mazza et al., 1999] 95 Italy White NIDDM patients 53±10 35 High  CCA Far Both Mean of 6 sites 
[McQuillan et al., 1999]
†
 1111 Australia White Population sample 53±13 50 Low  CCA Far Both Mean of 6 sites 
[Kawamoto et al., 2001]
†
 136 Japan E.Asian Patients with vascular risk factors 74±12 45 High  CCA Far Both Mean 
[Lim et al., 2001] 151 Taiwan E.Asian End stage renal disease patients 55±14 42 High  CCA Both * Mean 
[Markus et al., 2001]
†
 279 UK White Population sample 61±8 100 Low  CCA Far Both Mean  
[Pallaud et al., 2001]
‡
 121 France White Population sample 43±5 64 Low  CCA Far Both Mean 
[Passaro et al., 2001] 120 Italy White Healthy post-menopausal women 62±4 0 Low  CCA Both Both Mean of max 
[Ravera et al., 2001] 206 Italy White Hypertensive patients 48±9 * High  CCA Far Both Mean of 3 sites 
[Scaglione et al., 2002] 124 Italy White NIDDM patients 65±8 76 High  CCA Far Both Mean of 6 sites 
[de Maat et al., 2003] 691 Denmark White Population sample All 60 47 Low  CCA/BIF/ICA Both Right Mean of 3 sites 
[Inamoto et al., 2003] 3247 Japan E.Asian Population sample 59±13 48 Low  CCA Both Both Mean 
[Kelemen et al., 2004]i 260 Canada White Population sample 49±* 49 Low  CCA/BIF/ICA Both Both Mean of max 
[Kelemen et al., 2004]ii 275 Canada E.Asian Population sample 47±* 53 Low  CCA/BIF/ICA Both Both Mean of max 
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[Kelemen et al., 2004]iii 283 Canada S.Asian Population sample 48±* 54 Low  CCA/BIF/ICA Both Both Mean of max 
[Durga et al., 2005] 815 Netherlands White Patients with high homocysteine 60±6 72 High  CCA Both Both Mean of max 
[McDonald et al., 2005] 201 Australia White Population sample 37±* 44 Low X CCA Both * Mean of 6 sites 
[Linnebank et al., 2006] 714 Germany White Vascular event patients 64±9 49 High  CCA Far * Mean 
[Yamasaki et al., 2006]
†
 690 Japan E.Asian NIDDM patients 63±7 52 High * CCA/BIF/ICA * Both Mean of max 
[Fernandez et al., 2007]
‡
 61 Spain White Patients with coronary disease 68±7 82 High * CCA Far Both Mean of 6 sites 
[Liu et al., 2007] 541 Taiwan E.Asian Healthy volunteers 53±15 50 Low  CCA Far Either Mean of 4 sites 
NOS3             
[Lembo et al., 2001] 375 Italy White Hypertensive patients 54±* 55 High  CCA/BIF/ICA Both Both Maximum 
[Karvonen et al., 2002a]i 505 Finland White Hypertensive patients 51±6 49 High  CCA Far Both Mean of 10 sites 
[Karvonen et al., 2002a]ii 519 Finland White Population sample 51±7 50 Low  CCA Far Both Mean of 10 sites 
[Asakimori et al., 2003]
†
 163 Japan E.Asian Haemodialysis patients 55±11 52 High  CCA Far Both Maximum 
[Schmoelzer et al., 2003]
‡
 932 Italy White Population sample 53±6 55 Low  CCA/BIF/ICA Both Both Mean of 12 sites 
[Paradossi et al., 2004] 118 Italy White Population sample 30±5 39 Low  CCA * Both Mean of max 
[Czarnecka et al., 2005]i 127 Poland White Population sample – parents 51±5 40 Low  CCA Both Both * 
[Czarnecka et al., 2005]ii 167 Poland White Population sample – offspring 24±5 50 Low  CCA Both Both * 
[Spoto et al., 2005] 131 Italy White Haemodialysis patients 61±13 60 High  CCA/BIF/ICA Far Both Mean of 12 sites 
[Wolff et al., 2005] 2448 Germany White Population sample 62±10 51 Low  CCA Far Both Mean of 20 sites 
[Brenner et al., 2006]
†
 470 France White Ischaemic stroke patients range 18-85 * High * CCA Far Both Mean of right and left 
[Burdon et al., 2006]
†
 737 US White NIDDM patients & their siblings 61±10 43 High  CCA Both Both Mean of 20 sites 
[Lekakis et al., 2006]
‡
 122 Greece White Coronary angiography patients 61±10 84 High * CCA/BIF/ICA Far Both Mean of max of 6 sites 
[Bhuiyan et al., 2007]
‡
 661 US White Population sample 37±4 40 Low  CCA Far Both Mean of max of 6 sites 
ADD1             
[Castellano et al., 1997] 173 Italy White Population sample 57±5 50 Low  CCA Far Both Mean 
[Balkestein et al., 2002] 380 Belgium White 
Population sample 
40±16 49 Low  CCA Far Right Mean of 3 sites 
[Sarzani et al., 2006]
‡
 420 Italy White Medical student volunteers 23±2 52 Low X CCA/BIF Both Both Mean of max of 8 sites 
[Yazdanpanah et al., 2006] 5083 Netherlands White Population sample 69±9 40 Low  CCA Both Both Mean of 6 sites 
PON1             
[Cao et al., 1998]
‡
 170 France White NIDDM patients 55±8 78 High  CCA * Both Mean of 32 sites 
[Sakai et al., 1998] 139 Japan E.Asian NIDDM patients 62±14 47 High  CCA Far Both Mean of max 
[Dessi et al., 1999] 196 Italy White Population sample 55±12 61 Low  CCA Far Both Mean of 6 sites 
[Visvikis et al., 2000] 362 France White Population sample * 48 Low  CCA Both Both Mean of 4 sites 
[Markus et al., 2001]
†
 288 UK White Population sample 61±8 100 Low  CCA Far Both Mean  
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[Fortunato et al., 2003] 286 Italy White Population sample 55±8 0 Low  CCA Both Both Mean of 6 sites 
[Hu et al., 2003] 152 China E.Asian NIDDM patients 59±12 63 High  CCA * Both Mean of 6 sites 
[Campo et al., 2004]
†
 208 Italy White Hypercholesterolemia patients 57±10 48 High  CCA/BIF/ICA * Both Mean 
[Karvonen et al., 2004]i 496 Finland White Hypertensive patients * * High  CCA/BIF/ICA Far Both Mean of 6 sites 
[Karvonen et al., 2004]ii 503 Finland White Population sample * * Low  CCA/BIF/ICA Far Both Mean of 6 sites 
[Srinivasan et al., 2004]i
‡
  307 US White Population sample 33±7** 44** Low  CCA/BIF/ICA Far Both Mean of maximum 
[Srinivasan et al., 2004]ii
‡
  129 US Black Population sample 33±7** 44** Low  CCA/BIF/ICA Far Both Mean of maximum 
[Burdon et al., 2005]
†
 527 US White NIDDM patients & their siblings 62±10 44 High X CCA Both Both Mean of 20 sites 
[Van Himbergen et al., 
2004] 
285 Netherlands White Familial hypercholesterolaemia patients 48±* 40 High  CCA Both Both Mean 
[Brenner et al., 2006]
†
 470 France White Ischaemic stroke patients range 18-85 * High * CCA Far Both Mean of right and left 
[Roest et al., 2006] 133 Netherlands White Paediatric lipid clinic patients * * High  CCA Far Both Mean 
IL6             
[Rauramaa et al., 2000] 92 Finland White Population sample  55±3 100 Low  BIF Far Both Mean of maximum 
[Rundek et al., 2002] 71 US Black& 
White 
Population sample  70±12 45 Low  CCABIF/ICA Both Both Mean of 12 sites 
[Chapman et al., 2003] 1109 Australia White Population sample 53±13 50 Low  CCA Far Both Mean of 6 sites 
[Jerrard-Dunne et al., 
2003b] 
1000 UK White Population sample range 50-65 * Low  CCA Far Both * 
[Mayosi et al., 2005] 823 UK White Hypertensive patients & their relatives 54±* 48 High  CCA Far Both Maximum 
[Markus et al., 2006]
†
 810 Italy White Population sample 58±11 50 Low  CCA Far Both Mean of max 
[Yamasaki et al., 2006]
†
 690 Japan E.Asian NIDDM patients 63±7 52 High * CCA/BIF/ICA * Both Mean of max 
IGF1             
[Schut et al., 2003] 5132 Netherlands White Population sample 65±6 43 Low  CCA Both Both Mean 
ADRB2              
[Hindorff et al., 2005]
‡
 5249 US Black& 
White 
Population sample 73±* 44 Low  CCA Both Both Mean of max 
CRP             
[Lange et al., 2006] 4641 US White Population sample 73±6 40 Low  CCA/ICA * Both Mean of maximum 
FGG/FGA             
[Kardys et al., 2007]
†
 4274 Netherlands White Population sample 70±9 41 Low  CCA Both Both Mean 
AGT             
[Barley et al., 1995] 100 UK White Patients with TIA or stroke 65±9 66 High  CCA Far * Maximum 
[Arnett et al., 1998] 475 US White Population sample 59±6 42 Low X CCA/BIF/ICA Far Both Mean of 6 sites 
[Jeng, 1999] 175 Taiwan E.Asian Hypertensive patients 57±9 52 High X CCA Far Both Mean of right and left 
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[Pontremoli et al., 2000]
†
 215 Italy White Hypertensive patients 48±9 62 High  CCA Far Both Mean of 3 sites 
[Pallaud et al., 2001]
†
 161 France White Population sample 43±5 48 Low  CCA Far Both Mean 
[Tabara et al., 2001] 205 Japan E.Asian Population sample 70±9 32 Low  CCA Far Right Mean of 3 sites 
[Bozec et al., 2003] 98 France White Hypertensive patients 51±8 62 High X CCA Far Right Mean of 3 sites 
[Brenner et al., 2006]
†
 470 France White Ischaemic stroke patients range 18-85 * High * CCA Far Both Mean of right and left 
[Burdon et al., 2006]
†
 737 US White NIDDM patients & their siblings 61±10 43 High  CCA Both Both Mean of 20 sites 
[Islam et al., 2006] 202 Finland White Population sample 34±3 54 Low  CCA Far Left Maximum of 4 sites 
[Yamasaki et al., 2006]
†
 690 Japan E.Asian NIDDM patients 63±7 52 High * CCA/BIF/ICA * Both Mean of maximum 
FV             
[Garg et al., 1998]
‡
 1292 US Black& 
White 
CHD patients & their siblings 56±11 47 High * CCA/BIF/ICA Far Both Mean of 6 sites 
[Fox et al., 2004b]
‡
 1763 US White CHD patients’ offspring 57±10 49 High  CCA Both Both Mean of maximum 
[Brenner et al., 2006]
†
 470 France White Ischaemic stroke patients range 18-85 * High * CCA Far Both Mean of right and left 
Grey shaded studies are those which were not included in the analyses because complete data were unavailable. 
* information not available from publication, **data only available for whole study so estimated to be equal for each sub-study, †studies with all result data 
unavailable from the publication, ‡ studies with result data only relating to a particular genetic model available in the pub lication. 
APOE: apolipoprotein E; ACE: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1; MTHFR: 5,10-methylenetetrahydrofolate reductase (NADPH); NOS3: 
nitric oxide synthase 3 (endothelial cell); ADD1: adducin 1 (alpha); PON1: paraoxonase 1; IL6: interleukin 6 (interferon, beta 2); IGF1: insulin-like growth factor 1 
(somatomedin C); ADRB2: adrenergic, beta- 2-, receptor, surface; CRP: C-reactive protein, pentraxin-related; FGG/FGA: fibrinogen gamma chain/alpha chain; 
AGT: angiotensinogen (serpin peptidase inhibitor, clade A, member 8); FV: coagulation factor V (proaccelerin, labile factor); HWE: Hardy Weinberg equilibrium; 
CCA: common carotid artery; BIF: bifurcation; ICA: internal carotid artery; NIDDM: non-insulin-dependent diabetes mellitus; CHD: coronary heart disease; CVD: 
cerebrovascular disease; IDDM: insulin-dependent diabetes mellitus; PAD: peripheral artery disease. 
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Method of CIMT measurement varied quite considerably between studies.  
Where possible I had selected the common carotid artery measurement, and 
so most studies’ results are from this segment only (115 studies, using the 
authors’ definitions).  In a smaller number of studies (43), the authors had 
only presented data combining multiple segments (e.g. overall mean of CCA, 
ICA & BIF).  In two studies, only the bifurcation was measured. 
 
Most studies measured the far wall only (92), a smaller number measured 
both walls (40), none measured the near wall only, and 27 studies did not 
report which wall was measured. 
 
The majority of studies (133) combined measurements from both the right 
and left carotid arteries to produce a value for each patient, fewer studies 
measured only the right (11) or the left (2), and one study reported 
measuring ‘either’.  Thirteen studies did not report which side they had 
measured. 
 
By far the most variable part of the measurement method was the number of 
sites measured and whether means or maximums were recorded.  Most (110) 
recorded the mean of all sites measured, with the number of sites measured 
varying enormously from three to 32.  12 recorded the maximum 
measurement from all sites (often not reporting how many sites were 
measured, so the sonographer may have looked for the thickest portion from 
all scans).  27 studies recorded the ‘mean of maximum’, where the maximum 
from each site or each side was averaged, again with varying numbers of 
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sites measured.  A few other studies used other methods: one study reported 
‘maximum of mean’, measuring the mean from each side and the reporting 
the maximum of these; two studies reported that they only made one 
measurement for each subject.  Eight studies did not report how they 
combined measurements for the overall value. 
 
Often the CIMT measurement methods used were poorly reported and it 
was difficult to tell exactly how many measurements were taken and how 
these were combined to create the overall value.  If we ignore the number of 
measurements taken, the most common method was to measure the mean of 
the far wall of both common carotid arteries (in 48 studies). 
 
Table 3.7 shows the relevant CIMT data per genotype extracted from each 
study. 
 
3.3.5 Overall Results 
Table 3.8 shows the overall results from the three steps of the analysis. 
Of the 13 genes reviewed: 
 
 Eight genes (APOE, ACE, MTHFR, NOS3, ADD1, PON1, IL6 & AGT) 
had been studied in more than one study and could be analysed using 





Table 3.7 CIMT data for each study with full data available.  Sample size, CIMT mean and CIMT SD per genotype are shown. 
Study  N mean SD N mean SD N mean SD 
APOE E4 E3 E2 
Terry 1996 66 1 0.24 155 0.97 0.25 33 0.85 0.23 
Cattin 1997 45 1.95 0.45 177 1.84 0.15 32 1.80 0.10 
Kogawa 1997i 62 1.098 0.482 261 1.043 0.485 26 0.993 0.495 
Kogawa 1997ii 33 0.640 0.149 176 0.631 0.172 22 0.624 0.172 
Sass 1998 30 0.52 0.04 90 0.54 0.05 24 0.52 0.05 
Zhang 1998 10 1.5 0.5 38 1.1 0.3 4 1.2 0.6 
Guz 2000 28 0.75 0.35 200 0.63 0.38 33 0.59 0.13 
Hanon 2000 66 0.545 0.105 208 0.533 0.115 38 0.536 0.134 
Horejsi 2000 25 0.8 0.25 77 0.7 0.25 10 0.72 0.25 
Ilveskoski 2000 60 1.03 0.16 109 1.05 0.17 20 0.95 0.12 
Slooter 2001 1392 0.77 0.18 3122 0.77 0.14 750 0.75 0.14 
Tabara 2001 38 0.83 0.16 137 0.79 0.13 27 0.79 0.12 
Haraki 2002 20 0.76 0.17 65 0.64 0.14 10 0.61 0.15 
Karvonen 2002i 86 0.98 0.26 160 0.90 0.19 12 0.89 0.18 
Karvonen 2002ii  90 0.93 0.23 150 0.93 0.21 13 0.78 0.15 
Asakimori 2003 31 0.93 0.42 109 0.99 0.52 22 0.91 0.37 
Beilby 2003 283 0.70 0.13 650 0.72 0.15 146 0.69 0.13 
Li 2003  18 1.02 0.19 64 0.88 0.16 10 0.81 0.17 
Xiang 2003i  58 0.89 0.15 161 0.68 0.17 34 0.62 0.12 
Xiang 2003ii  20 0.71 0.14 75 0.60 0.13 11 0.59 0.11 
Elosua 2004  568 0.74 0.20 1782 0.74 0.18 373 0.73 0.16 
Fernandez 2004  49 0.83 0.23 158 0.81 0.21 18 0.76 0.17 
Kahraman 2004  14 0.7 0.4 92 0.7 0.4 12 0.6 0.2 
Bednarska 2005  21 0.88 0.30 89 0.78 0.16 17 0.86 0.23 
Bleil 2006  39 0.875 0.16 120 0.932 0.16 23 0.89 0.16 
Debette 2006  1124 0.722 0.129 3923 0.712 0.125 717 0.713 0.107 
Junyent 2006  31 0.69 0.19 122 0.65 0.16 10 0.60 0.15 
Volcik 2006i  1126 0.746 0.134 1427 0.734 0.113 634 0.722 0.126 
Volcik 2006ii  2311 0.743 0.144 5534 0.733 0.149 1459 0.723 0.115 
Altamura 2007i  24 0.986 0.190 40 0.887 0.136 4 0.788 0.063 
Altamura 2007ii  7 0.867 0.082 22 0.960 0.168 4 0.900 0 
Wohlin 2007  144 0.74 0.21 242 0.79 0.21 59 0.72 0.12 
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ACE DD ID II 
Castellano 1995  76 0.74 0.17 88 0.68 0.19 23 0.75 0.19 
Dessi 1995  93 1.05 0.4 124 1.06 0.3 23 1.02 0.2 
Markus 1994  36 0.811 0.276 47 0.939 0.279 18 1.135 0.395 
Kauma 1996  148 0.83 0.19 264 0.80 0.15 103 0.81 0.18 
Pujia 1996  46 0.778 0.07 70 0.759 0.08 16 0.700 0.08 
Kogawa 1997i  60 1.200 0.586 149 1.062 0.541 147 0.990 0.364 
Kogawa 1997ii  32 0.640 0.173 116 0.631 0.171 87 0.629 0.162 
Arnett 1998  151 0.731 0.15 256 0.730 0.16 88 0.720 0.15 
Frost 1998  62 0.63 0.13 55 0.63 0.18 31 0.62 0.15 
Girerd 1998  118 0.547 0.111 165 0.538 0.129 57 0.536 0.103 
Sass 1998  37 0.53 0.04 80 0.54 0.06 33 0.52 0.04 
Ferrieres 1999  135 0.64 0.12 150 0.62 0.10 70 0.63 0.12 
Huang 1999  77 1.01 0.19 100 1.08 0.33 42 1.04 0.23 
Hung 1999  343 0.71 0.15 535 0.71 0.14 228 0.71 0.14 
Nergizoglu 1999  22 0.80 0.10 22 0.76 0.09 7 0.71 0.05 
Pit'ha 1999  14 0.747 0.16 25 0.713 0.12 8 0.723 0.13 
Jeng 2000  41 0.877 0.354 69 0.756 0.307 65 0.737 0.273 
Taute 2000  33 1.06 0.26 46 1.10 0.25 19 1.01 0.29 
Mannami 2001  477 0.87 0.26 1640 0.87 0.29 1540 0.87 0.28 
Tabara 2001  27 0.81 0.14 95 0.80 0.14 83 0.79 0.12 
Balkestein 2002  84 0.582 0.17 180 0.585 0.23 116 0.555 0.16 
Diamantopoulos 2002  69 0.98 0.21 86 0.97 0.20 29 0.94 0.20 
Czarnecka 2004i  36 0.91 0.48 62 0.77 0.55 29 0.73 0.54 
Czarnecka 2004ii  44 0.61 0.33 84 0.56 0.37 29 0.53 0.32 
Li 2004  45 0.79 0.18 27 0.67 0.11 30 0.58 0.12 
Pall 2004i  28 0.57 0.11 57 0.53 0.10 35 0.55 0.10 
Pall 2004ii  15 0.46 0.10 25 0.48 0.10 18 0.49 0.10 
Bednarska 2005  30 0.81 0.21 62 0.80 0.19 38 0.82 0.21 
Sleegers 2005  1806 0.80 0.16 3264 0.80 0.16 1418 0.79 0.15 
Varda 2005i  9 0.48 0.06 31 0.43 0.09 16 0.42 0.07 
Varda 2005ii  17 0.40 0.08 21 0.43 0.07 10 0.42 0.06 
Bilici 2006  28 1.29 0.30 28 1.29 0.33 8 1.32 0.29 
Islam 2006  79 0.57 0.08 106 0.59 0.10 39 0.60 0.08 
Tanriverdi 2007  29 0.78 0.06 34 0.72 0.05 25 0.64 0.06 
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MTHFR TT TC CC 
Arai 1997  39 1.58 0.54 94 1.35 0.35 89 1.31 0.31 
Mazza 1999  22 0.875 0.197 38 0.862 0.193 35 0.833 0.186 
Lim 2001 10 0.93 0.07 54 0.85 0.15 87 0.79 0.13 
Passaro 2001  20 1.23 0.18 72 1.03 0.17 28 0.98 0.21 
Ravera 2001  36 0.79 0.30 111 0.69 0.21 59 0.64 0.23 
Scaglione 2002  22 0.89 0.22 55 0.93 0.22 47 0.86 0.29 
DeMaat 2003  62 0.682 0.112 304 0.720 0.134 325 0.732 0.153 
Inamoto 2003  508 0.860 0.107 1542 0.861 0.099 1197 0.854 0.114 
Kelemen 2004i 30 0.7874 0.2421 120 0.7272 0.1734 110 0.7443 0.1847 
Kelemen 2004ii  20 0.6653 0.1540 84 0.6675 0.1179 171 0.6737 0.1311 
Kelemen 2004iii  13 0.7852 0.2020 72 0.6906 0.1563 198 0.6947 0.1693 
Durga 2005  125 1.03 0.16 378 1.02 0.17 312 1.02 0.16 
McDonald 2005  24 0.586 0.099 117 0.665 0.149 60 0.641 0.142 
Linnebank 2006  52 0.74 0.18 316 0.75 0.18 346 0.76 0.2 
Liu 2007  31 0.77 0.18 220 0.75 0.16 290 0.75 0.23 
NOS3 Glu/Glu Glu/Asp Asp/Asp 
Lembo 2001  158 1.24 0.44 179 1.27 0.52 38 1.29 0.36 
Karvonen 2002i 244 0.915 0.214 220 0.959 0.311 41 0.878 0.173 
Karvonen 2002ii  262 0.896 0.225 215 0.922 0.243 42 0.911 0.183 
Paradossi 2004  43 0.37 0.07 57 0.35 0.08 18 0.45 0.13 
Czarnecka 2005i  73 0.70 0.43 46 0.92 0.47 8 1.10 0.51 
Czarnecka 2005ii  89 0.53 0.38 72 0.55 0.34 6 0.60 0.42 
Spoto 2005  59 0.98 0.10 56 1.07 0.23 16 1.16 0.36 
Wolff 2005  1218 0.79 0.35 1013 0.79 0.32 217 0.81 0.29 
ADD1 Gly/Gly Gly/Trp Trp/Trp 
Castellano 1997  130 0.74 0.23 36 0.67 0.18 7 0.74 0.08 
Balkestein 2002 213 0.551 0.156 142 0.572 0.182 25 0.611 0.177 
Yazdanpanah 2006  3170 0.77 0.36 1668 0.78 0.44 245 0.76 0.37 
PON1 QQ QR RR 
Sakai 1998  14 0.89 0.38 63 0.72 0.17 62 0.74 0.18 
Dessi 1999  88 0.755 0.151 91 0.758 0.130 17 0.779 0.184 
Visvikis 2000  165 0.51 0.05 169 0.51 0.05 28 0.49 0.03 
Fortunato 2003  140 1.14 0.22 111 1.13 0.21 35 1.12 0.23 
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Hu 2003  30 0.65 0.27 77 0.83 0.27 45 1.05 0.32 
Karvonen 2004i  262 0.88 0.19 198 0.88 0.18 36 0.90 0.17 
Karvonen 2004ii  273 0.87 0.17 198 0.87 0.19 32 0.86 0.23 
van Himbergen 2005  110 0.88 0.19 146 0.85 0.16 29 0.9 0.17 
Roest 2006  55 0.51 0.07 66 0.52 0.08 12 0.54 0.09 
IL6 GG GC CC 
Rauramaa 2000  19 1.30 0.42 38 1.09 0.25 35 1.17 0.24 
Rundek 2002  47 0.85 0.17 19 0.78 0.21 5 0.72 0.15 
Chapman 2003  381 0.69 0.15 557 0.70 0.12 171 0.70 0.17 
Jerrard-Dunne 2003  317 0.77 0.14 495 0.77 0.14 188 0.79 0.16 
Mayosi 2005  265 0.98 0.29 422 0.98 0.26 136 1.10 0.26 
IGF1 noncarriers 1 192bp allele 2 192bp alleles 
Schut 2003  617 0.78 0.14 2275 0.77 0.15 2240 0.76 0.14 
ADRB2 Gln/Gln Gln/Glu & Glu/Glu 
Hindorff 2005  1952 1.49 0.71 3221 1.50 0.68 
CRP* 1919A/T 2667G/C 3872G/A 5237A/G 790A/T 
Lange 2006 P=0.48 P=0.88 P=0.33 P=0.29 P=0.46 P=0.33 P=0.13 P=0.65 P=0.12 
FGG/FGA Haplotype 1 Haplotype 2 Haplotype 3 Haplotype 4 Haplotype 5 Haplotype 6 Haplotype 7 
Kardys 2007  P=0.50 P=0.30 P=0.03 P=0.39 P=0.57 P=0.93 P=0.14 
AGT MM MT TT 
Barley 1995  44 0.879 0.230 44 0.948 0.343 12 0.873 0.175 
Arnett 1998  123 0.730 0.152 213 0.726 0.156 139 0.728 0.144 
Jeng 1999  32 0.781 0.330 37 0.818 0.445 106 0.762 0.241 
Tabara 2001  10 0.77 0.15 69 0.80 0.13 126 0.80 0.13 
Bozec 2003  42 0.550 0.129 35 0.583 0.156 21 0.596 0.101 
Islam 2006  76 0.59 0.08 86 0.60 0.09 40 0.57 0.09 
FV Wildtype factor V Containing leiden mutation 
Garg 1998  1209 0.810 0.283 83 0.782 0.283 
Fox 2004  1692 0.6 0.17 71 0.58 0.08 
* there are 2 p-values for each CRP SNP because the association was tested in both white and black participants, except 790A/T which  
  was only studied in black participants. 
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Of the others: 
 One genes (IGF1) had been studied in only one study, and was 
analysed using ANOVA rather than meta-ANOVA. 
 Two genes (ADRB2 & FV) had only been studied using a dominant 
genetic model and so I had to analyse them using this model.  
 One gene (FGG/FGA), from only one study did not have SNP-specific 
data presented as only a haplotype analysis had been done.  I simply 
reported the results from this haplotype analysis. 
 One gene (CRP) did not have the necessary result data presented in 
the paper, but I could extract the association p-values. 
 
Meta-ANOVA/ANOVA found no overall association between genotype and 
CIMT for six of the ten genetic polymorphisms for which this analysis was 
possible: NOS3, ADD1, PON1, IL6, AGT, and so these genes were not 
studied further.  Overall significant associations (p<0.05) between genotype 
and CIMT were found for four of the ten genetic polymorphisms: APOE, 
ACE, MTHFR & IGF1.  These genes went onto stage 2, where the most 
appropriate genetic model was estimated, and then in stage 3 the mean 
differences were estimated for the selected genetic models for each 
polymorphism.  The estimated sizes of the effects of the polymorphisms are 
reported under the gene specific headings below. 
 
As ADRB2 and FV had only been analysed in a dominant fashion, these 




Table 3.8  Results of the 3-step meta-analysis of the association between CIMT and polymorphisms in 13 selected genes. 
  Step 1: Step 2: Step 3: 





λ (95% CI) Selected 
genetic model 
Random effects pooled mean CIMT 
difference between genotypes with 
selected model,  µm (95% CI) 
APOE (ε2,ε3,ε4) 32 (32253) p<0.001 0.4 (0.3 to 0.6) co-dominant 25 (17 to 33) 
ACE (I/D) 34 (17038) p=0.005 0.5 (0.4 to 0.6) co-dominant 14 (5 to 22) 
MTHFR (677 C/T) 15 (7945) p=0.02 0.2 (0.1 to 0.4) recessive/none 31 (0 to 61) 
NOS3 (Glu298Asp) 8 (4390) p=0.3 - - - 
ADD1 (Gly460Trp) 3 (5636) p=0.7 - - - 
PON1 (Gln192Arg) 9 (2552) p=0.6 - - - 
IL6 (-174 G/C) 5 (3095) p=0.4 - - - 
AGT (Met235Thr) 6 (1255) p=0.5    
IGF1 (192 bp allele) 1 (5132) p=0.004 0.50 (no CI) co-dominant 10 (4 to 16) 
CRP (5 SNPs)  1 (4641) No SNPs associated - p-values range from 0.12 to 0.88 
ADRB2 (Gln27Glu) 1 (5173) study used dominant model dominant 10 (-29 to 49) 
FV (Leiden) 2 (3055) both studies used dominant model dominant -20 (-29 to -12) 
FGG/FGA (7 SNP haplotype) 1 (4274) haplotype analyses: no significant association - 
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mean difference for ADRB2 was not significant, but for FV a significant mean 
difference was found (further details below).  The FGG/FGA study had only 
reported haplotype analyses, and found that there were no significant 
associations, so I did not study this gene further. 
 
3.3.6 Apolipoprotein E Results 
I found 30 relevant studies (36 sub-studies, 32,995 subjects) for the 
association between the APOE ε polymorphism and CIMT.  After contacting 
authors, full data were still unavailable for three studies (4 sub-studies, 742 
subjects), resulting in 2% missing data.   
 
The meta-ANOVA of 32 sub-studies (32,253 subjects) found an overall 












Figure 3.3.  λ estimation for APOE using weighted linear regression, λ=0.4 (95% CI, 0.3 
to 0.6). 
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regression to estimate λ is shown in figure 3.3.  λ was estimated to be 0.4 
(95% CI, 0.3 to 0.6), which is close to and has a CI including 0.5, suggesting 
that a co-dominant model is the most appropriate. 
 
Figure 3.4 shows the forest plot of the co-dominant mean difference analysis.  
‘Co-dominant’ in the case of APOE implies an equal difference between E4 
-100 0 100 200 300 400
Study Mean CIMT difference per genotype group, E4 v E3 & E3 v E2, (95% CI)
Terry 1996 67 (20 to 114)
Cattin 1997 47 (9 to 86)
Kogawa 1997i 52 (-52 to 156)
Kogawa 1997ii 8 (-34 to 50)
Sass 1998 -4 (-16 to 8)
Zhang 1998 281 (2 to 560)
Guz 2000 60 (7 to 114)
Hanon 2000 7 (-16 to 30)
Horejsi 2000 59 (-27 to 144)
Ilveskoski 2000 32 (-1 to 65)
Slooter 2001 10 (3 to 16)
Tabara 2001 18 (-16 to 52)
Haraki 2002 82 (24 to 141)
Karvonen 2002i 60 (10 to 111)
Karvonen 2002ii 50 (7 to 94)
Asakimori 2003 8 (-99 to 115)
Beilby 2003 1 (-12 to 13)
Li 2003 110 (42 to 177)
Xiang 2003i 137 (109 to 165)
Xiang 2003ii 62 (17 to 107)
Elosua 2004 5 (-7 to 17)
Fernandez 2004 33 (-17 to 83)
Kahraman 2004 76 (-39 to 190)
Bednarska 2005 -2 (-86 to 81)
Bleil 2006 -16 (-56 to 24)
Debette 2006 5 (-1 to 10)
Junyent 2006 44 (-11 to 99)
Volcik 2006i 12 (6 to 18)
Volcik 2006ii 10 (6 to 14)
Altamura 2007i 99 ( 51 to 147)
Altamura 2007ii -4 (-32 to 23)
Wohlin 2007 13 (-10 to 36)
Overall 25 (17 to 33)
Olmer 1997 E4 associated with higher CIMT
Vauhkonen 1997i no association
Vauhkonen 1997ii E4 associated with higher CIMT










































Figure 3.4  Study and pooled mean difference in CIMT between APOE genotype groups E4 
and E3 and between E3 and E2, using a random effects method. 
32253 
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and E3, and between E3 and E2 genotypes, and the ‘mean difference’ 
estimates the size of this equal step-wise difference.  The random effects 
pooled mean difference was 25μm (95% CI 17 to 33, p<0.001).  When carrying 
out the same analysis using a fixed effects method the pooled mean 
difference was 10μm (95% CI 8 to 13, p<0.001) (not shown). 
 
The I2 estimate of heterogeneity amongst the studies was 80%, showing 
substantial heterogeneity beyond that expected by chance.  The subgroup 
analyses shown in figure 3.5 go some way to explaining the sources of this 
heterogeneity.  There was a substantially larger pooled mean CIMT 
difference amongst subjects of vascular high risk, compared with low risk 
subjects and in Eastern Asian subjects compared with White or Black 
subjects, for both comparisons the heterogeneity was statistically significant 
between subgroups (Q-test p<0.001 for both).  There was significant 






13 (6 to 19)
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Figure 3.5  Subgroup sensitivity meta-analysis for APOE.   
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suggesting the presence of small study bias, with the smaller studies 
showing a more pronounced effect.  Focusing on just the larger (and 
presumably more reliable) studies, a significant association between APOE 
and CIMT remains, and the excess heterogeneity (I2) is reduced to 11%.  The 
mean difference estimate is however smaller than the overall estimate, with a 
mean difference of 8μm (95% CI 6 to 11) per step from E2 to E3 to E4 
genotype groups, suggesting that the biases in the literature lead to over-
estimation of the effect.  
 
Qualitative statements of the results from studies that could not be included 
in the meta-analysis are shown at the bottom of figure 3.4.  Of the three 
studies with unavailable data for APOE, one found an association between 
E4 genotypes and higher CIMT [Olmer et al., 1997], another found a similar 
association, but only in the non-diabetic subgroup [Vauhkonen et al., 1997], 
and the other found no association [Brenner et al., 2006].  All three of these 
studies were comparatively small (66, 206 and 470 subjects) and would not 
have contributed to the analysis including only larger subjects. 
 
3.3.7 Angiotensin Converting Enzyme Results 
I found 39 relevant studies (43 sub-studies, 20,105 subjects) for the 
association between the ACE I/D polymorphism and CIMT.  After contacting 
authors, full data were still unavailable for nine studies (3067 subjects), 
resulting in 15% missing data. 
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The meta-ANOVA of 34 sub-studies (17,038 subjects) found an overall 
association between ACE and CIMT, with a p-value of 0.005.  The linear 
regression to estimate λ is shown in figure 3.6  λ was estimated to be 0.5 (95% 
CI, 0.4 to 0.6), suggesting that a co-dominant model is the most appropriate. 
 
Figure 3.7 shows the forest plot of the co-dominant mean difference analysis.  
The random effects pooled per-allele mean difference was 14μm (95% CI, 5 to 
22, p=0.002).  When carrying out the same analysis using a fixed effects 

















Figure 3.6  λ estimation for ACE using weighted linear regression, λ=0.5 (95% CI, 0.4 to 0.6) 
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-200 -100 0 100 200
Study Mean CIMT difference per D allele in µm (95% CI)
Castellano 1995 (-2 to 55)
Dessi 1995 15 (-43 to 73)
Markus 1995 -149 (-239 to -60)
Kauma 1996 12 (-11 to 35)
Pujia 1996 32 (12 to 52)
Kogawa 1997ii 5 (-27 to 36)
Kogawa 1997i 94 (25 to 163)
Arnett 1998 5 (-15 to 24)
Frost 1998 4 (-26 to 34)
Girerd 1998 6 (-11 to 22)
Sass 1998 5 (-5 to 14)
Ferrieres 1999 8 (-9 to 24)
Huang 1999 -22 (-62 to 17)
Hung 1999 0 (-12 to 12)
Nergizoglu 1999 45 (17 to 73)
Pit'ha 1999 13 (-48 to 74)
Jeng 2000 60 (-1 to 121)
Taute 2000 12 (-64 to 88)
Mannami 2001 0 (-14 to 14)
Tabara 2001 10 (-16 to 36)
Balkestein 2002 11 (-12 to 35)
Diamantopoulos 2002 18 (-24 to 61)
Czarnecka 2004i 95 (-29 to 219)
Czarnecka 2004ii 41 (-35 to 116)
Li 2004 104 (70 to 137)
Pall 2004ii -15 (-49 to 19)
Pall 2004i 7 (-19 to 33)
Bednarska 2005 -6 (-56 to 44)
Sleegers 2005 5 (-1 to  10)
Varda 2005ii -10 (-36 to 17)
29 ( 3 to 55)
Bilici 2006 -11 (-118 to 96)
Islam 2006 -16(-3 to -1)
Tanriverdi 2007 70 (54 to 86)
Overall 14 ( 5 to 22)
Varda 2005i
Pontremoli 2000 No association
Watanabe 1997 No association
Markus 2001 No association
Kawamoto 2002 No association
Brenner 2006 Trend towards higher CIMT with DD
Not reported
Burdon 2006 No association
Yamasaki 2006 DD associated with higher CIMT
















































Figure 3.7  Study and pooled mean difference in CIMT per D allele of the ACE I/D polymorphism, using a 
random effects method. 
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The I2 estimate of heterogeneity amongst the studies was 78%, showing 
substantial heterogeneity beyond that expected by chance.  In a similar way 
to APOE, the subgroup analyses shown in figure 3.8 go some way to 
explaining the sources of this heterogeneity.  There was a trend towards 
larger pooled mean CIMT difference amongst Eastern Asian subjects 
compared with White subjects, but the heterogeneity between subgroups 
was not statistically significant (Q-test, p=0.2).  The pooled mean CIMT was 
larger in high vascular risk subjects compared to low risk subjects and the 
heterogeneity was statistically significant between subgroups (Q-test 
p<0.001). 
There was significant heterogeneity between the small and large subgroups 
(Q-test, p=0.002), suggesting the presence of small study bias, with the 
smaller studies showing a more pronounced effect.  On pooling just the 
larger (more reliable) studies, the association between ACE and CIMT 
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Figure 3.8  Subgroup sensitivity meta-analysis for ACE. 
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Qualitative statements of the results from studies that could not be included 
in the meta-analysis are shown at the bottom of figure 3.7.  Most of the nine 
studies reported no association.  Three would have contributed to the ‘larger 
studies’ analysis (> the mean of 450) *Brenner et al., 2006; Burdon et al., 2006; 
Yamasaki et al., 2006].  Of these, two [Brenner et al., 2006; Yamasaki et al., 
2006] found that the D allele was associated with increased CIMT, so their 
inclusion could potentially have strengthened the association between ACE 
and CIMT.   
 
3.3.8 Methylenetetrahydrofolate Reductase Results 
I found 20 relevant studies (22 sub-studies, 10,487 subjects) for the 
association between the MTHFR C677T polymorphism and CIMT.  After 
contacting authors, full data were still unavailable for seven studies (2,542 
subjects), resulting in 24% missing data.   
 
The meta-ANOVA of 15 sub-studies (7,945) found an overall association 
between MTHFR and CIMT, with a p-value of 0.02.  The linear regression to 
estimate λ is shown in figure 3.9.  λ was estimated to be 0.2 (95% CI, 0.1 to 
0.4).  The CI range does not include any of the genetic model values of λ.  It is 
however, closest to 0 and so I chose to carry out the mean difference analysis 
using a recessive model. 
 
Figure 3.10 shows the forest plot of the recessive mean difference analysis.  
The random effects pooled mean difference was 31μm (95% CI 0 to 61, 
p=0.051). This is not quite statistically significant, despite there being a 
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significant overall association.  When carrying out the same analysis using a 
fixed effects method the pooled mean difference was 2μm (95% CI -6 to 10, 
p=0.646) (not shown). 
 
The I2 estimate of heterogeneity amongst the studies was 83%, showing 
substantial heterogeneity beyond that expected by chance.  In a similar way 
to APOE and ACE, the subgroup analyses shown in figure 3.10 go some way 
to explaining the sources of this heterogeneity.  The trends seen are similar to 
those of APOE and ACE.  Studies of Eastern and Southern Asian subjects 
showed a trend towards higher mean CIMT difference than those of white 
subjects, although the heterogeneity between subgroups was not statistically 
significant (Q-test, p=0.1).  Studies of subjects at high vascular risk showed a 










Figure 3.9.  λ estimation for MTHFR using weighted linear regression, λ=0.2 (95% CI, 0.1 
to 0.4) 
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heterogeneity between subgroups was significant (Q-test, p=0.002).  There 
was significant heterogeneity between the small and large subgroups (Q-test, 
p<0.001), suggesting the presence of small study bias, with the smaller 
studies showing a much more pronounced effect.  On pooling just the larger 
(more reliable) studies, there was no significant association between MTHFR 
and CIMT and the trend was in the opposite direction to the overall result. 
 
-200 -100 0 100 200 300 400
Study Mean CIMT difference between TT and CT/CC genotypes in µm (95% CI)
Arai 1997 250 (74 to 426)
Lim 2001 120 (71 to 169)
Durga 2005 10 (-21 to 41)
Linnebank 2006 -20 (-71 to 31)
Mazza 1999 25 (-68 to 118)
Ravera 2001 120 (17 to 223)
Scaglione 2002 -10 (-115 to 95)
Inamoto 2003 0 (-9 to 9)
Liu 2007 20 (-46 to 86)
Kelemen 200ii -5 (-74 to 65)
Kelemen 200iii 95 (-16 to 207)
deMaat 2003 -48 (-78 to-18)
Passaro 2001 210 ( 124 to 296)
Keleman 200i 47 (-42 to 137)
McDonald 2005 -74 (-119 to -29)
Overall 31 (0 to 61)
Markus 2001 No association
Yamasaki 2006 TT associated with higher CIMT
Fernandez 2007 TT associated with higher CIMT
McQuillan 1999 No association
Kawamoto 2001 T allele associated with higher CIMT
Demuth 1998 TT associated with lower CIMT



























Figure 3.10  Study and pooled mean difference in CIMT between TT and CT/CC genotypes 
of the MTHFR C677T polymorphism, using a random effects method. 
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Qualitative statements of the results from studies that could not be included 
in the meta-analysis are shown at the bottom of figure 3.10.  Of these seven 
studies, two would have contributed to the ‘larger studies’ analysis (> the 
mean of 500).  The larger [McQuillan et al., 1999] reported no association 
between MTHFR and CIMT while the other [Yamasaki et al., 2006] did find 
an association, so overall their inclusion would be unlikely to greatly affect 
the overall conclusions. 
 
3.3.9 Nitric Oxide Synthase 3 Results 
I found 12 relevant studies (14 sub-studies, 7,475 subjects) for the association 
between the NOS3 Glu298Asp polymorphism and CIMT.  After contacting 
authors, full data were still unavailable for six studies (3,085 subjects), 
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Figure 3.11  Subgroup sensitivity meta-analysis for MTHFR. 
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The meta-ANOVA found no overall association between NOS3 and CIMT, 
with a p-value of 0.3, and so this gene was not analysed further. 
 
One of the studies with missing data reported a marginal association 
between the T allele and CIMT [Bhuiyan et al., 2007].  This paper had a 
sample size of 661, so its inclusion would be unlikely to greatly affect the 
overall conclusion.  The other five ‘missing’ studies reported no association. 
 
3.3.10 Adducin 1 Results 
I found four relevant studies (6,056 subjects) for the association between the 
ADD1 Gly460Trp polymorphism and CIMT.  After contacting authors, full 
data were still unavailable for one studies (420 subjects), resulting in 7% 
missing data.   
 
The meta-ANOVA of three studies (5636 subjects) found no overall 
association between ADD1 and CIMT, with a p-value of 0.7.   
 
The study with missing data [Sarzani et al., 2006] had analysed the 
association according to a dominant model and found that the Trp allele was 
associated with an increased CIMT, but only in male subjects.  This could be 
a spurious result or there could be a real interaction.  Sex-specific data was 
not available from the other studies and so this could not be tested, and so 
this gene was not analysed further. 
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3.3.11 Paraoxonase 1 Results 
I found 14 relevant studies (16 sub-studies, 4,651 subjects) for the association 
between PON1 Gln192Arg polymorphism and CIMT.  After contacting 
authors, full data were still unavailable for six studies (seven sub-studies, 
2,099 subjects), resulting in 45% missing data.   
 
The meta-ANOVA of eight studies (nine sub-studies, 2,552 subjects) found 
no overall association between PON1 and CIMT, with a p-value of 0.6. 
 
 A large proportion of the relevant data were unavailable for this gene.  Only 
one of the studies with missing data reported a significant association, but 
only in females [Srinivasan et al., 2004].  Again, this could be due to an 
interaction effect or just spurious and there were insufficient data to test this 
in the whole dataset, so this gene was not analysed further. 
 
3.3.12 Interleukin 6 results 
I found seven relevant studies (4,595 subjects) for the association between the 
IL6 -174G/C polymorphism and CIMT.  After contacting authors, full data 
were still unavailable for two studies (1,500 subjects), resulting in 33% 
missing data.   
 
The meta-ANOVA of five studies (3,095 subjects) found no overall 
association between IL6 and CIMT, with a p-value of 0.4. 
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Of the two studies with missing data, one had only studied haplotypes 
(which included this gene and two other inflammatory genes – IL1 and 
CD14) and reported a statistically significant association between the gene-
variant score and CIMT [Markus et al., 2006] and the other found no 
association between IL6 and CIMT [Yamasaki et al., 2006], and so this gene 
was not analysed further. 
 
3.3.13 Angiotensinogen Results 
I found eleven relevant studies (3,528 subjects) for the association between 
the AGT Met235Thr polymorphism and CIMT.  After contacting authors, full 
data were still unavailable for five studies (2,273 subjects), resulting in 64% 
missing data.   
 
The meta-ANOVA of six studies (1,255 subjects) found no overall association 
between AGT and CIMT, with a p-value of 0.5, and so this gene was not 
analysed further. 
 
A large proportion of the relevant data were unavailable for this gene.  
However, none of these studies reported a significant association between 
AGT and CIMT and so they would seem unlikely to have altered the result 
shown here. 
 
3.3.14 Insulin-like Growth Factor 1 Results 
Only 1 study (5132 subjects) had analysed the association between the IGF1 
192bp allele and CIMT [Schut et al., 2003].  ANOVA found an overall 
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association between IGF1 and CIMT, with a p-value of 0.004.  MD1/MD2 for 
this study gave a λ of 0.5, suggesting that the polymorphism is co-dominant.  
The co-dominant random effects per-allele mean difference was 10μm (95% 
CI, 4 to 16, p=0.001).  Although this is a statistically significant association, it 
relies only on one study. 
 
3.3.15 C-Reactive Protein Results 
Only one study (4641 subjects) had analysed the association between CRP 
and CIMT [Lange et al., 2006].  Five SNPs were studied in this gene.  The 
results data were not available and could not be back-calculated, to enable 
ANOVA analysis for this paper.  However, they reported that there was no 
association between any of these SNPs and CIMT (p-values ranging from 
0.12 to 088). 
 
3.3.16 Adrenergic Beta-2 Receptor Results 
Only one study (1573 subjects) had analysed the association between the 
ADRB2 Gln27Glu polymorphism and CIMT [Hindorff et al., 2005].  This 
study analysed the polymorphism in a dominant model, and only presented 
data for the two groups.  I therefore calculated the mean difference between 
these two groups for this study and found that the dominant model mean 
difference was not significant, 10μm (95% CI -29 to 49, p=0.618). 
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3.3.17 Factor V Results 
I found three relevant studies (3,525 subjects) for the association between the 
FV Leiden mutation and CIMT.  After contacting authors, full data were still 
unavailable for one study (470 subjects), resulting in 13% missing data.   
 
The two studies with available data both analysed the data using a dominant 
model, and only presented data for the corresponding two groups.  I 
therefore calculated the random effects pooled mean difference between FV 
Leiden-positive and -negative subjects.  There was a significant association, -
20μm (95% CI, -29 to -12, p<0.001), suggesting the FV Leiden mutation may 
be associated with a decrease in CIMT, despite neither study reporting an 
independently significant result.  The study with unavailable data [Brenner 
et al., 2006] found no association between the FV Leiden mutation and CIMT.  
Since it was much smaller than the two included studies, its inclusion would 
be unlikely to have greatly altered the overall result. 
 
3.3.18 Fibrinogen Gamma/Fibrinogen Alpha Results 
Only one study (4,274 subjects) had analysed the association between the 
FGG and FGA gene polymorphisms [Kardys et al., 2007].  However, this 
study only carried out a haplotype analysis of both genes (including 7 SNPs) 
and did not report individual SNP distributions in relation to CIMT 
phenotypes.  Therefore, it was not possible to carry out a straightforward 
association analysis on these data.  However, the paper reported that no 
haplotypes were significantly associated. 
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3.3.19 Comparison of Sub-Group Analyses for APOE, ACE & MTHFR 
Figure 3.12 shows the subgroup meta-analyses for APOE, ACE and MTHFR, 
grouped by analysis.  This shows that all three polymorphisms show very 
similar subgroup patterns.  The studies of Asian subjects consistently had 
larger pooled mean differences than White or Black American populations.  
The difference between subgroups was highly significant for APOE 
(p<0.001), but not significant for the other two polymorphisms (ACE p=0.2; 
MTHFR p=0.1).  Studies of subjects at high vascular risk consistently showed 
larger pooled mean differences.  The difference between subgroups was 
significant for all polymorphisms (APOE p<0.001; ACE p<0.001; MTHFR 
p=0.002).  Smaller studies, also consistently showed larger pooled mean 
differences.  The difference between subgroups was significant for all 
polymorphisms (APOE p<0.001; ACE p=0.002; MTHFR p<0.001).  The larger 
pooled mean differences amongst smaller studies are suggestive of small 
study bias.  For each polymorphism, there was less heterogeneity between 
the larger studies (I2 values are between 80 and 85 for small studies and 
between 0 and 62 for large studies).  The results from the ethnicity and 
vascular risk status subgroup analyses may suggest that there is an 
interaction effect with these factors.  However, the high risk studies that 
show significantly larger pooled differences were smaller than the low risk 
studies for all polymorphisms (mean sample sizes for APOE, ACE and 
MTHFR were 169, 159 and 332 respectively for the high risk studies and 
1847, 843 and 702 for the low risk studies) and for APOE the studies of East 
Asian subjects had a smaller mean sample size (171) than the studies of 
White subjects (1251).  Therefore, study size may explain the apparent 
differences seen for ethnicity and vascular risk status. 
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Figure 3.12  Subgroup meta-analyses for APOE, ACE and MTHFR. A. shows the ethnicity 
subgroup analysis. B. shows the vascular risk status subgroup analysis. C. shows the study 
size subgroup analysis where for each gene the mean study size was used to split into 
small and large.  For each gene the appropriate genetic model was used. Co-dominant for 
APOE and ACE and recessive for MTHFR. 
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3.3.20 Minimising Bias by Obtaining Unpublished Data 
I determined the impact of attempting to collect missing data by comparing 
the before and after data collection percentages of missing data, and by 
carrying out the same analyses without the extra acquired data to see if 
different conclusions would have been drawn had I not included these 
papers.  Results are shown in table 3.9.  The percentage of missing data for 
some polymorphisms reduced hugely after acquisition of extra data.  
However, in most cases this did not have a significant effect on the results.  
The only polymorphism for which the overall conclusions would have been 
different is MTHFR, which showed a stronger association with CIMT before 
the extra data were collected, and had a mean difference that was much 
larger and a confidence interval that did not include 0 (54µm, 95% CI 16 to 
91). 
 
Table 3.9  % of missing data, meta-ANOVA p-values and mean differences before and 
after the acquisition of extra data by contacting authors. 




Meta-analysis mean difference 
before after before after before after 
APOE 5 2 <0.001 <0.001 22 (14 to 30) 25 (17 to 33) 
ACE 16 15 0.01 0.01 14 (5 to 23) 14 (5 to 22) 
MTHFR 41 24 0.01 0.02 54 (16 to 91) 31 (0 to 61) 
NOS3 45 40 0.3 0.3   
PON1 64 45 0.3 0.6   
IL6 51 33 0.7 0.4   
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3.3.21 Other Potential Genes of Interest 
There were 132 other genes studied in smaller numbers, which did not make 
it through to the meta-analysis stage of this review.  Many of these showed 
preliminary evidence for an association, but these findings would need to be 




Through carrying out a large systematic search, I identified more than 140 
genes that had been studied in association with CIMT.  I then reviewed in 
detail 122 studies (112,713 subjects) that had analysed the association 
between CIMT and the 13 most commonly studied genes.  Most of these did 
not show convincing evidence for an association.  APOE, ACE and MTHFR 
all showed a significant association with CIMT in the meta-ANOVA analysis.  
Of these, APOE ε was the only polymorphism that still showed an 
association when the analysis was restricted to larger studies only.  The 
results suggest that although there is an association between APOE and 
CIMT, the size of this association is over-estimated in the literature, due to 
small study bias.  I also found significant associations with CIMT of IGF1 and 
FV Leiden, but as they were only analysed in a few studies, these findings 
are still preliminary and warrant further investigation. 
 
3.4.1 Meaning of Effect Size 
The pooled estimate for the per-group mean difference between E4 and E3, 
and E3 and E2 groups across all studies was 25μm (95% CI 17 to 33).  When 
restricted to only the larger studies this estimate dropped to 8μm (95% CI 6 
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to 11).  Whilst still significant this is a rather small difference (equivalent to 
approximately 0.05 of one standard deviation) 
 
3.4.2 Effect of Sample Size 
Despite large numbers of studies (with hundreds of thousands of subjects) 
assessing the associations between candidate genes and CIMT, very few firm 
conclusions can be made.  However, this may not be surprising due to the 
nature of complex traits.  CIMT is a complex trait with many possible 
environmental and genetic risk factors, and it is likely that any genes that are 
associated will show only modest effects.  This may explain why APOE was 
the only gene with robust enough data to still show a significant effect in the 
large studies.  If the effect size is very small, then the number of subjects 
required for the test of association to be powerful enough is extremely large 
and perhaps APOE was the only gene with sufficient numbers.  The meta-
analysis of APOE was the largest, comprising of 32,253 subjects.  The overall 
number of subjects in the ‘large studies’ APOE subgroup was 27,231, much 
larger than the 12,261 for ACE or 6,008 for MTHFR.  This is important for 
informing new studies.  Probably, many tens of thousands of subjects in very 
well carried out studies are required before effects as small as that seen for 
CIMT can be properly identified. 
 
3.4.3 Subgroup Analyses 
The subgroup analyses for all three polymorphisms (APOE, ACE & MTHFR) 
show similar trends.  Asian subjects and subjects at high vascular risk tended 
to have greater mean differences than white subjects and subjects at low 
vascular risk, across all polymorphisms.  However, Asian ethnicity and 
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vascular high-risk status correlate with sample size, i.e. high-risk subjects 
and Asian subjects tend to be studied in smaller studies than population 
volunteers and white subjects.  Therefore, when there is heterogeneity 
between studies it is difficult to determine the cause.  It may be the case that 
there is an interaction effect with vascular risk or ethnicity, or perhaps the 
heterogeneity observed is caused by small study bias and it just so happens 
that Eastern Asian and high vascular risk subjects tend to be studied in 
smaller numbers.  As this phenomenon is observed for all polymorphisms it 
is more likely that it is caused by small study bias rather than real 
interactions.  In a previous meta-analysis of ACE and CIMT [Sayed-
Tabatabaei et al., 2003] (which is updated in the present study), the increased 
size of the association in high risk subjects was attributed to an interaction 
with smoking after further investigation [Sayed-Tabatabaei et al., 2004].  
Whilst this is possible, their investigations do not rule out the possibility that 
it is just due to small study bias.  
 
3.4.4 Genetic Model Selection 
For each polymorphism with an overall association, I chose the best genetic 
model using a linear regression method.  For APOE and ACE, the analysis 
suggested a co-dominant model should be used.  These are likely to be 
correct as APOE has been shown to follow a linear genetic model for lipid 
levels and coronary risk [Matsuoka et al., 2000] and serum levels for ACE 
follow a co-dominant genetic model [Rigat et al., 1990].  For MTHFR the 
estimated λ was 0.2 (95% CI ranging from 0.1 to 0.4).  This does not include 
any of the assumed genetic models (recessive=0, co-dominant=0.5, 
dominant=1), suggesting that none of these models are appropriate for this 
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polymorphism.  It is biologically feasible that λ could be equal to 0.2 in a (not 
completely) co-dominant model and this result demonstrates how genetic 
studies are limited by assuming certain genetic models.  For two 
polymorphisms (ADRB2 and FV) the data available from publications only 
allowed me to analyse the associations using dominant models.  However, it 
is likely that this is the most appropriate model as it was chosen by the 
paper’s authors because it is the accepted genetic model for these 
polymorphisms. 
 
3.4.5 Missing Data 
I attempted to obtain all relevant data by contacting authors when important 
data were unavailable from the publications.  Despite this, I was unable to 
collect full data for a large number of studies and for some polymorphisms 
the majority of studies. The large proportion of unavailable data highlights 
the impact of not collecting all data.  Many systematic reviews include in 
their selection criteria only papers with available data. I have shown this can 
miss a large proportion of the relevant data.  This probably introduces bias 
(known as reporting bias), as papers which do not fully report the data may 
not have found an association and so any estimates from a meta-analysis 
may over-estimate the association.  I aimed to minimise this bias by 
consistently reporting the overall qualitative results from these studies 
alongside the meta-analyses.  For most polymorphisms, I found that these 
missing studies would be unlikely to change the results significantly.  
However, two large studies for ACE with missing data found significant 
associations and so may have strengthened the association between ACE and 
CIMT.   
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The comparison from before and after the additional data were acquired 
from some authors showed similar results for most polymorphisms.  The 
only polymorphism for which different conclusions would have been drawn 
before the extra data collection was MTHFR.  The meta-ANOVA p-value was 
smaller (p=0.01, compared to 0.02 after) and the recessive mean difference 
was 54µm (95% CI 16 to 91) before and 31µm (95% CI 0 to 61) after.  
Therefore, without the inclusion of the extra data one would have concluded 
that there was a clear association between MTHFR and CIMT.  However, 
after inclusion of the extra data the influence of MTHFR on CIMT is much 
less clear.  Even for the polymorphisms for which the results did not 
significantly change, the inclusion of the extra data was important as it 
allows more of the data of interest to be assessed and so removes some of the 
potential bias that only including published results can cause. 
 
3.4.6 Linkage Studies 
Two linkage studies have identified quantitative trait loci for CIMT.  
Although none have replicated any of the candidate gene findings, they have 
identified some potential novel genes for CIMT.  One reported a maximum 
log odds (LOD) score of 4.1 at 161cM on chromosome 12, and subsequently 
found evidence of association with an atherosclerosis candidate gene 
(SCARB1, a high density lipoprotein receptor, cell-surface glycoprotein) from 
the region of linkage [Fox et al., 2004a].  The other identified 2q33-35 as a 
region with significant linkage (LOD=3.08), including the NOSTRIN, IGFBP2 
and IGFBP5 genes, none of which have yet been independently tested for an 
association with CIMT [Wang et al., 2005]. 
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3.4.7 Missing Heritability 
CIMT seemed to be a promising candidate as an intermediate trait for 
studying the genetics of stroke.  It seems to correlate with and predict stroke 
risk and is highly heritable, so why has studying it been so far fruitless in 
identifying associated genes?  Perhaps the initial estimates of heritability are 
over-estimated, there are many genes that influence CIMT and each have a 
very small undetectable effect, and/or the ‘wrong’ genes or polymorphisms 
could have been studied as candidates to date. 
 
There is evidence that APOE may be specifically associated with large artery 
stroke and so one would perhaps expect an association with CIMT.  Despite 
a significant overall association being found in the meta-analysis (even after 
restricting to only the larger studies), it is smaller than expected if APOE acts 
through CIMT to have an influence on susceptibility to stroke.  It may be the 
case that there are other stroke pathways in addition to the CIMT pathway 
that APOE affects.  If that was the case then instead of analysing CIMT 
increasing the power to detect an association with APOE compared with 
stroke, it may decrease the power. 
 
CIMT may follow the trend of other genetic studies for complex traits.  
Recent extremely large genome wide association studies have identified 
genetic association with important genes for complex traits such as diabetes, 
despite the candidate gene studies for these traits being relatively fruitless 
*The Wellcome Trust Case Control Consortium, 2007+.  The ‘big players’ may 
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emerge from these huge genome wide association studies simply because 
they have not been previously studied as candidates. 
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4 WMH Systematic Review and Meta-analysis 
 
This chapter comprises a systematic review and meta-analyses of the most 
commonly studied genetic polymorphisms in association with white matter 
hyperintensities. 
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4.1 Introduction 
4.1.1 White Matter Hyperintensities 
White matter hyperintensities (WMH) are changes of the white matter in the 
brain which show up as hyperintensities (increased signal intensities) on 
MRI (magnetic resonance imaging) or hypointensities on CT (computed 
tomography) [Fazekas et al., 2002].  Small amounts of WMH are thought to 
be the consequence of normal ageing [Awad et al., 1986].  These changes in 
the brain are often asymptomatic, but it has been shown that the presence of 
WMH is associated with a history of, and later progression to small-vessel 
 
Figure 4.1  Taken from Bronge et al. [1999], showing various types/stages of white 
matter hyperintensities (WMH). (a) small ‘caps’ adjacent to the frontal horns. (b) 
pronounced caps next to the frontal and posterior horns. (c) periventricular bands. (d) 
pronounced periventricular bands extending into deep WM. (e) punctuate deep WMH. 
(f) and (g) punctuate and patchy deep WMH. (h) confluent deep WMH. 
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disease (lacunar infarcts) and clinical small artery stroke [Leys et al., 1999].  
 
WMH are more prevalent in patients with lacunar ischemic stroke than in 
those with other stroke subtypes [Wiszniewska et al., 2000] and so are 
considered a useful quantitative trait for studying small artery (lacunar) 
ischemic stroke [Dichgans & Markus, 2005].  It has been suggested that 
lacunar infarction associated with WMH may reflect one subtype of small 
vessel disease pathology, with isolated lacunar infarction being the other 
subtype and having a different underlying vascular pathology [Markus, 
2008].  WMH are commonly seen in normal ageing, with prevalence estimates 
between 10% and 100% in different elderly populations [Bronge et al., 1999].  
WMH are more prevalent and severe in patients with cardiovascular disease 
and cardiovascular disease risk factors [Meyer et al., 1992].  Figure 4.1 shows 
the various stages and types of WMH. 
 
4.1.2 Definitions 
The term ‘WMH’ describes the phenomenon of a hyperintensity on an MRI 
scan in an area of white matter within the brain.  Several other terms used in 
the literature also describe WMH.  ‘Leukoaraiosis’, ‘white matter changes’ 
(‘WMC’) and ‘white matter lesions’ (‘WML’) are all broad terms that describe 
disease of the white matter, whether benign changes seen with normal 
ageing or changes associated with stroke, dementia or other diseases.  Often 
individual papers will use these terms with their own definition to describe a 
particular type of WMH.  ‘Age-related white matter changes’ (‘ARWMC’) 
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specifically refers to the benign changes seen with normal ageing.  For 
consistency I use the term WMH throughout this thesis. 
 
4.1.3 Measurement Methods 
As well as heterogeneity of terminology used to describe WMH, there is also 
heterogeneity in how these changes are measured.  WMH can be graded 
according to scales of hyperintensity severity or the volume of the ‘lesion’ 
can be estimated.   
 Methods which aim to estimate the volume of WMH are appealing 
because they provide an objective quantitative measure of the changes 
seen in the brain, which may in turn increase statistical power when 
testing for associations with WMH.  However, the measurement stage 
is time consuming and requires expensive equipment and high quality 
MRI protocols [Fazekas et al., 2002].  In addition, the WMH volume 
may not fully represent the clinical impact, since distribution and 
location are also of importance.   
 Grading scales have been developed to categorize the severity of 
WMH semi-quantitatively.  There are many scales in use; some for use 
with CT, some for use with MRI and some for use with either  
[Scheltens et al., 1998].  All scales rate WMH according to extent and 
severity, some rate periventricular hyperintensities (PVH) and deep 
white matter hyperintensities (DWMH) separately and some rate 
different parts of the brain separately.  Three commonly used rating 
scales are shown in table 4.1.  Many more grading scales also exist, 
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Table 4.1. Three commonly used grading scales for white matter hyperintensity (WMH) 
Name/Author Scan PVH/DWMH Grades (numbers and definitions) Areas scored Total score 
Fazekas 
[Fazekas et al., 1987] 
MRI PVH 0= absence 
1= ‘caps’ or pencil-thin lining 
2= smooth ‘halo’ 
3= irregular PVH extending into the DWM 
PVH as whole 0-3 
  DWMH 0 = absence 
1= punctuate foci 
2= beginning confluence of foci 
3= large confluent areas 
DWMH as whole 0-3 
Scheltens 
[Scheltens et al., 1993] 
MRI PVH 0= absent 
1= ≤ 5mm 
2= > 5mm and <10mm 
scored separately & summed: 
Occipital ‘caps’ 
Frontal ‘caps’ 
Lateral ventricle ‘bands’ 
0-6 
  DWMH 0= absent 
1= < 3mm, n ≤5 
2= <3mm, n>6 
3= 4-10mm, n≤5 
4= 4mm, n≤5 
5= >11mm, n>1 
6= confluent 







[Wahlund et al., 2001] 
Both Both 0= no lesions 
1= focal lesions 
2= beginning confluence of lesions 
3= diffuse involvement of the entire region 
one score for both PVH & 
DWMH 
0-3 
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including simply dichotomising patients into those with and without WMH 
(often with very different cut-offs).  Almost every study uses a subtly 
different scale, having imposed their own slight modification on the 
popularly reported scales.  Scheltens et. al. [1998] provides an overview of 
most of these scales.  They conclude that many scales lack reproducibility 
and that ‘the ideal rating scale does not yet exist’. 
 
4.1.4 Heritability 
The NHLBI twin study, amongst 74 monozygotic and 71 dizygotic World 
War II veteran twins, showed that 0.71 of the variability of WMH volume 
was due to additive genetic influences (after correcting for age and head size 
[Carmelli et al., 1998].  This is surprisingly high for a late developing 
condition, but twin studies tend to over-estimate genetic effects and this 
study was small and limited to an older population at probable high 
cerebrovascular risk.  However, in 2004, two studies confirmed the high 
heritability of WMH volume.  The Genetic Epidemiology Network Of 
Arteriopathy (GENOA) carried out a study in 483 subjects that were part of 
434 hypertensive sibling pairs.  They reported a heritability of 0.80 amongst 
this sample [Turner et al., 2004]. Also in 2004, the Framingham Study 
estimated that 0.55 of the variability of WMH volume was due to additive 
genetic effects (after adjusting for sex, age and cranial volume) in a large 
population based study (n=1330), spanning a broad age range [Atwood et al., 
2004].   
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4.1.5 Genetic Associations 
As heritability estimates for WMH have been consistently moderate to high it 
is possible that there are individual polymorphisms which have a reasonably 
large effect on this trait.  Many studies have analysed the association 
between candidate gene polymorphisms and WMH.  Most of these have 




I aimed to bring together all studies of the association between any genetic 
polymorphism and WMH and to perform detailed methodological 
assessments and meta-analyses of studies of polymorphisms studied in 
sufficiently large numbers of subjects to make this appropriate.  My intention 
was to provide an up-to-date summary of what is so far reliably known 
about genetics of WMH and which genes have been studied.  By pooling 
studies, the power to detect associations can be increased and potential 
reasons for heterogeneity of study results can be explored. 
 
4.2 Methods 
4.2.1 Initial Search Strategy 
I sought all papers describing studies of the association between any gene 
and WMH using a comprehensive search strategy in Medline (1966 to end 
2007) and Embase (1980 to end 2007), using all MeSH terms and textwords 
associated with WMH and all MeSH terms and textwords associated with 
genetics (see table 4.2) 




Table 4.2  Electronic literature search strategies. 
Medline (1966 to end 2007) 
 Search Terms 
1      exp genetics/ or exp genotype/ or exp inheritance patterns/ or exp "linkage 
(genetics)"/    or exp phenotype/ or exp "variation (genetics)"/ or chromosomes/ or 
exp genes/ or exp genome/ 
2      (polymorphi$ or genotyp$ or gene or genes or genetic$ or allel$ or mutat$).tw. 
3      1 or 2 
4      exp Leukoaraiosis/ 
5      (leukoaraiosis or leucoaraiosis or leukoariosis or leucoariosis or MARCD or 
microangiopathy related cerebral damage or microangiopathy-related cerebral 
damage).tw. 
6      (white matter lesion$ or WML or white matter hyperintensit$ or WMH or white 
matter change$ or small vessel disease or small-vessel disease or 
microangiopath$).tw. 
7      4 or 5 or 6 
8     7 and 3 
9      limit 8 to humans 
 
Embase (1980 to end 2007) 
 Search terms 
1      exp genetics/ or exp heredity/ or exp genetic disorder/ or genetic epidemiology/ or 
exp genetic analysis/ or exp population genetic parameters/ or quantitative trait/ or 
exp molecular genetics/ or exp genetic parameters/ or exp gene mapping/ 
2      (polymorphi$ or genotyp$ or gene or genes or genetic$ or allel$ or mutat$).tw. 
3      1 or 2 
4      exp LEUKOARAIOSIS/ 
5      (leukoariosis or leucoariosis or leukoaraiosis or leucoaraiosis or white matter 
lesion$ or WML or white matter hyperintensit$ or WMH or MARCD or 
microangiopath$ or white matter change$ or small vessel disease or small-vessel 
disease).tw. 
6      4 or 5 
7      3 and 6 
8      limit 7 to human 
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I read the titles of all studies identified from the search and excluded any 
papers that were obviously not relevant, then read the abstracts of all 
remaining studies and retained all potentially relevant studies (any original 
study of the association between any gene and WMH).  A second person 
(Wanting Chen) independently identified relevant papers from these 
searches.  I compared our two lists and compiled a final list of relevant 
studies.  Disagreements were resolved by discussion and where necessary by 
consultation with a third person (Cathie Sudlow).  I listed all genes that have 
been studied in association with WMH and calculated the number of studies 
and subjects for each gene. 
 
4.2.2 Genes/Studies Selected for Meta-Analysis 
Any gene for which the initial search identified more than 2000 subjects 
studied was carried forward to formal meta-analysis.  To ensure that all 
relevant papers were identified I carried out supplementary gene specific 
searches in Medline and Embase (replacing the general genetics terms with 
gene name terms) (see appendix 6).  Again, a second person (Wanting Chen) 
independently identified the relevant papers from these searches and 
disagreements were resolved by consultation with Cathie Sudlow.  I also 
checked the reference lists of the identified papers for further studies.  All 
studies that had measured the volume or grade of WMH in any area of the 
brain were included.  Studies with all types of subjects, including those with 
prior stroke were included.  Papers in all languages were sought.  Where 
studies appeared to use overlapping subject samples only the largest (with 
data available) were included in the analyses. 
 
Chapter 4 - WMH systematic review and meta-analysis 
132 
4.2.3 Data Extraction 
I designed a data extraction form (appendix 7), which two independent 
observers (myself and Wanting Chen) used to extract the following data from 
each study identified as potentially relevant: 
 
1. First author and year of publication 
2. Study name or research group name (if applicable) 
3. Number of subjects 
4. Gene and polymorphism studied 
5. Definition of WMH and the measurement method used 
6.  Country in which the study was conducted 
7. Genotyping method 
8. Whether genotyping was done blind to WMH assessment and vice 
versa 
9. Subject demographics; age, sex, ethnicity, whether from a particular 
patient group (e.g. patients with hypertension) or population 
sample/healthy volunteers. 
10. Concordance of genotypes with Hardy-Weinberg equilibrium (and I 
calculated this directly where possible) 
11. Results (see below for alternative forms) 
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Results were presented in three alternative forms in the papers: 
 WMH volume measured – mean & SD reported 
 WMH graded – mean & SD reported 
 WMH graded – numbers of subjects in each grade reported 
I analysed these three types of data separately.  For the studies where WMH 
was graded and numbers of subjects counted, the studies either reported the 
number of subjects in several grades or chose a particular grade to be the cut-
off and analysed the number of subjects above and below this cut-off for each 
genotype.  Where more than two groups were reported I chose as close to the 
following as possible for the cut-off: DWMH that were early confluent or 
confluent (Fazekas scale 2 or 3, or equivalent) were included in the upper 
group and only PVH that were classed as irregular (Fazekas scale 3 or 
equivalent) were included in the upper group.  This cut-off is the most 
commonly used and so reduced heterogeneity between studies.   
 
Where results were presented separately for several different brain locations 
I selected data from the deep white matter sub-scale only; this allowed the 
most consistent comparison across studies.  Where possible, the studies that 
included different groups of subjects were treated as separate sub-studies, 
for example those with and without dementia, hypertension or cerebral 
infarcts on brain imaging were separated for the purpose of the meta-
analyses. 
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4.2.4 Data Manipulation 
Where papers did not present data in the required format I had to carry out 
transformations of the data.  Some of these were similar to those for CIMT 
and I refer the reader to section 3.2.5.  Some specific manipulations of the 
data such as estimating values from graphs and back-calculating from odds 
ratios are presented in appendix 8. 
 
4.2.5 Statistical Analysis 
Most studies presented the data in either a dominant or recessive model, so 
for each polymorphism I analysed the data according to the most widely 
used genetic model from amongst the included studies.  The most commonly 
used model is generally the most biologically appropriate.  Furthermore, this 
approach allows the maximum number of relevant studies to be included in 
the meta-analyses.  
 
I carried out meta-analyses in Cochrane RevMan software (version 4.3[The 
Cochrane Collaboration, 2006]).  For dichotomous data studies I calculated 
study specific and pooled odds ratios (OR).  For continuous data studies I 
calculated study specific and pooled standardised mean differences (SMD), 
which measure the difference in units of standard deviation.  I used random 
effects in the primary analyses and also carried out the analyses using fixed 
effects. 
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I used the I2 statistic to assess heterogeneity between studies, where I2 
estimates the percentage of variation between studies that cannot be 
attributed to chance [Higgins et al., 2003]. 
  
4.3 Results 
4.3.1 Studies Identified in Initial Search 
Using the search strategies in table 4.2, 831 papers were found in Medline 
and 1239 papers were found in Embase. After duplicates were removed there 
were 1398 individual papers. After reading the titles and abstracts of these, 
45 studies were found to be potentially relevant for this review (after 
removing overlapping studies) [Amar et al., 1998; Bachmann et al., 1996; 
Barber et al., 1999; Bartres-Faz et al., 2001; Bigler et al., 2003; Bornebroek et al., 
1997b; Bornebroek et al., 1997a; Bracco et al., 2005; Bronge et al., 1999; de 
Leeuw et al., 2004; Decarli et al., 1999; Doody et al., 2000; Fornage et al., 2007; 
Gormley et al., 2007; Gurol et al., 2006; Hadjigeorgiou et al., 2007; Han et al., 
2005; Hassan et al., 2002; Hassan et al., 2004a; Hassan et al., 2004b; Henskens et 
al., 2005; Hirono et al., 2000; Hogh et al., 2007; Khan et al., 2007; Kohara et al., 
2003; Lunetta et al., 2007; Maia et al., 2006; Nebes et al., 2001; Purandare et al., 
2006; Reitz et al., 2007; Sawada et al., 2000; Schmidt et al., 1996; Schmidt et al., 
2000; Schmidt et al., 2001; Seifert et al., 2006; Sierra et al., 2002; Skoog et al., 
1998; Sleegers et al., 2005; Steffens et al., 2003; Szolnoki et al., 2004; Szolnoki, 
2007; van Rijn et al., 2006; van Rijn et al., 2007; Verpillat et al., 2001; Wen et al., 
2006].  After carrying out gene specific searches for the most commonly 
studied genes (APOE, ACE, MTHFR and AGT), only one further study was 
identified [Kuller et al., 1998] and searching the reference lists of included 
papers found no further studies.  This gave a total of 46 independent studies 
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that had analysed the association between a particular genetic polymorphism 
and WMH.  Table 4.3 shows the numbers of studies (and participants) for 
each of the genes studied for an association with WMH.  19 genes had been 
studied in a total of approximately 19,000 subjects (ranging between 40 and 
8546 for a particular gene).  Most of these genes are involved in lipid 
metabolism, vascular tone or blood pressure regulation.   
 
4.3.2 Study Selection for Meta-Analyses 
Four genetic polymorphisms (APOE (ε), ACE (I/D), MTHFR (C677T) and 
AGT (Met235Thr)) had been studied in more than 2000 subjects and so were 
included in the meta-analyses.  APOE was studied in 24 studies (8546 
subjects), MTHFR was studied in 3 studies (2796 subjects), ACE was studied 
in 9 studies (2319 subjects) and AGT was studied in 6 studies (2702 subjects).   
 
For APOE, ACE and AGT several relevant studies did not present the 
required data in their publications and so they could not contribute 
quantitatively to the meta-analyses.  However, I considered them 
qualitatively in the results.  All the relevant studies, along with details of the 
studied subjects are presented in table 4.4.  Studies were conducted in 
Europe, Japan, Hong Kong and USA.  Many of the studies recruited hospital 
patients while some recruited subjects from the general population.  Study 
participants were generally middle aged to elderly (mean age ranged from 52 
to 85).  Methodological details of the included studies are shown in table 4.5.  
Most studies reported that brain scan operators were blinded to genotype 
and that genotypes were in HWE.  The method of WMH quantification
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Table 4.3  Number of studies (and subjects) published by the end of 2007 assessing the association between any gene and WMH. 
Gene Polymorphism* Function
†




Apolipoprotein E ε2, ε3, ε4 Lipid metabolism 24 (8546) [Amar et al., 1998; Barber et al., 1999; 
Bartres-Faz et al., 2001; Bigler et al., 2003; 
Bornebroek et al., 1997b; Bracco et al., 
2005; Bronge et al., 1999; de Leeuw et al., 
2004; Decarli et al., 1999; Doody et al., 
2000; Gurol et al., 2006; Hirono et al., 2000; 
Hogh et al., 2007; Kuller et al., 1998; 
Lunetta et al., 2007; Maia et al., 2006; 
Nebes et al., 2001; Sawada et al., 2000; 
Schmidt et al., 1996; Seifert et al., 2006; 
Skoog et al., 1998; Steffens et al., 2003; 
Szolnoki et al., 2004; Wen et al., 2006] 
Methylenetetrahydrofolate 
reductase 
677 C/T Homocysteine metabolism 3 (2796) [Hassan et al., 2004b; Kohara et al., 2003; 
Szolnoki et al., 2004] 
Angiotensin converting 
enzyme 
I/D Renin-angiotensin system  
(BP/fluid balance) 
9 (2319) [Amar et al., 1998; Bartres-Faz et al., 2001; 
Gormley et al., 2007; Hassan et al., 2002; 
Henskens et al., 2005; Purandare et al., 
2006; Sierra et al., 2002; Sleegers et al., 
2005; Szolnoki et al., 2004] 
Angiotensinogen Met235Thr Renin-angiotensin system  
(BP/fluid balance) 
6 (2702) [Gormley et al., 2007; Henskens et al., 
2005; Schmidt et al., 2001; Sierra et al., 












Inflammation 1 (1323) [Reitz et al., 2007] 
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Endothelial nitric oxide 
synthase 
Glu298Asp Regulates vascular smooth muscle and 
endothelial function 
3 (1222) [Hassan et al., 2004a; Henskens et al., 
2005; Verpillat et al., 2001] 
Angiotensin II receptor 1 A1166C Renin-angiotensin system  
(BP/fluid balance) 
3 (1160) [Henskens et al., 2005; Sierra et al., 2002; 
van Rijn et al., 2007] 
Adducin 1 Gly460Trp Encodes cytoskeletal protein involved in 
blood pressure regulation 
1 (1014) [van Rijn et al., 2006] 
Endothelial 1 Not reported Vasoconstriction 1 (829) [Verpillat et al., 2001] 
Aldosterone synthase -344 C/T Blood pressure regulation 1 (758) [Verpillat et al., 2001] 
Kinesin light chain 1
 
185 A/C & 
406C/T 
Organelle transport 1 (493) [Szolnoki, 2007] 
Paraoxonase 1 Met55Leu & 
Arg192Gln 




242 C/T, 640 
A/G & 930 A/G 
Phagocyte oxidase system 1 (316) [Khan et al., 2007] 
Intercellular adhesion 
molecule 1 
Lys649Glu Inflammatory response (leukocyte-
endothelial adhesion) and endothelial barrier 
function 
1 (220) [Han et al., 2005] 
Presenilin 1 Not reported Catalyzes deposits of amyloid-beta  1 (65) [Bornebroek et al., 1997a] 
Apolipoprotein C Not reported Lipid metabolism 1 (58) [Bartres-Faz et al., 2001] 
Dystrophia myotonica-
protein kinase 
CTG repeat Modulation of cardiac contractility 1 (40) [Bachmann et al., 1996] 
* polymorphisms defined using their common name: 677 C/T notation refers  to the DNA base change; Glu298Asp notation refers to the amino acid 
change. 
†





Table 4.4  Subject characteristics of studies included in the meta-analyses of associations between WMH and APOE, ACE, MTHFR and AGT. 
 
Study N Country Subjects Male % Mean age HWE 
APOE       
[Schmidt et al., 1996]
 
214 Austria Population sample 50 61 yes 
[Bornebroek et al., 1997b] 25 Netherlands Patients with hereditary cerebral haemorrhage with amyloidosis - Dutch 
type  
48 52 yes 
[Amar et al., 1998](i) 29 UK Patients at memory disorder clinic with infarcts on CT/MRI brain scan NR 72 yes 
[Amar et al., 1998](ii) 149 UK Patients at memory disorder clinic without infarcts NR 72 yes 
[Kuller et al., 1998]* 3480 USA Elderly population sample NR >70 NR 
[Skoog et al., 1998](i) 72 Sweden Population  sample with dementia (DSM-III-R criteria) NR all 85 NR 
[Skoog et al., 1998](ii) 117 Sweden Population  sample without dementia NR all 85 NR 
[Barber et al., 1999]* 72 UK Patients with dementia 52 77 NR 
[Bronge et al., 1999]* 60 Sweden Patients with Alzheimer’s disease 38 64 yes 
[Decarli et al., 1999] 396 USA Twins recruited from register of Armed Forces veterans 100 72 NR 
[Doody et al., 2000] 104 USA Patients with Alzheimer’s disease 24 74 NR 
[Hirono et al., 2000] 131 Japan Patients with dementia 23 74 yes 
[Sawada et al., 2000] 55 Japan Patients with Alzheimer’s disease 36 76 NR 
[Bartres-Faz et al., 2001] 58 Spain Patients with age associated memory impairment NR 67 yes 
[Nebes et al., 2001] 92 USA Population sample NR 74 NR 
[Bigler et al., 2003]* 215 USA Population sample NR >65 NR 
[Steffens et al., 2003]* 245 USA Patients with major depression 33 70 NR 
[de Leeuw et al., 2004](i) 427 Netherlands Population - with hypertension 49 72 yes 
[de Leeuw et al., 2004](ii) 402 Netherlands Population - without hypertension 49 72 yes 
[Szolnoki et al., 2004] 944 Hungary Patients with cognitive complaints or headaches 54 62 yes 
[Bracco et al., 2005] 82 Italy Patients with Alzheimer’s disease 32 72 NR 
[Gurol et al., 2006]* 96 USA Patients with Alzheimer’s disease, mild cognitive impairment or 
cerebral amyloid angiopathy 
50 75 NR 
[Maia et al., 2006]* 23 Portugal Patients with primary intracerebral haemorrhage 50 72 yes 
[Seifert et al., 2006] 101 Austria Patients with nontraumatic intracerebral haemorrhage NR 69 yes 
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Study N Country Subjects Male % Mean age HWE 
[Wen et al., 2006] 67 Hong Kong Patients with lacunar infarct 46 71 NR 
[Hogh et al., 2007]* 75 Denmark Population sample NR 82 NR 
[Lunetta et al., 2007]* 815 MIRAGE
‡
 Patients with Alzheimer’s disease and siblings 41 73 NR 
ACE       
[Amar et al., 1998](i) 29 UK Patients at memory disorder clinic with infarcts on brain scan NR 72 yes 
[Amar et al., 1998](ii)
 
146 UK Patients at memory disorder clinic without infarcts NR 72 yes 
[Bartres-Faz et al., 2001]* 58 Spain Patients with age associated memory impairment NR 67 yes 
[Hassan et al., 2002] 84 UK Patients with lacunar syndrome + compatible lesion 52 70 yes 
[Sierra et al., 2002] 60 Spain Patients with hypertension 60 54 no 
[Sleegers et al., 2005] 494 Netherlands Population sample 52 69 yes 
[Szolnoki et al., 2004] 961 Hungary Patients with cognitive complaints or headaches 54 62 yes 
[Henskens et al., 2005]* 93 Netherlands Patients with hypertension 60 55 yes 
[Purandare et al., 2006] 97 UK Patients with dementia 53 75 yes 
[Gormley et al., 2007]
 
294 UK Patients with small vessel disease (& infarct on scan) 66 67 no 
MTHFR       
[Kohara et al., 2003] 1721 Japan Population sample 51 59 yes 
[Hassan et al., 2004b] 114 UK Patients with lacunar syndrome + compatible lesion on brain scan 59 67 yes 
[Szolnoki et al., 2004] 961 Hungary Patients with cognitive complaints or headaches 54 62 yes 
AGT       
[Schmidt et al., 2001] 396 Austria Population sample 48 60 yes 
[Verpillat et al., 2001]* 829 France Population sample 42 69 yes 
[Sierra et al., 2002] 60 Spain Patients with hypertension 60 54 yes 
[Henskens et al., 2005]* 93 Netherlands Patients with hypertension 60 55 yes 
[Gormley et al., 2007] 280 UK Patients with small vessel disease (& infarct on scan) 66 67 yes 
[van Rijn et al., 2007] 1044 Netherlands Population sample 41 70 yes 
 
* studies with result data unavailable, † MIRAGE sample includes subjects from USA, Canada, Greece and Germany. 
HWE= Hardy Weinberg equilibrium, NR= information not available 
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Table 4.5  Methods of genotyping and phenotyping for studies included in the meta-analyses of associations between WMH and APOE, ACE, MTHFR 
and AGT. 
Study Genotyping method scanner blind  
to genotype? 







APOE        
[Schmidt et al., 1996]
 
PCR + CfoI yes PV+DW grade Fazekas dichotomous PV3 DW2 
[Bornebroek et al., 1997b] PCR + HhaI yes DW grade Scheltens continuous - 
[Amar et al., 1998](i) PCR + CfoI yes PV grade +/- dichotomous +/- 
[Amar et al., 1998](ii) PCR + CfoI yes PV grade +/- dichotomous +/- 
[Kuller et al., 1998]* PCR + HhaI ? PV+DW grade 0-9 - - 
[Skoog et al., 1998](i) IEF yes PV+DW grade +/- dichotomous +/- 
[Skoog et al., 1998](ii) IEF yes PV+DW grade +/- dichotomous +/- 
[Barber et al., 1999]* PCR + CfoI yes DW grade Scheltens continuous - 
[Bronge et al., 1999]* micro-sequencing yes DW grade Scheltens continuous - 
[Decarli et al., 1999] PCR + HhaI yes ? volume - continuous - 
[Doody et al., 2000] PCR + HhaI yes DW grade Scheltens continuous - 
[Hirono et al., 2000] PCR + HhaI yes PV+DW grade Fazekas dichotomous PV3 DW2 
[Sawada et al., 2000] PCR + HhaI yes PV+DW grade Fazekas dichotomous PV3 DW2 
[Bartres-Faz et al., 2001] PCR + HhaI yes DW grade Scheltens continuous - 
[Nebes et al., 2001] ? ? DW grade 0-9 dichotomous 4 
[Bigler et al., 2003]* PCR +HhaI ? DW grade 4 point scale - - 
[Steffens et al., 2003]* PCR + HhaI ? DW volume segmentation continuous - 
[de Leeuw et al., 2004](i) PCR + CfoI yes DW volume 3 sizes, count continuous - 
[de Leeuw et al., 2004](ii) PCR + CfoI yes DW volume 3 sizes, count continuous - 
[Szolnoki et al., 2004] PCR + CfoI yes PV+DW grade Fazekas dichotomous PV3 DW2 
[Bracco et al., 2005] PCR + HhaI ? PV+DW grade ARWMC dichotomous 5 
[Gurol et al., 2006]* PCR + HhaI yes ? volume segmentation continuous - 
[Maia et al., 2006]* PCR + CfoI yes DW grade ARWMC - - 
[Seifert et al., 2006] PCR + HhaI ? ? grade Fazekas dichotomous 2 
[Wen et al., 2006] PCR + HhaI yes ? volume segmentation continuous - 
[Hogh et al., 2007]* PCR + CfoI ? PV+DW grade Scheltens continuous - 
[Lunetta et al., 2007]* ? yes ? grade 100 point scale continuous - 
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ACE        
[Amar et al., 1998](i) PCR yes PV grade +/- dichotomous +/- 
[Amar et al., 1998](ii)
 
PCR yes PV grade +/- dichotomous +/- 
[Bartres-Faz et al., 2001]* PCR yes DW grade Scheltens continuous - 
[Hassan et al., 2002] PCR yes PV grade 0-4 grade dichotomous 2 
[Sierra et al., 2002] PCR yes PV+DW grade Fazekas dichotomous 2 
[Sleegers et al., 2005] PCR yes DW volume 3 sizes, count continuous - 
[Szolnoki et al., 2004] I specific probe yes PV+DW grade Fazekas dichotomous PV3 DW2 
[Henskens et al., 2005]* PCR yes DW volume 3 sizes, count continuous - 
[Purandare et al., 2006] PCR yes DW grade Scheltens continuous - 
[Gormley et al., 2007]
 
RFLP yes ? grade Fazekas dichotomous 3 
MTHFR        
[Kohara et al., 2003] PCR yes PV+DW grade Fazekas dichotomous 3 
[Hassan et al., 2004b] ? yes PV+DW grade Fazekas dichotomous 3 
[Szolnoki et al., 2004] PCR yes PV+DW grade Fazekas dichotomous PV3 DW2 
AGT        
[Schmidt et al., 2001] PCR+ Asp I yes PV+DW grade Fazekas dichotomous 2 
[Verpillat et al., 2001]* ? ? PV+DW grade Scheltens dichotomous severe 
[Sierra et al., 2002] PCR+SfaNI yes PV+DW grade Fazekas dichotomous 2 
[Henskens et al., 2005]* multilocus assay yes DW volume 3 sizes, count continuous - 
[Gormley et al., 2007] RFLP yes ? grade Fazekas dichotomous 3 
[van Rijn et al., 2007] Taqman ? DW volume mean volume continuous - 
 
* studies with result data unavailable, ?=information not available, † numbers denote the grade which was considered to be in the upper group, +/- 
denotes where WMH was just defined as present or absent.  
PV= periventricular, DW= deep white matter. 
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varied between studies, but most studies used a grading scale and most only 
studied the deep WM.  Where two or more distinct populations were studied 
within one study, for the purposes of the meta-analyses, these were split into 
sub-studies.  These included subjects with and without dementia, infarcts 
and hypertension (substudies are denoted (i) and (ii) in tables and figures). 
 
4.3.3 Apolipoprotein E Results 
24 studies (8546 subjects) had assessed the association between WMH and 
the APOE ε polymorphism *Amar et al., 1998; Barber et al., 1999; Bartres-Faz 
et al., 2001; Bigler et al., 2003; Bornebroek et al., 1997b; Bracco et al., 2005; 
Bronge et al., 1999; de Leeuw et al., 2004; Decarli et al., 1999; Doody et al., 2000; 
Gurol et al., 2006; Hirono et al., 2000; Hogh et al., 2007; Kuller et al., 1998; 
Lunetta et al., 2007; Maia et al., 2006; Nebes et al., 2001; Sawada et al., 2000; 
Schmidt et al., 1996; Seifert et al., 2006; Skoog et al., 1998; Steffens et al., 2003; 
Szolnoki et al., 2004; Wen et al., 2006].  From nine of these (5081 subjects, i.e. 
59% of the total number of subjects from relevant studies) data were missing 
from the papers which prevented them from being included quantitatively in 
the meta-analyses [Barber et al., 1999; Bigler et al., 2003; Bronge et al., 1999; 
Gurol et al., 2006; Hogh et al., 2007; Kuller et al., 1998; Lunetta et al., 2007; 
Maia et al., 2006; Steffens et al., 2003].  However, I have shown qualitative 
results for these studies, which allows an informal assessment of their 
potential impact on the results.  Most studies presented data allowing 
analysis of the association between APOE and WMH with regards to the 
presence or absence of the ε4 allele in the genotype, and so this was the 
genetic model used in the meta-analysis (ε4+ versus ε4 -). 
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Depending on what data the papers presented they were included in one of 
three meta-analyses: 
 Eleven studies/sub-studies contributed to the comparison of numbers 
of subjects in lower and upper WMH grades between genotype 
groups (figure 4.2a).  None of the individual studies showed a 
significant association between ε4+/ε4- genotype and WMH, and 
overall there was no significant association with the random effects 
model (OR 0.97, 95% confidence interval (CI) 0.78 to 1.21), and no 
detectable heterogeneity between the contributing studies (I2=0%).  
Analysing the data using a fixed effects model gave a similar result 
(OR 0.96, 95% CI 0.77 to 1.20). 
 Three studies contributed to the analysis of standardised mean 
difference in grade between genotype groups (figure 4.2b).  Again, 
none of these studies showed a significant difference in WMH 
between ε4+/ε4- genotypes (pooled random effects SMD= 0.30, 95% CI 
-0.02 to 0.62), and there was no detectable heterogeneity between 
studies (I2=0%).  Analysing the data using a fixed effects model gave 
exactly the same result. 
 Four studies/sub-studies contributed towards the analysis of 
standardised mean difference in volume between genotype groups 
(figure 4.2c).  Although one of these studies found that ε4+ genotypes 
had a significantly larger standardised mean than ε4 - genotypes [de 
Leeuw et al., 2004], the pooled random effects SMD was not 
statistically significant (SMD=0.15, 95% CI -0.04 to 0.33).  There was, 
however, substantial heterogeneity between studies (I2=51%).  
Analysing the data using a fixed effects model gave a 
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Bartres Faz 2001 58
DeCarli 1999 396
De Leeuw 2004(i) 427
De Leeuw 2004(ii) 402
a. graded WMH (dichotomous)
b. graded WMH (continuous)
c. volume WMH (continuous)
Study Subjects
0.88 (0.34 to 2.28)
0.74 (0.16 to 3.50)
2.36 (0.87 to 6.44)
0.89 (0.41 to 1.92)
0.95 (0.47 to 1.89)
0.23 (0.03 to 2.09)
1.40 (0.52 to 3.72)
0.93 (0.67 to 1.31)
1.41 (0.57 to 3.45)
0.69 (0.26 to 1.84)
0.11 (-0.68 to 0.89)
0.35 (-0.07 to 0.78)
0.29 (-0.31 to 0.90)
0.05 (-0.19 to 0.29)
0.35 (0.14 to 0.55)
0.01 (-0.20 to 0.22)
Wen 2006 67 0.24 (-0.33 to0.82)
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e4e4 associated with WMH
No association
Gurol 2006 (96) E2 associated with WMH
*
-1.0 -0.5 0.0 0.5 1.0
*
Hogh 2007 (75)
Lunetta 2007 (815) E4 associated with WMH
SUB TOTAL 701/1986 0.97 (0.78 to 1.21)
SUB TOTAL 187 0.30 (-0.02 to 0.62)
SUB TOTAL 1292 0.15 (-0.04 to 0.33)
E4 associated with WMH
Figure 4.2  Study and pooled effects of the association between WMH and APOE genotype (ε4+ versus ε4-),using 
random effects. a. odds ratio between upper and lower WMH grade. b. standardised mean difference in WMH grade. c. 
standardised mean difference in WMH volume. Dashed lines – subjects with infarcts or hypertension. 
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marginally significant result (SMD=0.15, 95% CI 0.03 to 0.27). 
 
Of the nine studies from which data for meta-analysis could not be extracted, 
six had measured grade of WMH (figure 4.2).  Two of these reported a 
significant association, one was very small (n=75) [Hogh et al., 2007] and the 
other was relatively large (n=815) [Lunetta et al., 2007].  Of the four that 
reported no association, three were small [Barber et al., 1999; Bigler et al., 
2003; Maia et al., 2006], but one was conducted among 3480 subjects and so 
was larger than the total number of subjects from all studies contributing to 
the current meta-analysis [Kuller et al., 1998].  Three studies with missing 
data had measured WMH volume.  The largest of these (n=245) found no 
overall difference in WMH volume between genotypes [Steffens et al., 2003].  
The other two reported apparent, but different, associations between APOE 
and WMH (one found that ε4ε4 homozygotes had a significantly increased 
WMH volume compared to other genotypes [Bronge et al., 1999], and the 
other that ε2+ genotypes increased WMH volume [Gurol et al., 2006]). These 
were both very small studies with <100 subjects.   
 
4.3.4 Angiotensin Converting Enzyme Results  
Nine studies (2316 subjects) had assessed the association between ACE (I/D) 
and WMH [Amar et al., 1998; Bartres-Faz et al., 2001; Gormley et al., 2007; 
Hassan et al., 2002; Henskens et al., 2005; Purandare et al., 2006; Sierra et al., 
2002; Sleegers et al., 2005; Szolnoki et al., 2004].  From two of these (151 
subjects, i.e. 7% of the total number of subjects from relevant studies) data for 
meta-analyses were not available in the publications, but qualitative results 
could be extracted and are shown [Bartres-Faz et al., 2001; Henskens et al., 
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2005].   The largest included study analysed the data according to a recessive 
model (DD v ID/II) [Szolnoki et al., 2004].  Furthermore, this model has been 
used in previous large analyses of the association between ACE and both MI 
and ischaemic stroke [Agerholm-Larsen et al., 2000], and so was the model 
used in the meta-analyses.  
 Six studies/sub-studies measured grade of WMH and contributed to 
the comparison of numbers of subjects with upper and lower WMH 
grades between genotype groups (figure 4.3 a).  The pooled random 
effects estimate suggests a significant association between ACE (I/D) 
and WMH (OR 1.95, 95%CI 1.09 to 3.48).  The fixed effects model was 
also significant (OR 1.36, 95% 1.08 to 1.72).  However, there was 
substantial heterogeneity between study results (I2=71%).  Although 
three individual studies/sub-studies found a significant association, all 
were small.  However, it is of possible interest that these three studies 
were conducted among subjects with lacunar syndrome [Hassan et al., 
2002], infarcts on scan [Amar et al., 1998] or hypertension [Sierra et al., 
2002] and so at high risk of developing small vessel disease.  
 One study with data available analysed the WMH grade as a 
continuous variable, but this study was small [Purandare et al., 2006].  
Although the result is in the same direction as for the dichotomous 
analysis, the SMD was not significant (figure 4.3b). 
 One study with data available measured WMH volume [Sleegers et al., 
2005] and found no association with ACE genotype (figure 4.3c).  
 
The required data for meta-analysis could not be extracted from two studies.  
One had measured WMH volume and analysed data under a recessive 
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model (as used above) [Henskens et al., 2005], while the other had measured 
WMH grade and analysed these data according to a dominant model 
[Bartres-Faz et al., 2001].   Neither study reported an association between 
ACE (I/D) and WMH. 
*
Study








a. graded WMH (dichotomous)
b. graded WMH (continuous)
SUB TOTAL 623/1574
Study Subjects
15.43 (1.60 to 148.82)
1.54 (0.77 to 3.07)
7.89 (1.70 to 36.62)
4.44 (1.48 to 13.32)
1.11 (0.81 to 1.53)
1.95 (1.09 to 3.48)
No association under dominant model
Sleegers 2004 494
c. volume WMH (continuous)
-0.06 (-0.26 to 0.13)
0.1 1.0 10.0 100.0
Henskens 2005 (93) No association *
Standardised mean difference
Odds Ratio and 95% CI
Purandare 2006 97 0.41 (-0.07 to 0.89)
-1.0 -0.5 0.0 0.5 1.0
Gormley 2007 158/294 0.99 (0.60 to 1.65)
 
Figure 4.3  Study and pooled effects of the association between WMH and ACE genotype (DD versus ID / 
II) using random effects. a. odds ratio between upper and lower WMH grade. b. standardised mean 
difference in WMH grade. c. standardised mean difference in WMH volume. Dashed lines – subjects with 
infarcts or hypertension. 
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4.3.5 Methylenetetrahydrofolate Reductase Results 
Three studies (2796 subjects) had assessed the association between MTHFR 
(C677T) and WMH [Hassan et al., 2004b; Kohara et al., 2003; Szolnoki et al., 
2004].  The most common genetic model for analysing the data was the 
recessive model (TT v CT/CC), and so this was used in the meta-analysis.  All 
studies had measured WMH grade and none lacked data for inclusion in our 
meta-analysis.  
 None of the studies individually showed an association between the 
MTHFR polymorphism and WMH, and overall there was no 
significant association with the random effects model (OR 1.10, 95% CI 
0.85 to 1.43) (figure 4.4) or the fixed effects model (OR 1.11, 95% CI 
0.85 to 1.43).  There was no excess heterogeneity (I2=0%).  
 
4.3.6 Angiotensinogen Results 
Six studies (2702 subjects) had assessed the association between AGT 
(Met235Thr) and WMH [Gormley et al., 2007; Henskens et al., 2005; Schmidt 







1.57 (0.64 to 3.87)
1.12 (0.77 to 1.64)
1.02 (0.69 to 1.50)
1.10 (0.85 to 1.43)
Odds Ratio and 95% CI
0.1 1 10  
Figure 4.4  Study and pooled odds ratios of the association between upper and lower WMH 
and MTHFR genotype (TT versus TC / CC) using random effects. Dashed lines – subjects with 
infarcts. 
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et al., 2001; Sierra et al., 2002; van Rijn et al., 2007; Verpillat et al., 2001].  From 
two of these (922 subjects, i.e. 34% of the total number of subjects from 
relevant studies) data for meta-analyses were not available in the 
publications, but qualitative results could be extracted and are shown 
[Henskens et al., 2005; Verpillat et al., 2001].  The most common genetic 
model for analysing the data was the recessive model (TT v MT/MM), and so 
this was used in the meta-analysis. 
 
 Three studies measured grade of WMH and contributed to the 
comparison of numbers of subjects with upper and lower WMH 
grades between genotype groups (figure 4.5a).  The pooled random 
effects estimate suggests no association between AGT and WMH (OR 





a. graded WMH (dichotomous)
0.82 (0.18 to 3.79)
2.20 (1.23 to 3.94)
0.87 (0.44 to 1.71)
Odds Ratio and 95% CI
0.1 1 10
Verpillat 2001 (829) No association *
b. volume WMH (continuous)
Henskens 2005 (93) No association
Van Rijn 2007 1044
SUB TOTAL 248/736 1.29 (0.62 to 2.68)
*
0.18 (0.01 to 0.35)
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Standardised mean difference
 
Figure 4.5  Study and pooled effects of the association between WMH and AGT genotype 
(TT versus TM / MM) using random effects. a. odds ratio between upper and lower WMH 
grade. b. standardised mean difference in WMH volume. Dashed lines – subjects with infarcts 
or hypertension. 
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1.29, 95% CI 0.62 to 2.68) and the fixed effects model gave a similar 
result (OR 1.38, 95% CI 0.90 to 2.11).   
 One study with data available measured WMH volume.  They found a 
small but significant association between TT and WMH (figure 4.5b) 
[van Rijn et al., 2007].  
 
One large study (n=829) with data unavailable had measured WMH grade 
[Verpillat et al., 2001].  This study reported no significant association.  One 
study with data unavailable had measured WMH volume [Henskens et al., 
2005].  This study was small (n=93) and reported no significant association. 
 
4.3.7 Other Potential Genes of Interest 
Table 4.3 includes all the other genes that have been studied for their 
association with WMH, generally just in one or a few studies and small 
numbers (<1500 subjects).  Many of these genes showed preliminary 
evidence for an association with WMH (e.g. CYP11B2, protein kinase on 
chromosome 19, and ICAM), but these need to be replicated in much larger 
samples before any conclusions can be drawn. 
 
4.4 Discussion 
Through carrying out a large systematic search I identified 19 genes that had 
been studied for an association with WMH.  I then reviewed in detail and 
carried out meta-analyses for those genes which had been studied in more 
than 2000 subjects: APOE ( ), ACE (I/D), MTHFR (C677T) and AGT 
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(Met235Thr).  None of these showed a convincing association with WMH 
and ACE I/D was the only polymorphism for which the evidence suggests a 
possible association. 
 
4.4.1 Lack of Evidence 
Despite the potential promise of WMH as a quantitative intermediate 
phenotype for study of genetic influences on small vessel disease, and the 
large number of studies of many genes (representing mainly lipid 
metabolism, vascular tone and blood pressure regulation pathways), these 
studies are generally individually small and by the end of 2007 only four 
genetic polymorphisms had been studied in a total of more than 2000 
subjects. 
 
Reliable conclusions cannot be drawn when the number of subjects studied is 
small because of lack of precision of results.  Thus, meta-analyses were only 
conducted where the total number of subjects was in excess of 2000.  Even 
with this approach there is much potential for small study (mainly 
publication) and other sources of bias. 
 
4.4.2 No Association Found with APOE, MTHFR or AGT 
No convincing association was found between WMH and APOE, MTHFR or 
AGT.  Although there was a substantially large proportion of missing data in 
the APOE and AGT analyses it is unlikely that the inclusion of any these 
missing studies would have led to the identification of an association 
between APOE or AGT and WMH – indeed their inclusion would almost 
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certainly have strengthened the conclusion of no association, based on 
qualitative assessment. 
 
For APOE, 95% CIs of the meta-analyses include the possibility of a small or 
moderate association, but studies not included (because of missing data) 
mainly showed no association and so anything other than an extremely 
modest association seems unlikely.  This is consistent with results of 
previous work by our group.  In a previous meta-analysis of the association 
between APOE and stroke, it was found that in the few studies that studied 
the association of APOE with subtypes of ischaemic stroke, there appeared to 
be an association with large artery stroke, but not small artery stroke 
[Sudlow et al., 2006].  As WMH are associated with - and reflect the vascular 
pathology underlying of - small artery stroke, this is consistent with the 
notion that APOE is less important in the disease pathway of small artery 
stroke.   
 
For MTHFR and AGT, the wide 95% CI includes the possibility of an 
association, but so far no association has been found with WMH, and much 
larger studies will be needed to detect a small to moderate association. 
 
4.4.3 ACE May be Associated With WMH 
ACE I/D was the only polymorphism to show an overall association with 
WMH (measured and analysed as a grade).  However, none of the four 
studies which had missing data (and so did not contribute to our graded 
meta-analysis) found an association and so the apparent association from our 
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meta-analysis may well be prone to bias.  Only 7% of the data were missing, 
but often unreported results are negative (reporting bias) and so would 
probably decrease the association if included. 
 
4.4.4 Infarct and Hypertension Samples 
For all polymorphisms studied in this meta-analysis, the only studies which 
gave individually positive results are those carried out in subjects that have 
had a clinical stroke, have infarcts on scan or are hypertensive (dotted lines 
in the figures).  It could be that there is actually an interaction effect and the 
genotype is more influential on WMH in those subjects already with infarcts 
or hypertension.  This result could also represent bias as these studies use 
hospital subjects, which tend to be small and so may be prone to small study 
bias.  The three studies that were significant in the ACE analysis all had 
infarcts or hypertension and were very small studies (number of subjects 
ranging from 29 to 84).  Further work with large numbers of patient subjects 
is required to ascertain whether the association is a result of bias or a real 
interaction effect.  This correlation between high-risk samples and small 
samples has been observed in other meta-analyses [Sayed-Tabatabaei et al., 
2003] and one needs to be careful to interpret the meaning of this. 
 
4.4.5 Limitations 
As always the comprehensiveness of a meta-analysis depends on the data 
available from the individual studies of which it is made up of.  Several 
restrictions on the data from these studies prevented me from being as 
thorough in my analyses as I would have liked.   
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4.4.5.1 WMH measurement method 
Several methods for measuring WMH have been implemented and so for 
each polymorphism the data could not always be combined into one 
analysis.  It may be that there is only enough power to observe an association 
when an accurate measurement of WMH volume is taken and that grading 
simply is not powerful enough, or that the real difference is observed when 
the subjects are dichotomised into ‘normal’ WMH variation and ‘abnomal’ 
WMH variation.  Volume methods have the advantage of theoretically 
increased statistical power but require more sophisticated and costly imaging 
equipment and software and also lack information on the WMH location and 
so may lack information on the clinical impact.  Some grading scales grade 
various parts of the brain separately and so may provide more clinically 
relevant information.  However, since these separate grades are then often 
combined into one global estimate of WMH, the information on severity in 
different regions is lost.  A further problem with dichotomous analyses is 
that they may be data derived and so prone to bias.  I also question whether 
data using the grading scale should be analysed as a continuous trait.  
Grading WMH into several categories is unlikely to produce a normal 
distribution and assumptions made in the analysis of a continuous trait break 
down. 
 
Within the grade and volume methods many different techniques were used.  
I attempted to make these as consistent as possible across studies when 
selecting which data to extract.  For example, despite several grades being 
used across studies it was fairly easy to consistently pick a cut-off that 
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represented the same amount of WMH irrespective of the scale used.  Most 
studies analysed here use graded measures of WMH.  Volume studies (if 
carried out carefully) may produce more consistent results. 
 
4.4.5.2 Genotype model 
The analysis was also limited by the genotype models used in individual 
studies.  For all four polymorphisms analysed here I chose the most 
commonly used genotypic model to allow the largest analysis of the data.  
These models were usually chosen by the individual authors because they 
were backed up with plausible biological explanations but it is possible that 
the model is incorrect with regards to WMH.  For example one excluded 
study for APOE [Gurol et al., 2006] showed an association between ε2+ 
genotypes and WMH but as almost all the other papers had analysed the 
data with respect to the ε4 allele, a meta-analysis of the impact of ε2 was not 
possible. 
 
4.4.5.3 Missing Data 
Missing data obviously adds to the limitations of the analyses.  However, I 
attempted to minimise this by qualitatively assessing these studies and in 
most cases it seemed that their inclusion would be unlikely to affect the 
results.  Most meta-analysis studies in stroke have used ‘availability of 
relevant data from publication’ as a study inclusion criterion.  They are 
therefore not as comprehensive as perhaps a meta-analysis should be, 
especially as reporting bias is likely to mean that the unavailable data are 
quite different to the available data.  And so, one strength of this WMH 
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meta-analysis is that I did attempt to assess qualitatively the impact of the 
missing data.  I did not attempt to obtain missing data from the individual 
authors as the value of this would have been minimal.  
 
4.4.6 Comparing Results to Genome-Wide Linkage Scans 
A genome-wide linkage scan for WMH volume has been carried out in the 
Framingham study [DeStefano et al., 2006].  A 10cM density microsatellite 
genome linkage scan was performed on 747 subjects in 237 families.  A 
significant log odds (LOD) score of 3.69 was observed at 4cM on 
chromosome 4; a region in which no candidate gene has so far been studied 
in WMH.  A suggestive LOD score of 1.78 was also observed at 95cM on 
chromosome 17; this region is within 10cM of the ACE gene and so this could 
tie in with the results observed in this meta-analysis.  It could be that the 
ACE I/D polymorphism is the causal allele and linkage disequilibrium in the 
region caused a suggestive linkage peak at 95cM, or perhaps the causal allele 
is at a different location in the region and linkage disequilibrium explains the 
association with ACE, or even that there are multiple alleles of interest in this 
region.  It is also possible that this suggestive peak is just a spurious artefact 
and there could be no true linkage between a gene in this region and WMH. 
 
Another genome-wide scan of 366 microsatellites carried out in the GENOA 
(Genetic Epidemiology Network of Arteriopathy) study using 488 subjects 
from 223 sibships found only tentative evidence of linkage (maximum LOD 
scores of 1.30 to 1.99) for WMH volume in several novel regions [Turner et 
al., 2005]. 
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Regions containing APOE, MTHFR and AGT have not yet been highlighted 
as possible regions of interest in genome-wide linkage scans.  This could be 
because these genes are not associated with WMH at all, that the genome-
wide linkage scans have not been powerful enough to pick up modest 
signals or that the regions which these three genes lie in may not be well 
covered by the genotyping chips used in these studies.  More recently 
designed SNP (single  nucleotide polymorphism) chips have much greater 
coverage (newest generation of chips in excess of one million SNPs). 
 
4.4.7 Missing Heritablility 
As quoted in the introduction to this chapter, the estimates for the 
heritability of WMH have been consistently high, ranging from 55 to 71% 
[Atwood et al., 2004; Carmelli et al., 1998; Turner et al., 2004]. Of all the genes 
studied in candidate gene association studies, no large genetic influences 
have yet been found.  There are several explanations for this.  The initial 
estimates of heritability may have been false or misleading.  Of particular 
note is that the heritability studies were of WMH volume and the association 
studies were predominantly of WMH grade.  Therefore, volume may be a 
more heritable trait than WMH grade.  This may suggest that using WMH 
volume may be more appropriate in the association studies.  However this 
would need to be investigated further.  Other possible explanations are the 
polymorphisms analysed here are associated but that methodological issues 
have prevented the detection of this, or that other novel genetic 
polymorphisms yet to be studied have important effects on WMH.  All of 
these reasons probably contribute somewhat to the discrepancy between 
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high heritability of WMH and the lack of convincing genetic associations 
identified so far. 
 
4.5 Conclusion 
No genetic polymorphism has been convincingly associated with WMH and 
ACE I/D is the only polymorphism for which the evidence suggests a 
possible association with WMH.  This meta-analysis shows that APOE (ε) is 
unlikely to be associated with WMH consistent with previous work showing 
APOE to be associated with large artery but not small artery stroke.  The 
genetics of WMH is a promising area of study, but like many other areas of 
complex disease genetics it requires much larger studies and internationally 
agreed measurement methods to allow comparability of study results and to 
improve opportunities for pooling data and meta-analyses.  The ideal WMH 
measure for future studies would need to be heritable, representative of 





5 Systematic Review Discussion 
 
In this chapter I discuss the results from the two systematic reviews from 
chapters 3 and 4 and I put the results in the context of the wider stroke 
literature.  I also discuss the strengths and limitations of the meta-analyses.  
Finally, I use the results of the meta-analyses to design a hypothesis to test in 
the Edinburgh Stroke Study 
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5.1 Findings 
Despite carotid intima-media thickness (CIMT) and white matter 
hyperintensities on brain scans (WMH) having been studied in association 
with many genes in hundreds of studies using thousands of subjects, few 
firm conclusions can yet be made about which genes are associated with 
these traits.  The study methodologies for both traits were somewhat 
heterogeneous, particularly for WMH, where the different ways of reporting 
extent of WMH meant that not all studies could be combined to obtain a 
single pooled estimate.  No gene has shown a convincing association with 
WMH, with ACE showing only a possible association.  APOE is the only 
gene showing a convincing association with CIMT, with a meta-analysis 
restricted to the large studies showing an overall per genotype group mean 
difference of 8µm (95% CI, 6 to 11), with E4 greater than E3, and E3 greater 
than E2. 
 
5.1.1 Sample Size 
The fact that the meta-analysis between APOE and CIMT was both the 
largest (>32,000 subjects) and the only one showing significant overall 
association may indicate that the others are still under-powered.  Or, this 
pattern may just be because a promising genetic association with many 
positive studies is more likely to be replicated in different populations and 
by different groups, whilst an association that has shown little promise in 
early studies is less likely to be studied further.  Regardless, it appears that 
very large numbers of subjects are required reliably to detect what appear to 
be only small associations with intermediate traits for stroke.  
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The sample size calculations for CIMT associations are shown in table 5.1.  
Most genes in the CIMT meta-analyses had minor allele frequencies (MAFs) 
of (or the equivalent of, for APOE) approximately 0.45 (APOE, ACE, IL6, 
AGT), 0.30 (MTHFR, NOS3, PON1, IGF1) or 0.20 (ADD1).  The table shows 
that the required number of individuals to detect a 10µm per genotype 
difference for a co-dominant model with a MAF of 0.45, to achieve 80% 
power at p < 0.05 is  >4000 (assuming a mean and SD CIMT of 700 ± 160µm 
[Lorenz et al., 2007]).  The mean sample size of the ‘large’ studies for APOE 
was 4539 and so these were powered adequately to detect this effect size.  
The mean sample size of the ‘large’ studies for ACE was 2452 and so these 
were only powered to detect effect sizes in the region of 20µm.  The CI for 
the mean CIMT difference between the ACE genotypes was 0 to 8µm and so 
studies have not been adequately powered to detect any small effect that 
ACE might have.  The sample size calculations suggest that if there is a small 
effect for ACE (~5µm) then more than 16,000 subjects will be needed to detect 
a significant association (p<0.05).  The combined total of the ‘large’ studies do 
not reach this total (n=12,260).  Table 5.1 shows that compared to the co-
dominant model, recessive and dominant models require much larger 
sample sizes to detect the same effect size.  For MTHFR (MAF = 0.30, 
recessive) to detect a 10µm difference requires more than 24,000 subjects.   
 
Table 5.2 shows the sample size calculations for dichotomous WMH graded 
associations.  If there is a true association between WMH and APOE or 
MTHFR then the odds ratio (OR) is likely to only be in the region of 1.2.  The 
table shows that overall no polymorphisms were studied in enough subjects 
(pooled) to be adequately powered to detect an odds ratio (OR) of 1.2 (>4650 




Table 5.1  Sample sizes required to achieve 80% power to detect a p<0.05 significant mean difference (ranging from 5 to 50µm), with minor allele 
frequencies of 0.2, 0.3 and 0.45.  The shaded columns show the values for APOE and ACE (MAF 0.45, co-dominant) and MTHFR (MAF 0.30, 








Table 5.2  Sample sizes required to achieve 80% power to detect a p<0.05 significant OR (ranging from 1.1 to 2), with minor allele frequencies of 0.2, 
0.3 and 0.45.  The shaded columns show the values for APOE and ACE (MAF 0.45, dominant) and MTHFR (MAF 0.30, recessive), assume a 
case:control ratio of 1:1 (with and without WMH). Calculated using Quanto version 1.2.3 [Gauderman WJ & Morrison JM, 2006]. 
 
 Minor allele frequency 
 0.20 0.30 0.45 
Odds ratio Recessive (r) Co-dominant (c) Dominant (d) r c d r c d 
1.1 86154 10504 14814 40594 8082 13854 20814 6956 16704 
1.2 22628 2802 4008 10714 2176 3798 5552 1898 4652 
1.5 4138 536 794 1986 426 780 1060 386 992 
2.0 1248 174 268 610 142 276 340 136 368 
 Minor allele frequency 
 0.20 0.30 0.45 
Effect size Recessive (r) Co-dominant (c) Dominant (d) r c d r c d 
5μm 209,300 25,112 34,880 98,131 19,132 32,158 49,764 16,233 38,088 
10μm 52,322 6,275 8,717 24,560 4,780 8,037 12,438 4,055 9,519 
20μm 13,078 1,566 2,176 6,130 1,192 2,006 3,107 1,001 2,377 
50μm 2,089 247 345 977 187 318 494 158 377 
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frequency), >10,700 for MTHFR – MAF 0.30 recessive).  Most individual 
studies were not powered to detect an OR of less than 2 (>368 subjects for 
APOE and ACE, >610 subjects for MTHFR).  Calculations assume a 
case:control ratio of 1:1.  All sample size calculations were carried out in 
Quanto (version 1.2.3 [Gauderman WJ & Morrison JM, 2006]). 
 
Generally very few studies have been large enough to detect the small effect 
sizes that probably exist, and if there are interacting factors and/or 
phenotypic heterogeneity within studies that increase the complexity of the 
association, then even larger studies will be needed to achieve the same 
power.  Even after pooling studies in meta-analyses in this thesis, the sample 
sizes achieved are not sufficient to detect the most likely effect sizes with 
strong power in most cases.  The samples required to achieve appropriate 
statistical power are often well outside the scope of what single studies can 
feasibly achieve.  This highlights the need for large and consistent studies 
that can be pooled successfully in the future. 
 
5.1.2 The Effects of Risk Factors, Ethnicity, and Study Size 
For both the CIMT and WMH meta-analyses the more extreme estimates of 
effect (mean differences or odds ratios) were seen in studies of subjects 
considered to be at high risk of vascular disease.  This included those with a 
history of vascular disease or with vascular risk factors such as hypertension.  
However, these studies tended to be based on small hospital samples and so 
are prone to small study bias.  CIMT subgroup analyses also showed that 
studies of Eastern Asian subjects appeared to have more extreme estimates 
than studies of White subjects.  But, again the Eastern Asian studies tended 
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to be smaller and so may be prone to small study bias.  An ethnicity 
sensitivity analysis was not carried out for WMH as there were very few 
non-white studies and no evidence of heterogeneity between studies. 
 
The same subgroup patterns appear for all genes (higher effect estimates in 
Eastern Asian and high vascular risk subjects).  In a previous study 
investigators have noticed a tendency for high risk subjects to show more 
extreme estimates of association and have concluded that there must be 
important interactions [Sayed-Tabatabaei et al., 2003].  However, the 
consistent pattern seen in the CIMT and WMH results show that these 
differences may be explained by study size bias and so results of this type  
need to be interpreted with caution. 
 
5.2 Potentially Important Genes and Gene Pathways for 
Stroke 
The genes that have been studied for an association with CIMT, WMH or 
even stroke have been chosen by the investigators of these studies because 
they make good candidates.  This is often because they are already known to 
play a major role in a pathway that is considered important for the trait or 
disease endpoint.  This explains why the same genes have been investigated 
for WMH, CIMT, ischaemic stroke (IS) and ischaemic heart disease (IHD).  
Many of the genes studied in my meta-analyses have also been included in a 
recent meta-analysis of commonly studied genes for IHD [Kitsios & 
Zintzaras, 2007].  It also explains why many of the genes studied are related.  
When a pathway is considered important, it is common for several of the key 
players in this pathway to be investigated.  For each of the genes reviewed in 
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this thesis, I will now discuss the pathways that they are involved in, 
showing why various candidates seem attractive choices for influencing 
stroke and its intermediate traits.  Table 5.3 shows the pathways that genes 
from the meta-analyses (chapter 3 and 4) are involved in. 
 
5.2.1 Lipid Metabolism 
Since cholesterol levels are an important risk factor for stroke and other 
vascular diseases, genes from the lipid metabolism pathway are ideal 
candidates for stroke and have been studied extensively for both IHD and IS.  
APOE (which I studied in both the CIMT and WMH meta-analyses) and 
PON1 (in the CIMT meta-analysis) are both key candidates from this 
pathway. 
 
Table 5.3  Pathways and genes included in my meta-analyses of the association of 
commonly studied genes with CIMT and WMH. 
 
Pathway Genes in CIMT 
meta-analysis 
Genes in WMH 
meta-analysis 
   
Lipid metabolism APOE APOE 
 PON1  
   
Vascular homeostasis ACE ACE 
 AGT AGT 
 NOS3  
 IGF1  
 ADRB2  
   
Metabolic factors MTHFR MTHFR 
   
Haemostasis Factor V  
 FGG/FGA  
   
Inflammation CRP  
 IL6  
   
Blood pressure regulation ADD1 ADD1 
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5.2.1.1 Apolipoprotein E (APOE) 
The apolipoprotein E protein (ApoE) is an LDL receptor ligand encoded by 
the APOE gene, located on chromosome 19q13.2.  Three common alleles 
exist: ε2, ε3, and ε4, resulting from missense mutations at two locations.  
These produce three isoforms: E2, E3 and E4.  The E3 isoform has a cysteine 
amino acid at position 112 and an arginine amino acid at position 158, E2 has 
cysteine at both positions and E4 has arginine at both.  The ε3 allele 
(considered the ‘normal’ allele) is the most frequent, accounting for between 
50 and 90% in different populations; the ε4 allele is the next most frequent (5-
35%); ε2 the least frequent (1-15%) [Mahley & Rall, Jr., 2000]. 
 
Apolipoprotein levels vary according to genotype, with ε2 associated with 
increased plasma levels and ε4 with decreased plasma levels *Davignon et al., 
1988].  Apolipoproteins bind with free cholesterol, phospholipids, cholesterol 
esters and some triacylglycerols to form lipoproteins.  ApoE helps to stabilize 
and solubolize lipoproteins as they circulate in the blood and interacts with 
specific lipoprotein receptors to alter the circulating levels of cholesterol 
[Eichner et al., 2002]. 
 
The association between APOE and cholesterol levels is well documented.  ε2 
is associated with lower- low-density lipoprotein (LDL) cholesterol levels, 
and ε4 with higher levels *Cattin et al., 1997].  LDL cholesterol molecules 
contribute to the development and progression of atherosclerosis.  It has 
been shown that ε2 lowers cholesterol levels by ~14 mg/dl and ε4 raises them 
by ~8 mg/dl [Hallman et al., 1991].  As much as 10% of the total variation in 
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cholesterol levels in the population is accounted for by the APOE gene locus, 
more than for any other gene identified so far [Mahley & Rall, Jr., 2000]. 
 
As the association between high cholesterol (specifically LDL cholesterol) 
and IHD risk is well established, it is unsurprising that APOE has been 
considered an important genetic risk factor candidate for IHD.  APOE 
knockout mice develop spontaneous atherosclerosis, suggesting that the 
presence of the APOE gene and its protein product apoE is protective [Zhang 
et al., 1992].  A meta-analysis of large human studies (only including studies 
with more than 500 IHD cases) reported that there was an approximately 
linear relationship between APOE  genotype and IHD risk (ordered ε2ε2, 
ε2ε3, ε2ε4, ε3ε3, ε3ε4, ε4ε4).  The OR for ε2 carriers compared to ε3ε3 
subjects was 0.80 (95% CI, 0.70 to 0.90) and for ε4 carriers compared to ε3ε3 
subjects was 1.06 (95% CI, 0.99 to 1.13) [Bennet et al., 2007].   
 
A systematic review and meta-analysis of APOE ε genotypes and IS found 
no clear evidence for an overall association between ε4 carriers and IS when 
restricting the analysis to only the larger (more than 200 cases) studies (OR= 
0.99, 95% CI, 0.88 to 1.11).  There was some evidence that there may be a 
specific association between ε4 carriers and the large artery subtype of stroke 
(OR= 1.33, 95% CI, 0.99 to 1.78) [Sudlow et al., 2006].  However, this is based 
on a small proportion of the studies, so may be susceptible to reporting bias 
and so warrants further investigation.  
 
Taking all this evidence together with the results of my meta-analysis of the 
association between APOE and CIMT, it seems likely that the APOE ε4 is 
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associated with increased CIMT and confers a risk of atherosclerosis, which 
may lead to large artery IS or IHD.  The apparent lack of association with 
WMH (a phenotype related to small vessel disease) and other ischaemic 
stroke subtypes including small vessel disease stroke, suggests that small 
vessel disease is distinct from atherosclerosis and large vessel disease and is 
not influenced by APOE. 
 
Other apolipoproteins (apoA-I/C-III/A-IV and apoB), lipoprotein receptors 
and key enzymes with functional roles in homeostasis and lipid metabolism 
have been suggested as possible genetic sources of risk for lipid levels and so 
for cardiovascular and cerebrovascular disease, but so far little is known 
about the influence of these genes on atherosclerosis and vascular disease 
[Nieminen, 2006].   
 
5.2.1.2 Paraoxonase 1 
Paraoxonase 1 is a calcium–dependent glycoprotein synthesised in the liver.  
It binds to HDL and prevents oxidation of LDL [Mackness et al., 1998].  
Oxidised LDL is important in the atherosclerotic pathway [Mertens & 
Holvoet, 2001]. 
 
The PON1 gene is on 7q21.3.  There are two commonly studied missense 
mutations: Q192R and L55M.  The L55M polymorphism affects serum 
concentration of PON1 [Garin et al., 1997] and Q192R affects efficiency of the 
enzyme [Humbert et al., 1993].  PON1 knockout mice have high levels of 
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oxidised LDL and are more prone to atherosclerosis than wild type mice 
when fed a high fat diet [Shih et al., 1998]. 
 
A meta-analysis of the association between PON1 polymorphisms and IHD 
found a significant overall association between the 192 R allele and IHD (RR 
1.12, 95% CI 1.07 to 1.16).  However, sub-analysis of only the larger studies 
suggest this result could be prone to small study bias (RR 1.05, 95% CI 0.98 to 
1.13) [Wheeler et al., 2004].  A narrative review reports that depleted PON1 
serum concentration and activity may be better predictors of IHD than any 
polymorphism studied so far, as studies have found statistically significant 
associations with activity and concentration, but not with genetic 
polymorphisms [Mackness & Mackness, 2004].  This may indicate that other 
polymorphisms of the gene yet to be investigated could be important or that 
there are other factors regulating PON1 including other genetic 
polymorphisms or environmental factors.  This finding could also suggest 
that PON1 activity and concentration is associated with IHD by reverse 
causation, where the onset of IHD is the cause of the decreased activity and 
not a consequence of it. 
 
A meta-analysis of the association between the Q192R PON1 polymorphism 
and stroke found an overall significant association (OR 1.64, 95% CI, 1.39 to 
1.94).  However, this only included four studies and 460 stroke patients and 
so may be prone to publication bias [Ranade et al., 2005]. 
 
I included the Q192R polymorphism in my meta-analyses of genetic 
influences on CIMT, but found no overall statistically significant association.  
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Studies of PON1 associations with WMH were only assessed in two small 
studies and so were not included in my meta-analyses.  However, one study 
reported no association between L55M or Q192R and WMH [Schmidt et al., 
2000] , while the other reported that the QQ genotype at the Q192R locus was 
associated with WMH [Hadjigeorgiou et al., 2007] (the opposite direction of 
the association proposed for stroke and IHD).  However this was of marginal 
statistical significance (p=0.02) and the study was very small (n=79) and so 
this is probably due to chance. 
 
A review has suggested that the discrepancies seen for PON1 association for 
IHD and CIMT may be due to an interaction with smoking, based on recent 
findings in a small study (of less than 200 Finnish men) that non-smokers 
with LL at residue 55 had a higher mean CIMT than M carriers, whereas 
smokers who were M carriers had a higher mean CIMT than LL subjects 
[Humphries & Morgan, 2004].  This requires further investigation. 
 
This pathway is a strong candidate for influencing atherosclerosis and large 
artery ischaemic stroke.  Other genes of the lipid metabolism pathway, yet to 
be studied in large numbers, may prove to be important.  Many of these are 
likely to have very small effects and so only very large studies (and – 
perhaps – meta-analyses of these) which consider interactions and focus on 
specific disease or trait definitions, will help to tease apart the associations. 
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5.2.2 Vascular Homeostasis 
Pathways controlling vascular architecture and function are an obvious place 
to search for genes that predispose to atherosclerosis, stroke and CVD.  The 
renin angiotensin (RA) system and the nitric oxide synthase (NOS) system 
both have important roles in function of the vessels.  The RA system has been 
extensively studied (ACE and AGT genes featured in both the CIMT and 
WMH meta-analyses) and NOS3 from the NOS system was studied in the 
CIMT meta-analysis.  Other genes involved in vascular homeostasis were 
also included in the CIMT meta-analysis (IGF1 and ADRB2). 
 
5.2.2.1 Renin angiotensin system  
The RA system is a hormone system involved in blood pressure regulation.  
Angiotensin converting enyme (ACE) converts inactive angiotensinogen 
(AGT) to the vasconstrictor angiotensin II (which is mediated by angiotensin 
II receptor type 1 (AGTR1)) and also inactivates the vasodilator bradykinin, 
hence regulating vascular tone, vascular smooth muscle proliferation, and 
endothelial function [Carluccio et al., 2001]. 
 
Angiotensin converting enzyme gene (ACE) 
ACE is the most extensively studied gene in the RA system.  The presence 
(insertion, I) or absence (deletion, D) of a 287 base-pair alu (a short 
interspersed nuclear element) repeat sequence in reverse orientation in 
intron 16 17q23 of this gene has been shown to be associated with 
substantially different levels of plasma ACE [Rigat et al., 1990]. This 
polymorphism accounts for 47% of the variation in ACE plasma level with 
the DD genotype being associated with the highest levels.  
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Two meta-analyses of the association between the ACE I/D polymorphism 
and MI or IHD only found an overall significant association in the smaller 
studies (IHD (whites) OR 1.29, 95% CI 1.15 to 1.43; MI (whites) OR 1.47, 95% 
CI 1.30 to 1.66; MI (all ethnicities) RR 1.57, 95% CI 1.38 to 1.78); meta-analyses 
of the larger studies showed no association (IHD OR 1.07, 95% CI 0.97 to 
1.17; MI (whites) OR 0.99, 95% CI 0.88 to 1.12; MI (all ethnicities) RR 0.99, 
95% CI 0.90 to 1.08) [Agerholm-Larsen et al., 2000; Keavney et al., 2000]. 
 
A meta-analysis of the association between ACE I/D and IS in persons of 
European descent found an overall significant association between the DD 
genotype and ischaemic stroke risk (OR 1.21, 95% CI 1.08 to 1.35) [Casas et 
al., 2004].  A meta-analysis of this association in persons of non-European 
descent also found an overall significant association in the Chinese 
individuals (OR 1.90, 95% CI 1.23 to 2.93), but not the Japanese (OR 1.74, 95% 
CI 0.88 to 3.42) [Ariyaratnam et al., 2007].  However, there was evidence in 
this second meta-analysis of small study bias and significant heterogeneity.  
Some studies have suggested that the association with ischaemic stroke is 
specific to lacunar stroke, whilst others have not found an association 
between lacunar stroke and the ACE DD genotype, and a meta-analysis of 
these studies shows that this relationship is still unclear [Gormley et al., 
2007].  
 
The ACE I/D polymorphism featured in both my CIMT and WMH meta-
analyses.  I found an overall significant association between the D allele and 
increased CIMT, but no significant pooled mean CIMT difference when only 
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the large studies where analysed.  Some large studies that I could not include 
in my analysis because data were unavailable, did show an association 
between the D allele and increased CIMT and so their inclusion may have 
strengthened the evidence for an association.  Therefore, I cannot rule out a 
modest association between ACE and CIMT.   
 
It has been suggested that MTHFR and APOE genotypes, smoking and 
alcohol consumption may be important interacting factors for the association 
between ACE I/D and ischaemic stroke [Szolnoki & Melegh, 2006].  
However, this was based on the findings of one study with 1341 subjects.  
These interactions could not be tested in my meta-analysis, but may warrant 
further investigation.  The ACE – CIMT meta-analysis I carried out in chapter 
3 is an update of that by [Sayed-Tabatabaei et al. 2003].  They too found that 
the association was more pronounced in the high risk subjects, but they did 
not investigate the effects of study size as a potential confounder of this 
finding.  They attributed this finding to gene-environment interaction and 
went on to investigate potential interacting risk factors in their own cohort 
study, discovering a significant association between ACE I/D and CIMT only 
in the presence of smoking [Sayed-Tabatabaei et al., 2004].  However, other 
studies assessing this interaction have been inconsistent [Sass et al., 1998].  It 
is quite likely that if ACE I/D is associated with CIMT that there are 
important interactions with traditional risk and environmental factors.  
However, the correlation between high risk individuals and study size 
means that the positive studies may be biased and there is no convincing 
evidence for any association between ACE I/D and CIMT at present.  It will 
be important to consider potential interacting factors in future studies of 
ACE. 




AGT has also been studied for its involvement in IHD and stroke.  A 
methionine to threonine substitution in exon 2 of the AGT gene on 1q42-43 
(M235T) has been shown to associated with AGT concentration [Bloem et al., 
1997].   
 
Many studies have assessed the association between AGT M235T and IHD, 
but these have been conflicting and a meta-analysis reported no overall 
association [Sethi et al., 2003].  Studies assessing the association between AGT 
and stroke have been conflicting [Bersano et al., 2008].  But, some studies 
have found specific associations with lacunar stroke [Nakase et al., 2007; 
Takami et al., 2000]. 
 
AGT M235T was included in my meta-analyses for both CIMT and WMH. I 
found no overall association in either meta-analysis.  However, the largest 
WMH study (n = 1044) did report a significant association and this 
polymorphism has been studied in very relatively small numbers so far, so 
there may be an association yet to be confirmed in larger studies.   
 
Other renin angiotensin system genes 
Other genes of this important pathway may be associated with CIMT and 
WMH and/or confer a risk of ischaemic stroke.  Angiotensin II receptor, type 
1 (AGTR1) is another gene which has been studied for associations with IHD, 
IS, CIMT and WMH.  It was not studied in enough subjects to be included in 
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either of my meta-analyses.  But has been implicated in individual studies 
with MI (in an interation with ACE I/D) [Tiret et al., 1994] and IS (in a small 
study) [Rubattu et al., 2004], and possibly particularly with lacunar stroke 
(althought this was a very small study) [Takami et al., 2000]. 
 
Genes from the RA pathway are likely to be the focus of many candidate 
gene associations in the future.  Studying very large numbers of individuals 
and carefully defining disease and phenotypes, will enable the role of these 
genes in vascular disease to be determined. 
 
5.2.2.2 Nitric oxide synthase 
The nitric oxide synthase (NOS) system is important for endothelial function, 
including regulation of tone, integrity and growth.  NOS is an enzyme which 
acts on L-arginine to produce nitric oxide (NO), a vasodilator [Andrew & 
Mayer, 1999].  Endothelial NOS (NOS3) is presumed to be responsible for 
most of the endothelial and vascular effects of NO. 
 
A G to T mutation at nucleotide position 894 of the NOS3 gene results in a 
glutamic acid to aspartic acid substitution at amino acid 298, which reduces 
NOS3 activity [Tesauro et al., 2000].  This is the only common non-
synonymous variant, but other potentially important polymorphisms include 
a 27-base pair repeat polymorphism in intron 4 and a T to C mutation 786 
base pairs upstream of the NOS3 gene (T-786C).  NOS3 knockout mice are 
highly sensitive to focal cerebral ischemia [Samdani et al., 1997].   
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A meta-analysis of three NOS3 polymorphisms found that the intron 4 
polymorphism was significantly associated with IHD (per-allele OR 1.12, 
95% CI 1.01 to 1.24).  Significant associations were also found for the 
Glu298Asp (per-allele OR 1.17, 95% CI 1.07 to 1.28) and T-786C (per-allele 
OR 1.17, 95% CI 1.07 to 1.28) polymorphisms.  However, these were prone to 
small study bias [Casas et al., 2006].  A meta-analysis of Glu298Asp NOS3 
polymorphism and ischaemic stroke reported no overall association 
(recessive OR 0.98, 95% CI 0.76 to 1.26) [Casas et al., 2004]. 
 
The NOS3 Glu298Asp polymorphism was included in my meta-analysis of 
CIMT.  I found no overall association.  NOS3 polymorphisms were only 
studied in three WMH studies (total n=1222) and so were not included in my 
WMH meta-analysis, but the studies showed mixed results. 
 
It has been reported that there may be interactions between smoking, ACE 
genotype, MTHFR genotype and NOS3 genotype which together associate 
with ischaemic stroke [Szolnoki & Melegh, 2006].  These interactions could 
not be tested in my meta-analysis, as the information on these factors was not 
available from the individual studies.  Unlike other genes, there is no 
definitive functional gene variant and studies of the association between 
NOS3 and cardiovascular events have not consistently studied the same 
polymorphisms [Napoli & Ignarro, 2007], making reviews of this literature 
difficult.  As the IHD meta-analysis referred to above suggests, perhaps the 
less-studied intron 4 polymorphism is more important than Glu298Asp 
[Casas et al., 2006].  The authors of this study suggest that future work for 
this gene and CVD should include gene-wide tagging polymorphisms to 
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capture variation across the whole gene, in a large-scale genetic association 
study. 
 
5.2.2.3 Insulin-like growth factor 1 (IGF1) 
IGF1 is a mitogenic peptide hormone with an established role in growth and 
differentiation.  More recent work suggest that it also acts as a vascular 
protective factor by stimulating NO production, resulting in decreased 
vascular smooth muscle proliferation and vasodilation [Walsh et al., 1996].   
 
IGF1 levels have been shown to be decreased in atherosclerotic plaques 
[Okura et al., 2001] and circulating levels are decreased in patients with 
cardiovascular disease [Ezzat et al., 2008].  IGF1 levels have been shown to be 
~20% lower in individuals without the 192-base pair wildtype allele of the 
gene [Vaessen et al., 2001]. 
 
This polymorphism featured in my meta-analysis for CIMT.  Only one study 
had assessed the association between the 192-base pair polymorphism of 
IGF1 and CIMT, but this study was of substantial size (5132 subjects) and 
found a significant association [Schut et al., 2003].  I found the per-allele mean 
difference (for the non-192-base pair allele) to be 10µm, suggesting that, as 
might be expected, this mutation of the IGF1 gene confers a risk of 
atherosclerosis.  The association reported was particularly pronounced in a 
subset of hypertensive subjects, suggesting the polymorphism may modulate 
the risk in these individuals more than in non-hypertensive subjects.  As the 
only evidence for this association comes from one study, this will need to be 
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repeated in other studies before any firm conclusions can be made, but this 
gene looks like a promising candidate for atherosclerosis, CIMT, and so for 
IHD and IS. 
 
5.2.2.4 Adrenergic beta 2 receptor (ADRB2) 
Adrenergic beta 2 receptors are G protein-coupled receptors that mediate a 
cardiovascular response when stimulated by adrenaline [Guimaraes & 
Moura, 2001].  Specifically, they regulate dilation of arteries, resulting in the 
increased perfusion of organs needed for the fight-or-flight response.   
 
The gene ADRB2, which encodes the β2 adrenergic receptor, is located on 
5q31-32.  Several polymorphisms have been identified [Johnson & Terra, 
2002], the most commonly studied being Gln27Glu and Arg16Gly, which are 
in almost complete linkage dysequilibrium with each other.  These two 
polymorphisms have been shown to be related to down regulation of the 
receptor [Green et al., 1994+.  Beta adrenergic receptor agonists (β-blockers) 
are used to treat and prevent further coronary events and so polymorphisms 
of the ADRB2 are potential candidates for cardiovascular disease. 
 
In a large single prospective study of more than 5000 subjects (702 of which 
had a coronary event and 438 of which had a stroke in the 10 years of follow-
up) Glu27 carriers were found to have a lower risk of coronary events than 
Gln27 homozygotes (RR 0.82, 95% CI 0.70 to 0.95).  However, there was no 
such association found for stroke (RR 0.94, 95% CI 0.77 to 1.15) or 
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cardiovascular events as a whole (RR 0.93, 95% CI 0.82 to 1.05) [Heckbert et 
al., 2003; Johnson & Terra, 2002]. 
 
The ADRB2 Gln27Glu polymorphism was included in my meta-analysis for 
CIMT.  Only one large study was identified and this found no association 
(mean CIMT difference between Glu carriers and Gln homozygotes was 
10μm, 95% CI –29 to 49).  This finding along with the lack of association seen 
for stroke could imply that although ADRB2 may be an important risk factor 
and drug target for coronary events, it is not associated with other 
cardiovascular disease.  Although this is based on only a few studies and 
ADRB2 could still be found to have a wider role in cardiovascular disease. 
 
Other polymorphisms and complex promoter region haplotypes of this gene 
have been shown to alter receptor expression [Drysdale et al., 2000] and 
could also be studied for an association with CIMT and/or stroke. 
 
5.2.3 Metabolic Factors 
5.2.3.1 MTHFR 
Methylenetetrahydrofolate reductase (MTHFR) is an enzyme which reduces 
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which acts as a 
carbon donor in the remethylation of homocysteine to methionine.  Elevated 
homocysteine levels have been shown to promote atherosclerosis, potentially 
through several mechanisms including endothelial dysfunction [Welch & 
Loscalzo, 1998].  
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The C677T polymorphism of the MTHFR gene produces an alanine to valine 
substitution, which increases the thermolability of the enzyme, hence 
reducing activity (especially in folate-deficient individuals) [Frost et al., 1998]. 
Homocysteine levels have been found to be ~25% higher in TT individuals 
compared with CC individuals [Brattstrom et al., 1998].  
 
A meta-analysis of 32 studies (14870 subjects) of the association between 
C677T and stroke found that overall there was a significant association 
between the T allele and increased stroke risk (OR 1.18, 95% CI 1.09 to 1.29) 
[Cronin et al., 2005], largely mediated through homocysteine levels [Casas et 
al., 2005].  However, there were insufficient data in the individual studies to 
detect stroke subtype differences or an interaction with folate levels.  MTHFR 
and homocysteine seem to be important in conferring risk of stroke, but so 
far the efficacy of homocysteine lowering treatment (namely folic acid 
supplementation) in reducing the risk of stroke is unclear [Hankey, 2006].   
 
The case for an association between MTHFR and IHD has been less 
convincing.  A meta-analysis of 80 studies (>57,000 subjects) found a small 
overall association between TT genotype and increased risk of IHD (OR 1.14, 
95% CI 1.05 to 1.24), but this was prone to bias and when stratified 
geographically the association was only significant in the Middle Eastern 
subjects (OR 2.61, 95% CI 1.81 to 3.75) [Lewis et al., 2005].  An earlier meta-
analysis reported that the TT genotype was associated with IHD, particularly 
under low folate conditions.  It also suggested that heterogeneity between 
geographic populations may result from varying levels of folate in the diets 
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of these populations, particularly in the use of vitamin supplements and 
folate fortification of breakfast cereal in North America [Klerk et al., 2002].  
 
MTHFR was included in my meta-analyses for both CIMT and WMH.  I 
found no overall association between MTHFR C677T polymorphism and 
WMH.  I found a significant association for CIMT, but this was very small 
and prone to study bias.  The larger studies showed no association between 
C677T and CIMT.  
 
As mentioned above, MTHFR activity is particularly reduced when, in 
addition to the mutation at 677, there is also folate deficiency, suggesting that 
folate may be an important interacting factor for CIMT association and risk 
of stroke.  It has been suggested that folate intake may only be associated 
with CIMT when it is at a critically low level [Durga et al., 2005] and 
therefore the association between CIMT and MTHFR C677T may only be 
detected in individuals below this critical folate level.  Information on folate 
status of individuals was lacking in most studies and so assessment of this 
potential interacting risk factor was not possible in my meta-analysis but 
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5.2.4 Haemostasis 
The formation of a clot, and its potential blockage of an artery can partially or 
completely occlude blood flow to vital organs.  Lack of blood supply to the 
heart or brain leads to ischemic damage, resulting in an MI or stroke and so 
genes with a role in haemostasis are ideal candidates for stroke genetics. 
 
5.2.4.1 Factor V 
The Factor V Leiden variant of the gene has a missense mutation (G1691A), 
which abolishes the activated protein C (APC) cleavage site, resulting in 
factor V being resistant to APC inactivation.  Resistance to APC inactivation 
has been found to be a risk factor for venous thrombosis [Svensson & 
Dahlback, 1994], but its role in arterial thrombosis is still debated. 
 
A meta-analysis of 20 studies (>40,000 subjects) found that there was a 
significant overall association between factor V Leiden and IHD (per-allele 
RR 1.17, 95% CI 1.08 to 1.28), but this result is prone to small study bias and 
the seven studies with >500 subjects showed no significant association [Ye et 
al., 2006].  A meta-analysis of genetic associations for stroke found a 
significant overall association between factor V Leiden and IS (dominant OR 
1.33, 95% CI 1.12 to 1.58), with no evidence of publication bias[Casas et al., 
2004]. 
 
The factor V Leiden polymorphism was included in my meta-analysis for 
CIMT, but has so far not been studied for WMH.  I found a statistically 
significant overall association between factor V Leiden and CIMT, but in the 
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opposite direction to that expected from the disease meta-analyses described 
above (the factor V Leiden mutation appears to decrease CIMT, whereas it 
increases risk of IHD and IS).  However, only two studies were included in 
this meta-analysis and both were in families of IHD patients, so this could a 
chance result or due to bias.  It would be interesting to see if the association 
can be replicated in a community based study. 
 
5.2.4.2 Fibrinogen 
Fibrinogen is an important coagulation factor.  It is cleaved by thrombin to 
form fibrin after vascular injury [Herrick et al., 1999].  Fibrinogen has three 
polypeptide chains: α, β and γ, encode by three genes clustered on 
chromosome 4q: FGA, FGB and FGG, respectively.   
 
FGG/FGA haplotypes have been shown to be associated with the structure of 
the fibrin network [Mannila et al., 2006] and fibrin structure has been shown 
to be associated with IHD [Fatah et al., 1992].  FGG/FGA haplotypes have 
been shown to be associated with ischaemic stroke (OR 1.36, 95% CI 1.09 to 
1.69) and MI (OR 1.51, 95% CI 1.18 to 1.93) in single studies, but these have 
been relatively small (less than 400 subjects) [Cheung et al., 2008; Mannila et 
al., 2005].  In my systematic review, only one study had assessed the 
association between FGG/FGA haplotypes and CIMT.  This study found no 
association.  No study had assessed the association between WMH and any 
fibrinogen polymorphism. 
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There is also evidence for association between FGB mutations and fibrinogen 
plasma levels, as well as stroke, but only in small numbers [Hassan & 
Markus, 2000].  In addition, a large individual participant data meta-analysis 
(154211 subjects) has shown a significant association between plasma 
fibrinogen levels and IHD (HR 2.42, 95% CI 2.24 to 2.60, per 1g/L increase in 
fibrinogen level) and plasma fibrinogen levels and stroke (HR 2.06, 95% CI 
1.83 to 2.33, per 1g/L increase in fibrinogen level) [Danesh et al., 2005]. 
 
There is some preliminary evidence and background reasoning for an 
association between polymorphisms of the fibrinogen genes and stroke (and 
its intermediate traits).  However, much more work is needed on these 
polymorphisms before conclusions can be made with any confidence. 
 
5.2.4.3 Other haemostatic genes 
Other haemostatic genes (e.g. factor VII, prothrombin, factor XIII, platelet 
glycoprotein receptor, HPA2, von Willebrand factor, plasminogen activator 
inhibitor-I) have been studied for an association with stroke and MI, but 
these have mostly been relatively small and with conflicting results [Hassan 
& Markus, 2000].  A meta-analysis of seven haemostatic gene polymorphisms 
and IHD found that both plasminogen activator inhibitor 1 (RR 1.06, 95% CI 
1.02 to 1.10) and prothrombin (G20210A) (RR 1.31, 95% CI 1.12 to 1.52) were 
significantly associated with MI [Ye et al., 2006] and in a meta-analysis of 
genetic polymorphisms and stroke, significant associations were found for 
prothrombin (G20210A) (OR 1.44, 95% CI 1.11 to 1.86), plasminogen activator 
inhibitor 1 (OR 1.47, 95% CI 1.13 to 1.92) and glycoprotein Ib-α (OR 1.88, 95% 
CI 1.28 to 2.76) polymorphisms [Casas et al., 2004].  Therefore, it seems likely 
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that genes of the haemostatic system play a role in stroke susceptibility, but 
which genes are the key players and how exactly they are associated with 
stroke and its intermediate phenotypes is still relatively unknown. 
 
5.2.5 Inflammation 
Inflammation is the process by which the body responds to injury.  Therefore 
atherogenesis will elicit an inflammatory response.  The nature of this 
inflammatory response may play a key role in the extent and outcome of the 
disease process.  Considerable evidence now exists for inflammation as a key 
process in pathogenesis of atherosclerosis and stroke [Libby et al., 2002]. 
   
5.2.5.1 C-reactive protein (CRP) 
C-reactive protein is as an inflammatory marker, present in atherosclerotic 
plaques [Torzewski et al., 2000].  CRP levels can rise rapidly in response to 
cytokines (such as IL6).  Several polymorphisms of the CRP gene are 
associated with plasma levels of the protein [Lange et al., 2006].  However, 
the association of CRP plasma levels with IHD, stroke and CIMT remain 
controversial 
 
CRP levels have been consistently associated with increased risk of IHD and 
several polymorphisms in the gene encoding CRP have been consistently 
associated with CRP levels.  However, it is not clear whether the association 
between CRP and IHD is causal or just reflects CRP being a marker of 
disease.  Studies attempting to test for associations between CRP genetic 
polymorphisms and IHD have so far been found no significant association.  
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However, they may have been massively underpowered (collectively 
including only a few thousand cases), as a sample size calculation suggests 
that 15000 IHD cases may be required for such a study to be sufficiently 
powered [Casas et al., 2008].  A meta-analysis found that high concentrations 
of plasma CRP are associated with stroke [Kuo et al., 2005].  However, 
whether this relationship is causal is still to be determined.  
 
The association between CIMT and polymorphisms in the gene encoding 
CRP was only studied in one study in my meta-analysis.  This study found 
no association between CIMT and any of the five polymorphisms assessed, 
but included 4641 subjects and may have been under-powered and perhaps 
much larger studies need to be carried out. 
 
5.2.5.2 Interleukin 6 (IL6) 
IL6 is a cytokine that regulates C-reactive protein production during the 
inflammatory response [Heinrich et al., 2003].  There are several common 
polymorphisms in the IL6 gene, G-174C being the most widely studied.  This 
polymorphism has been shown to be associated with plasma IL6 [Terry et al., 
2000] and CRP levels [Vickers et al., 2002].  As mentioned above there does 
appear to be an association between CRP levels and IHD, but it is unclear 
whether this is causal or a result of reverse causation [Casas et al., 2008]. 
 
The G-174C polymorphism has been shown to be associated with IHD and 
stroke.  However, the direction of the association differs between studies 
[Georges et al., 2001; Humphries et al., 2001; Kelberman et al., 2004; Pola et al., 
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2003; Um et al., 2005], with some concluding that GG is the risk genotype, 
and others, CC. 
 
I included IL6 in my meta-analysis for CIMT, and found no overall 
association.  However, a study for which separate G-174C data were 
unavailable, showed that when studying three inflammatory genes (IL-6, Il-1 
receptor antagonist and endotoxin receptor) in combination, the gene variant 
score was associated with CIMT [Markus et al., 2006].  This study was 
relatively small (810 subjects), but suggests that other inflammatory genes 
may be of importance and that interactions may exist between these genes. 
 
Other inflammatory genes have been studied for association with IHD, but 
so far none of these have been found to have a significant association [Kitsios 
& Zintzaras, 2007]. 
 
5.2.6 Blood Pressure Regulation 
Hypertension is an established risk factor for stroke and so genes that may 
regulate blood pressure are ideal candidates for stroke. 
 
5.2.6.1 Adducin 1 (ADD1) 
Adducin is a heterodymeric cytoskeletal protein consisting of three subunits 
(α,β and γ) encoded by three genes: ADD1, ADD2 and ADD3 [Matsuoka et 
al., 2000+.  The α subunit, encoded by ADD1 on chromosome 14p16.3, 
regulates the activity of transmembrane ion pumps. 
Chapter 5 – Systematic Review Discussion 
189 
 
Studies using Milan hypertensive and normotensive strains of rat have 
shown that the Phe316Tyr polymorphism of the ADD1 gene accounts for a 
large proportion of the blood pressure difference between these strains 
[Bianchi et al., 1994].  The Gly460Trp polymorphism and other 
polymorphisms in the ADD1 region have also been implicated in human 
hypertension, although results have not been consistent between studies 
[Bianchi et al., 2005].  It has been suggested that these inconsistencies are due 
to interactions with other variables including the ACE I/D polymorphism 
and sodium levels (which have not always been taken into account).  Even 
more conflicting are the results of studies assessing an association between 
ADD1 polymorphisms and cardiovascular disease and stroke. 
 
ADD1 was a commonly studied gene in my meta-analysis of CIMT.  I found 
no overall significant association between ADD1 and CIMT.  However, most 
studies suggested there could be important interacting factors that need to be 
studied further; sex [Sarzani et al., 2006]; diabetes [Yazdanpanah et al., 2006]; 
the ACE I/D polymorphism [Balkestein et al., 2002].  The association between 
ADD1 and WMH had only been assessed in one study (n=1014) and so did 
not reach the cut-off of 2000 set for ‘commonly studied’ genes for my WMH 
meta-analysis.  However, this study found no overall association.   
 
Although ADD1 appears to play an important role in hypertension, its 
association with stroke and intermediate traits remains uncertain.  As 
hypertension is an important risk factor for stroke, ADD1 seems likely to 
have some role in the susceptibility to stroke.  However, if the ADD1 
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influence on hypertension is small and involves interactions, the association 
with a trait or disease further down the causal pathway will be even smaller 
and more complex.  In addition it is unclear whether hypertension influences 
all stroke subtypes similarly.  In a very large meta-analysis of 61 prospective 
studies (>958,000 subjects) it was reported that at age 40-69 years, each 
difference of 20mm Hg usual systolic blood pressure is associated with a 
twofold difference in stroke death rate (but IS was not subdivided into 
subtypes).  History of hypertension is used in the TOAST classification for 
diagnosis of lacunar, but not large artery stroke [Adams, Jr. et al., 1993].  The 
available evidence from systematic reviews and meta-analyses of 
observational epidemiological studies suggests that there is no difference 
between pathological types and subtypes of stroke in the influence of 
hypertension on stroke risk [Jackson & Sudlow, 2005]. 
 
5.3 Limitations of the CIMT and WMH meta-analyses 
5.3.1 Novel Genetic Meta-Analysis Method for Continuous  
I devised a novel meta-analysis method that allows the pooled overall 
association to be assessed and the nature of this association to be estimated 
without the issue of multiple testing or relying on previous knowledge of the 
genetic model.  In my method I first tested the data for an overall association.  
If I detected an overall association, I went on to determine the most 
appropriate genetic model using linear regression, and then to estimate the 
pooled effect size (in this case the pooled mean difference in CIMT) 
corresponding to this genetic model.   
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This proved to be a useful method for my CIMT dataset.  Most traditional 
meta-analyses compare two groups.  However, deciding which two-way 
comparison to be made of the three genotypes was difficult and not really 
meaningful for the genes showing no overall association.  Only studying in 
detail those genes that first show an overall association seems sensible.   
 
A previous method for choosing the genetic model by comparing multiple, 
pooled mean differences [Thakkinstian et al., 2005], is flawed as it disregards 
the structure of the data (the connection between mean differences within an 
individual study).  The linear regression method I developed provides an 
obejective measure of the error around the chosen genetic model.  As can be 
seen for APOE and ACE, the evidence for a co-dominant model is strong 
(tight 95% CIs around a λ of 0.5). 
 
With my method, no forest plots are constructed for polymorphisms 
showing no overall association.  However, I believe that for my data showing 
plots of these ‘associations’ would not have been very meaningful.  If it is felt 
appropriate to view a forest plot of a mean difference for a polymorphism 
that showed no overall association, this can still be done, but should be 
reported as an exploratory exercise. 
 
My method cannot be carried out in the easy-to-use Cochrane RevMan 
software [The Cochrane Collaboration, 2006] and must be carried out in a 
more flexible statistical package and this does require some statistical 
knowledge and programming ability.  I carried out all stages of the method 
in STATA version 7.0 [StataCorp., 2001] and the code that I developed for 
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this can be applied universally (if data are supplied in a specific format), and 
so run by anyone with the STATA software. 
 
My three-step meta-analysis method was not used in the WMH analyses, as 
for these datasets the individual studies had often selected a genetic model 
and had only reported the data according to that model.  I therefore used the 
most common genetic model for my analysis and did not first test for an 
overall association.  This meant I could include a larger amount of data.  
However, I cannot exclude the possibility that other genetic models may 
have found associations where I found none.  For example, despite ACE I/D 
being analysed according to a recessive model, with a just significant overall 
effect on WMH, this does not necessarily mean that ACE  I/D acts on WMH 
in a recessive fashion. 
 
5.3.2 Missing Data 
In both my meta-analyses there was a large amount of ‘unavailable data’ 
(from studies that had not reported in sufficient detail to allow the necessary 
data extraction).  I contacted authors and attempted to collect the unavailable 
data for CIMT.  However, I did not attempt to retrieve data from authors of 
the WMH studies, as it seemed unlikely that the inclusion of these data 
would have influenced the results at all.   
 
A particular strength of the meta-analyses presented here is that, unlike other 
meta-analyses of stroke [Casas et al., 2004], I chose to assess qualitatively the 
impact that studies with unavailable data would have made, had I been able 
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to include them.  In most cases I was able to conclude that inclusion of these 
data would not have impacted substantially on the overall results, but it was 
only by considering ALL relevant published studies, whether or not they had 
data available for meta-analyses, that I could draw these conclusions.   
 
The large proportion of data that were unavailable from individual 
publications from my systematic reviews highlights the need to be thorough 
when publishing results and that results for all analyses performed should be 
presented, even results that are not statistically significant.  This avoids the 
reporting bias that otherwise occurs.  It is common for significant results to 
be published in full, whilst non-significant results are briefly mentioned 
without the appropriate data reported, or even more problematic, not 
published at all.  Scientists feel under pressure to selectively highlight only 
positive results, either because it fits with their prior beliefs or because they 
believe it is easier to impress journal editors and reviewers, and more 
interesting for readers.  Journals have increasingly stringent word limits and 
this puts further pressure on authors to not present all of their methods and 
findings in full.  This may be overcome in some journals by publishing 
supplementary material online.  However, not all journals offer this facility. 
 
5.3.3 Limitations of Meta-Analysis 
Despite meta-analysis being an extremely useful tool for systematically 
summarizing all available data on a topic, there are limitations.  Pooling 
large amounts of data should increase the power to detect associations, but 
when there is heterogeneity in study design and individuals participating, 
extra noise is introduced and true associations may be hard to detect.  One 
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criticism of meta-analyses is that they can only be as good as the individual 
studies that they comprise.  However even in cases of heterogeneous or 
methodologically poor individual studies, thoughtful meta-analyses which 
seek to explore reasons for heterogeneity by performing detailed assessments 
of study methodology, characteristics and sources of bias can be very 
informative. 
 
I attempted to limit the heterogeneity between studies in my meta-analyses 
by being consistent when selecting which specific trait to use (i.e. CIMT 
measured at a specific location, or choosing as consistent a definition of 
WMH as possible).  However, this was only possible so far as the individual 
studies allowed.  Some investigators have called for phenotypes and diseases 
to be more consistently reported in the literature to allow for more sensible 
meta-analyses to take place, and hopefully this will have a positive influence 
on meta-analyses in the future (e.g. the Mannheim Intima-Media Thickness 
Consensus [Touboul et al., 2004]). 
 
If studies use different populations and different definitions of disease, this 
may lead to real differences in their results (although large qualitative 
differences in the genetic effects under study seem unlikely – e.g. men and 
women may have their CIMT affected to a different degree by some genetic 
polymorphisms but the existence of or direction of effect is unlikely to differ).  
As seen in my meta-analyses the characteristics of studies often co-vary 
making it difficult to tell whether (for example) differences between study 
estimates of an association are due to the ethnicity, hypertensive status of the 
subjects, or the size of the study. 
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Covariates are important for almost all phenotypes.  However, unless all 
studies have measured and reported on the same set of covariates, one 
cannot assess these within a meta-analysis and so any association may be 
masked by other variables.  Interactions may also be important, whether 
with other genes or with environmental factors, and these too cannot be 
systematically assessed when individual studies have tested for different 
interactions.  Without thorough assessment of covariates it is unclear 
whether any significant association with a polymorphism is acting via an 
existing risk factor, or if it is associated independently of known risk factors.  
A further problem with studying covariates and interactions in a systematic 
review or meta-analysis is that it is probable that the studies may have tested 
many factors and only reported the significant results.  One important 
difference between the WMH and CIMT meta-analyses is that the WMH 
studies tended to use older subjects.  This difference could explain why 
APOE appears to be associated with CIMT, but not with WMH. 
 
Individual participant data (IPD) meta-analysis is a more thorough and 
powerful way of summarizing data from multiple studies, and has been 
described as the ‘yardstick’ for meta-analysis [Clarke & Stewart, 2001].  This 
method will still suffer from problems of heterogeneity if different 
definitions of the trait or different populations are studied, but at least with 
all of the raw individual data available it is more likely that these factors can 
be investigated.  IPD meta-analysis relies heavily on co-operation of study 
investigators and is best adopted within a consortium of the relevant 
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investigators.  It involves more work than meta-analysis of summary data, 
and is often not possible as many of the datasets cannot be obtained. 
 
However, meta-analyses of published data (with additional summary data 
from investigators if necessary and where feasible) are useful ways of 
summarizing all of the available data to date and identifying hypotheses that 
can be tested in future studies, as well as identifying pit-falls and informing 
on sample size and phenotypic definition issues for future studies.  
 
5.3.4 Are WMH and CIMT Useful Intermediate Traits? 
WMH and CIMT, being highly heritable and strongly related to stroke 
subtypes, appear to be powerful intermediate traits for the genetic study of 
stroke.  However, so far, when the available data are carefully scrutinised, 
they have not lived up to expectations and there are few convincing 
associations.  But this is true of many complex traits. 
 
The lack of success with these intermediate traits could be due to several 
factors:   
 
 The initial estimates of heritability may have been over-estimated 
Many studies have found heritability to be high for CIMT and WMH.  
However, twin, sib-ship and family history studies are all thought to over-
estimate the heritability, due to shared environmental factors along with the 
difficulty of completely controlling for their confounding effects [Guo, 2001].  
It is probably the case that these traits are heritable but not to the level of the 
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more extreme estimates (0.92 for CIMT; 0.80 for WMH) [Duggirala et al., 
1996; Turner et al., 2004], instead being rather closer to the more modest 
estimates (0.32 for CIMT; 0.55 for WMH) [Atwood et al., 2004; Lange et al., 
2002]. 
 
 The genes studied so far are associated with the traits, but studies 
have so far failed to detect this  
This may be due to insufficient sample sizes, heterogeneity, or interactions.  
If the ‘common disease common variant’ hypothesis is correct, there are 
likely to be many genes influencing CIMT and WMH, each with a small 
effect.  Identification of these may require much larger study sizes than those 
used so far.  There is obvious heterogeneity between studies.  Although I 
have attempted to limit this in my meta-analyses, it may still be present 
enough to cloud the underlying genetic associations.  For other complex 
traits, genetic interactions between multiple loci have been shown to produce 
larger effect sizes than the sum of the effects of the single gene variants (e.g. 
[Williams et al., 2000] and this may also be the case for WMH and CIMT.   
 
 Other polymorphisms, yet to be studied, are more important.   
Perhaps work so far has focused on the wrong genes and pathways.  
Although these genes all have strong biological evidence to justify their 
association with stroke and its intermediate traits, there are ~20,000 genes 
[Clamp et al., 2007] and selecting which are expected to be associated with a 
trait is akin to finding ‘a needle in a haystack’.  Novel polymorphisms may 
be identified by genome-wide association studies (GWAS).  We are now in 
an era of large scale GWAS, with promising novel polymorphisms being 
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identified for common complex disease [Cambien, 2007].  So far there has 
only been one small preliminary GWAS for stroke and none for CIMT or 
WMH, but this is likely to change in the near future.  The GWAS for stroke 
only included 249 cases, found no SNPs with genomewide significant 
association with stroke, but identified many SNPs for follow-up (p<1 x 10-5), 
none of which are in genes that have been considered strong candidates so 
far [Matarin et al., 2007].  In the next few years large scale GWAS and follow-
up studies will likely identify some important stroke genes that have yet to 
be studied. 
 
It could also be the case that the right genes, but the wrong polymorphisms 
have been studied.  On the whole the polymorphisms have been selected due 
to their impact on gene expression or function, and so would be expected to 
be of importance, but there may still be other more important 
polymorphisms.  Also of interest is the increasing evidence that copy number 
variation (CNV) may be as, or more, important than single nucleotide 
polymorphsisms (SNPs).  My meta-analyses have not just focused on SNPs, 
but have included small-scale insertions, deletions, and repeats, that have 
been shown to have functional effects.  However, the larger-scale variations 
in copy number (CNVs) have been more difficult to identify.  There is a lot of 
focus in the genetic community now to characterise CNVs within the genome 
and test these for association with traits and disease and this may be fruitful. 
 
Other traits may prove to be useful in identifying genetic factors for stroke. 
For example, total plaque area (TPA) and total plaque volume (TPV) have 
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been discussed as potential traits for large artery stroke [Pollex & Hegele, 
2006]. 
 
5.3.5 Are Small Associations Clinically Relevant? 
So far there is no clear evidence for any large genetic effects for CIMT, WMH 
or stroke itself.  Small associations have been identified (although, these are 
by no mean confirmed beyond doubt), for example the association I report 
here between CIMT and APOE.  This association is likely to be in the region 
of a 20µm difference between E2 and E4 individuals.  The question then, is 
how clinically relevant is such a small difference?   
 
A meta-analysis on the association between CIMT and stroke reported that a 
difference of 100µm confers a relative risk of 1.18 (95%CI 1.16 to 1.21) 
[Lorenz et al., 2007].  Therefore, if APOE acts only through CIMT, the risk 
that this gene confers on stroke is very small (E4 individuals will have a 3.5% 
increased risk compared to E2 individuals).  Identifying individuals’ APOE 
genotype status is therefore unlikely to be important alone in predicting 
stroke risk for individuals.  However, it has been suggested that these 
polymorphisms with small effects could be more important as drug targets.  
As the effects of inherited variants are limited, the effect of drug treatments 
are not.  An example is the gene for 3-hydroxy-3-methyl glutaryl-coenzyme 
A reductase (HMGCR), for which the SNPs in this gene have only a ~5% 
effect on LDL levels, whereas drugs targeting the encoded protein of this 
gene decrease LDL levels by ~30% [Altshuler et al., 2008]. 
 
Chapter 5 – Systematic Review Discussion 
200 
5.3.6 Lessons Learnt 
Future studies of genetic association for stroke and its intermediate 
phenotypes will need to address two concepts: 
 
 Heterogeneity of phenotypes 
 Interactions between risk factors (genetic and environmental) 
 
To do this successfully studies will need to: 
 
 Be much larger than previous studies. 
 Include careful consistent definitions of the disease/trait being 
studied. 
 Include extensive phenotyping, so heterogeneity and interactions can 
be considered. 
 Include extensive genotyping (using high-throughput genotyping 
techniques) to identify novel polymorphisms and study gene-gene 
interactions. 
 Perhaps use other intermediate traits in addition to CIMT and WMH 
to study small- and large- artery stroke and other stroke subtypes. 
 Attempt to carry out replications in similar populations. 
 Involve sophisticated methods of analysis to deal with the vast 
amounts of data and the identification of interactions and sources of 
heterogeneity. 
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5.4 Hypothesis for Further Investigation 
 
The strongest conclusions that can be made from the meta-analyses are for 
APOE.  APOE has been studied in by far the largest numbers for both CIMT 
and WMH.  APOE was the only gene that showed a significant association 
with CIMT overall and when restricting the analysis to only the larger (and 
probably more reliable) studies.  Conversely, there appeared to be no 
association between APOE and WMH in my meta-analysis.  This is in 
keeping with previous studies of the association between APOE and stroke 
that suggest an association with large artery stroke, but no association with 
small artery stroke.  However, few studies have tested explicitly for a 
difference in association of APOE with large versus small artery ischaemic 
stroke.  I decided to test this hypothesis in a large cohort of stroke patients.  









6 Association Between Ischaemic Stroke Subtype 
and APOE Genotype in a Hospital-Based Stroke 
Cohort 
(ESS APOE Genotyping Study) 
 
In this chapter I describe the methodology and analysis plan for the 
genotyping study I undertook, within the Edinburgh Stroke Study, in which 
I planned to test the association between Apolipoprotein E genotype and 
ischaemic stroke subtype.  Unfortunately, problems with the genotyping 
meant I could not carry out the planned association analysis, and so instead I 
present investigatory analyses to determine the causes of the genotyping 
problems. 
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6.1 Introduction 
The Edinburgh Stroke Study (ESS) recruited from May 2002 to May 2005 and 
aimed to register all stroke and TIA (transient ischaemic attack) patients seen 
at the Western General Hospital, and to follow-up all those who presented 
with a stroke for recurrent stroke, myocardial infarction, death and disability.  
The aim was to study causes and consequences of stroke and TIA.  Data 
collected included medical background and family history information, 
clinical details of the presenting stroke or TIA, investigation results 
(including imaging), and follow-up.  Follow-up of stroke patients was for 
between one and four years.  So far the ESS has produced several 
publications, including an assessment of the impact of the requirement for 
consent and comparisons between ischaemic stroke subtypes of the 
prevalence of traditional risk factors and of the prognosis for recurrent 
vascular events [Jackson et al., in press; Jackson et al., 2008; Jackson et al., in 
press].  Blood samples for extraction and storage of DNA, as well as for 
storage of plasma were taken from most of the patients included in the 
cohort, with a view to future genetic and other biomarker studies.    
 
I aimed to use this cohort to test the association between APOE epsilon 
genotype and ischaemic stroke subtypes, specifically comparing the 
distribution of APOE genotypes between patients who have had a large 
artery ischaemic stroke (LAS), with those that have had a small artery 
ischemic stroke (SAS).  This follows from the hypothesis generated from my 
systematic review work which suggests that the APOE epsilon genotype is 
associated with CIMT (and LAS), but not with WMH (and SAS).   
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6.2 Methods 
6.2.1 Subject Recruitment 
The aim was to recruit into the ESS any patient with a definite or probable 
stroke or TIA who was admitted as an inpatient to – or seen in an outpatient 
clinic at - the Western General Hospital, Edinburgh between May 2002 and 
May 2005.  All those recruited gave informed consent.  Patients could 
consent to any or all of the following: 
 
 use of their data for research 
 contact with their GP and access to their medical records 
 future follow-up  
 storage of blood samples for future biological and genetic analyses 
 
2160 patients were recruited, around 1500 of whom had a confirmed stroke.  
In a comparison of the ESS participants and a contemporaneous stroke audit 
from the same hospital, with the same target population but no requirement 
for consent, it was found that, during an 18 month period (October 2002 to 
March 2004 inclusive), the ESS recruited 88% of eligible participants [Jackson 
et al., 2008].  The need for consent may have introduced selection bias relative 
to the target population.  Participants were more likely than non-participants 
to have had a milder stroke, but there were some very mild stroke patients 
who were missed due to a shorter stay in hospital, meaning that consent 
could not always be obtained prior to discharge. 
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6.2.2 Data & Sample Collection 
Baseline data were collected on standardized forms by stroke specialist 
doctors who assessed the patients (see appendix 9).  Clinical diagnosis of 
stroke and the subtype was confirmed by clinical assessment and imaging 
investigations.  Stroke subtype was classified according to both the OCSP 
(Oxford Community Stroke Project) and a modified TOAST (Trial of Org 
10172 in Acute Stroke Treatment) classification (see section 1.1 for discussion 
of classification methods and appendix 10 for the modified TOAST algorithm 
used in the ESS).  2 x 2ml EDTA blood samples were collected by either 
doctors assessing each patient or trained research nurses from the Wellcome 
Trust Clinical Research Facility (WTCRF) within the Western General 
Hospital.  Both samples were transferred to the WTCRF on ice on the day of 
collection.  One sample was stored at -80°C prior to DNA extraction and 
storage in the Genetics Core Laboratory at the WTCRF.  The other was 
centrifuged and the plasma stored at -80°C prior to transfer to a research 
laboratory in Glasgow for measurement of various inflammatory and 
rheological biomarkers.  
 
Patients were followed up for recurrent stroke, myocardial infarction, death 
and disability by: asking patients to contact the ESS research team following 
any suspected stroke or myocardial infarction; posting questionnaires (about 
possible vascular events and disability) to participants at 6 months, 1 year 
and annually; asking GPs and hospital doctors of participants to inform the 
ESS research team of future vascular events or deaths (by way of letter to the 
GP and a sticker on the patients’ hospital notes); obtaining any death 
certificates for patients in the cohort from the General Register Office for 
Scotland. 
Chapter 6 – ESS APOE Genotyping Study 
207 
6.2.3 Sample Preparation 
DNA was extracted using the Nucleon BACC3 kit from Tepnel.  Extraction 
took place either immediately on receiving the samples, or up to three years 
later.  The extracted DNA was initially stored in tubes.  The tubes were spun 
for two weeks to re-suspend the DNA.  Half of each DNA sample (500μl) 
was plated into deep 384-well plates (the remaining stock (500μl) was kept in 
the tubes, both stored at -80°C). The concentration of each sample in the 384-
well stock plates was measured using PicoGreen® immediately after being 
plated. PicoGreen® contains a fluorescence stain for double-stranded DNA 
(dsDNA) that has a minimal fluorescent signal in solution, but a strong 
signal when bound to dsDNA.  Based on these concentrations, DNA samples 
from the 384-well stock plates were normalised to 10ng/μl in 96-well plates, 
ready for genotyping (where concentrations were <10ng/μl the samples were 
transferred to the 96-well plates neat).  On each 96-well normalised plate 
there were between one and four water controls. 
 
6.2.4 Genotyping  
The epsilon variant of APOE comprises two SNP mutations.  The ε3ε3 
wildtype genotype has a Cys amino acid at position 112 and an Arg at 
position 158.  A change to Cys at position 158 represents the ε2 allele and a 
change to Arg at position 112 represents the ε4 allele.  Genotyping was 
carried out on the 96-well normalised plates by the WTCRF Genetics Core 
Laboratory using Applied Biosystems TaqMan genotyping assays.  The 
TaqMan assays for the two SNPs (rs7412 and rs429358) are c904973 and 
c3084793, respectively.  TaqMan assays include PCR primers and allele 
specific probes.  The PCR step amplifies the genome region of interest and 
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then allelic discrimination is achieved by selective annealing of fluorescent 
probes.  
 
Genotype calling was performed by WTCRF Genetics Core laboratory staff 
using ABI 7900 and Applied Biosystems AutoCaller™ genotyping software.  
Genotyping was carried out blind to the identity and all clinical and 
phenotypic information of the subjects, and as the samples were plated in 
approximately the order they were taken, there should be no structure in the 
plating which could introduce bias. 
 
6.2.5 Data Analysis Plan 
I developed a plan for genotype-phenotype association analysis of the data 
as follows: 
 
6.2.5.1 Genotype definition 
I planned to combine the SNP data to produce epsilon (ε) genotypes (ε2ε2, 
ε2ε3, ε3ε3, ε3ε4, ε4ε4, ε2ε4).  The primary comparison was to be between the 
following groups: E2 (ε2ε2, ε2ε3), E3 (ε3ε3) and E4 (ε3ε4, ε4ε4). 
 
6.2.5.2 Phenotype definition 
The primary comparison was to use a modified TOAST classification 
(appendix 10), comparing large artery ischaemic stroke (LAS, n=154) with 
small artery ischemic stroke (SAS, n=282).  Secondary analyses were to 
include cardioembolic stroke (with LAS); include TIAs with a visible infarct 
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on brain imaging; and to use the OCSP classification, comparing TACI and 
PACI (total and partial anterior circulation infarcts) against LACI (lacunar 
infarcts) (see section 1.1.3).  The 1st event (within the ESS) was to be counted 
for each patient included. 
 
6.2.5.3 Covariates 
The following covariates were to be considered: 
Age at event, sex, hypertension, diabetes, smoking, excess alcohol intake, 
total cholesterol plasma concentration and internal carotid artery stenosis. 
 
6.2.5.4 Analysis 
APOE genotype and each covariate were to be tested separately for 
association with stroke subtype, using a t-test or Mann-Whitney U test (for 
continuous variables) or χ2 test (for categorical variables).   
The data were to be analysed using stepwise multiple logistic regression to 
obtain odds ratios for LAS vs SAS, comparing the genotypes in a stepwise 
manner – E2 to E3 to E4, using the following covariates in each model: 
 
 Model 1.  covariates: age & sex 
 Model 2. covariates: age, sex & significant (p<0.05) covariates 
(excluding cholesterol & carotid stenosis) 
 Model 3.  covariates: age, sex, significant covariates & cholesterol 
 Model 4.  covariates: age, sex, significant covariates & carotid stenosis 
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Comparison of models 3 and 4 with model 2 would show whether any 
effects of APOE are mediated through effects on cholesterol concentration 
and/or carotid stenosis (a measure of atheroma). 
 
6.3 Genotyping Problems 
6.3.1 1st Round of Genotyping Results 
This genotyping run included all 1858 samples that were collected at the 
recruitment stage, including from those patients that were later excluded 
from the study because they turned out not to have had a stroke or TIA.  The 
additional 158 blank controls for each assay were all called as undetermined.  
Call rates were 1700/1858 (91%) and 1711/1858 (92%) for SNPS rs429358 and 
rs7412 respectively.  Table 6.1 shows the numbers of patients with each call 




Table 6.1  Genotype frequencies for SNPs rs429358 and rs7412, with the corresponding 
epsilon genotypes. 
 
rs429358 TT TC CC undetermined subtotals 
rs7412 
CC 1034 (ε3ε3) 279   (ε3ε4) 29     (ε4ε4) 100 1442 
CT 206   (ε3ε2) 39     (ε2ε4) - 11 256 
TT 13     (ε2ε2) - - - 13 
undetermined 84 12 4 47 147 
subtotals 1337 330 33 158 1858 
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Table 6.2 shows the observed and expected genotype frequencies for both 
SNPs.  rs7412 did conform to Hardy-Weinberg equilibrium (HWE) expected 
proportions (p=0.66).  rs429358 did not conform to HWE expected 
frequencies (p=0.02).  This is a potential cause for concern, but as this is a 
selected sample of stroke patients, not a random population sample, I would 
not necessarily expect genotypes to be in HWE.   
 
Figures 6.1 and 6.2 show the allelic discrimination plots for the two assays, 
produced by the Applied Biosystems AutoCaller™ genotyping software.  
Each axis of these graphs represents the reporter fluorescent signal intensity 
(Rn) for one of two probes (each relating to an allele).  Therefore when the Rn 
for one probe is high and for the other is very low, this represents a 
homozygous genotype, and when both Rn are intermediate, this represents a 
heterozygous genotype.  Samples from up to four 96-well plates are 
displayed on each graph, and so three clusters of individuals with the same 
genotypes are normally observed.  The clusters observed in figures 6.1 and 
6.2 are not distinct as one would generally hope for.  The plots for both SNP
 
Table 6.2 Observed and expected genotype frequencies, the heterozygote 












HWE      
p-value 
rs429358 observed  33 330 1337   
                expected 23 350 1327 0.94 0.02 
rs7412    observed 1442 256 13   

















Figure 6.1  Allelic discrimination plots for assay c904973 (rs7412) from the 1
st
















Figure 6.2  Allelic discrimination plots for assay c3084793 (rs429358) from the 1
st
 round of APOE genotyping in the Edinburgh Stroke Study
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 assays show very large Rn ranges.  For assay c904973 the FAM range is ~0.5 
to ~7.  For assay c3084793 the range is ~1 to ~12. 
 
The clusters spread divergently and trail out from the origin radially, 
resulting in some overlapping of the clusters.  The genotypes could not be 
called reliably using the automatic algorithm in the AutoCaller™ software 
and had to be called manually by the WTCRF technicians.  In particular 
regions on the plots (where there was some overlap), the genotypes were 
called as ‘undetermined’.  This resulted in the systematic removal of 
particular samples (in this case, more heterozygotes than homozygotes are 
removed), which leads to bias.  As the accuracy of genotyping calling using 
this method relies on the accuracy of the clustering, when this clustering is 
unsuccessful, all genotyping ‘calls’ should be disregarded. 
 
6.3.2 Possible Reasons for Problems 
The genotyping may have been unsuccessful due to a problem with the 
samples, or a problem with the assay. 
 
6.3.2.1 Sample problems 
 A problem with the samples can be detected by carrying out TaqMan 
genotyping on the ESS samples using an assay known to perform well 
in another sample collection.  If the ESS samples genotype successfully 
with such an assay, then the problem is most likely to be with the 
APOE assays.  If the ESS samples do not genotype successfully with 
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this ‘good’ assay, then the samples are probably the source of the 
problem. 
 
 The large Rn ranges observed on the allelic discrimination plots could 
suggest that the DNA samples were not normalised correctly.  This 
could be due to lab error at the normalisation stage or incorrect initial 
DNA concentration measurements, resulting in incorrect dilutions 
being applied.  This could be checked by re-estimating the 
concentrations of the stock samples and comparing with the original 
concentration estimates, and by measuring the concentration of the 
diluted assay plates, to see if the samples are at 10ng/μl. 
 
 Contamination or impurity of the samples may also be the source of 
the problem.   This could be cross-contamination (although this is 
highly unlikely given the meticulous protocol used by the WTCRF 
technicians) or impurity caused by the presence of material other than 
DNA (including proteins, indicating problems at the DNA extraction 
phase).  The samples can be checked for DNA purity using a 
nanodrop technique that measures the absorbance of the samples at 
particular wavelengths, which represent particular impurities. 
  
6.3.2.2 Assay problems 
 The other possible reason for poor clustering is that the assay does not 
work well.  Using the same TaqMan assays on a separate sample 
collection could check this.  If the genotyping is successful this 
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suggests that the assay is not the source of the problem.  If the 
genotyping does not work well in this second sample, then this 
indicates that there is likely to be a problem with the assay. 
 
 If there is a problem with the assay, there may be a mutation present 
within the primer or probe sites that prevent the assay from working 
as designed. This can be investigated by searching a SNP database, for 
potential problem SNPs.  This problem could be present across all 
populations or be specific to particular population samples. 
 
I carried out all of the investigations described above, to determine potential 
sources of the genotyping problem.  The results of these investigations along 
with explanations and further investigations necessary are described. 
 
6.3.3 Testing Samples With Good Assay 
To test whether the ESS DNA samples were the source of the genotyping 
problem, TaqMan genotyping was carried out on four of the 96-well plates 
using assay c27915549.  This assay has been previously used in the WTCRF 
laboratory for a separate study, and produced a clear cluster plot (see figure 
6.3). 
 
Figure 6.4 shows the cluster plot for genotyping of 380 ESS samples using 
assay c27915549.  This plot does not have clear, distinct clusters (like figure 
6.3) and many samples have been called as ‘undetermined’.  A large range of 
fluorescence intensity can be seen on the y-axis for the ESS samples (~2 to  
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Figure 6.4  Genotyping of C27915549 on 380 Edinburgh Stroke Study samples 
 
Figure 6.3  Previous genotyping of C27915549 in a different sample, indicating that it is a 
good assay 
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 ~11).  The cluster plot for the previous genotyping using this assay has a 
much smaller fluorescent range on the y-axis (~3 to ~5).  Figure 6.4 is similar 
to the cluster plots produced in our study using the APOE assays.  This 
suggests that the genotyping problem encountered is probably due to poor 
quality samples, rather than poor assays.  Poor samples could be due to 
incorrect normalisation, cross-contamination or problems during the 
extraction process leading to sample impurity (i.e. the samples might still 
contain protein, not just DNA). 
 
6.3.4 Concentration Investigation 
6.3.4.1 Testing if 96-well ‘normalised’ plates are at 10ng/μl 
Two 96-well normalised plates were tested to check that the normalisation 
had been successful and that the samples were all at 10ng/μl using nanodrop 
(which uses a spectrophotometric method for quantifying DNA). 
 
Figure 6.5 shows the distribution of concentrations from 190 of the samples 
(two 96-well plates). The estimates of the concentrations of the samples 
ranged from -143 to 1347ng/μl (the four minus values have been excluded 
from the histogram).  The median was 40ng/μl and the inter quartile range 
(IQR) was 24 to 71ng/μl.  It is clear that most samples’ concentrations 
deviated markedly from the expected 10ng/μl.  This suggests that the DNA 
samples were not successfully normalised.  This could be due to the original 
concentration estimates on the 384-well stock plates being inaccurate (and 
therefore, inappropriate dilutions carried out) or another problem at the 
normalisation stage. 
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6.3.4.2 Re-measuring the 384-well stock plate concentrations 
To determine if the original concentration estimates of the 384-well stock 
plates were accurate, these were re-estimated using PicoGreen®, after robotic 
remixing of the samples, to ensure they were in solution.  Figure 6.6a shows 
the correlation between the 2nd measuring of the 384-well stock plate 
concentrations (A2) and the original 384-well stock plate concentration 
measurements (A1) for all samples.  As can be seen from the figure there is 
very poor agreement between the two measurements.  The range of 
concentration values in A2 was larger than the A1 estimates (max A1 = 
320ng/μl, max A2 = 543ng/μl) but the mean was smaller (mean A1 = 
79±50ng/μl, mean A2 = 69±74ng/μl).  The Bland-Altman plot (figure 6.6b) 



















































Figure 6.5  Nanodrop estimations of the concentrations of 190 of the Edinburgh 
Stroke Study ‘normalised’ samples.  Samples should be normalised to 10ng/µl. 























Figure 6.6  Comparison of A1 and A2 PicoGreen® concentration estimates.  A. The two 
concentrations plotted against each other, the line represents A1=A2.  B. A Bland-Altman 
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estimates ( [(A2 – A1)/(A1 + A2)/2]*100 ) plotted against the average 
concentration estimate ( (A1 + A2)/2 ) [Pollock et al., 1992]. The 95% limit of 
agreement (LOA, +/-1.96 SD of the mean) is -184 to 109%.  This implies that 
for most samples either one or both of the estimates are wrong.  It is possible 
that the samples were not in solution for one or both estimates, and so when 
sampling the plates for PicoGreen® a ‘glob’ of DNA could have been 
sampled and the concentration estimated on that.  The tube stock samples 
were originally spun on the wheel before plating out and the A1 
concentration estimates being made, but they were possibly not spun for 
long enough.  Before the A2 concentration estimates the samples were 
robotically mixed to get them back into solution.  Assuming this was 
successful, the A2 concentration estimates may be more correct than the 
original A1 estimates. This could explain the contradicting estimates and the 
fact that the plates for genotyping do not appear to be at 10ng/μl (i.e. 
normalisation was carried out using incorrect concentration estimates). 
 
6.3.4.3 Re-measuring the stock concentrations from tubes 
Taking the A2 concentrations as correct 210, samples have a concentration of 
less than 10ng/μl.  As the original tube stock samples may have not been in 
solution, these low concentrations for particular samples may be improved 
by going back to the tube stock.  The remaining stock samples in tubes, were 
plated out into 384- well stock plates (I refer to these as ‘B’ plates), robotically 
mixed and the concentrations estimated using PicoGreen.  252 of the samples 
in the B 384-well stock plates have a concentration of less than 10ng/μl (but 
130 of these had a concentration of more than 10ng/μl in A2).  88 samples  






















Figure 6.7  Comparison of A1 and B PicoGreen® concentration estimates.  A. The two 
concentrations plotted against each other, the line represents A1=B.  B. A Bland-Altman plot 
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which had a concentration of less than 10ng/μl in A2 had a concentration of 
at least 10ng/μl in the B 384-well stock plates. 
The concentration estimates of the B plate samples had a range of values up 
to 935, with mean 60±77ng/μl.  This is a lower mean but a higher maximum 
than the A1 and A2 estimates.  Figure 6.7a shows the comparison between 
the original 384 –well stock plates concentration estimations (A1) and the 
second 384–well stock plates concentration estimations (B).  There is quite 
substantial spread in the data indicating the agreement between the two 
measurements is not good.  Figure 6.7b shows the Bland-Altman plot for this 
comparison.  The limit of agreement is -192 to 80%.  The agreement between 
A2 and B is also not good, LOA= -163 to 200% (figure 6.8). 
 
These differences between the three concentration estimates can be explained 
by the tube samples not being in solution.  Hence, when they were split into 
the two sub-samples (A and B), they were at different concentrations.  The 
lab has taken subsequent steps, assuming that the robot mixing was 
successful in getting the samples into solution and so the A2 and B 
concentrations, although different, are assumed to be accurate. 
 
6.3.5  2nd Round of Genotyping Results 
The lab genotyped 1599 selected samples a second time (those with 
confirmed stroke in ESS database and with a deep well plate DNA 
concentration of >10ng/μl).  Samples were selected from stock plates B in the 
first instance and this was supplemented with some samples from 96-well 
stock plates A (using the A2 concentrations), if the B concentration did not 
reach 10ng/μl, but the A2 concentration did. 


























Figure 6.8  Comparison of A2 and B PicoGreen® concentration estimates.  A. The two 
concentrations plotted against each other, the line represents A2=B.  B. A Bland-Altman plot 
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Call rates were 1477/1599 (92%) and 1334/1599 (83%) for SNPS rs429358 and 
rs7412 respectively.  Table 6.3 shows the number of individuals with each 
call for both SNPs.  As in the 1st genotype round, rs7412 did conform to 
expected HWE proportions (p=0.67), but rs429358 did not (p=0.004). 
 
 A comparison of the results from the first and second genotyping attempts 
are shown in table 6.4.  Of the samples genotyped in this second attempt, 
Table 6.3  Genotype call frequencies for SNPs rs429358 and rs7412, with the corresponding 
epsilon genotypes, from the 2
nd
 round of genotyping 
 
rs429358 TT TC CC Undetermined Subtotals 
rs7412 
CC 785  (ε3ε3) 253   (ε3ε4) 32     (ε4ε4) 57 1127 
CT 163  (ε3ε2) 31     (ε2ε4) - 3 197 
TT 9      (ε2ε2) - - 1 10 
undetermined 192 10 2 61 265 
subtotals 1149 294 34 122 1599 
 
Table 6.4  Comparison of the two genotyping rounds for both SNPs for n=1599 
genotyped both times. 
 
 rs429358 rs7412 
Called same genotype in both  1304 1257 
undetermined→genotyped 88 74 
genotyped→ undetermined 93 238 
Undetermined in both 29 27 
Changed genotype 85 3 
            Change: 46 TT→CT   39 CT→TT 3 CT→CC 
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82% (1304/1599) were called the same in both attempts for rs419358 and 79% 
(1257/1599) were called the same for rs7412.  85/1599 (5%) were called as 
different genotypes in the two attempts for rs429358 (changing between TT 
and CT). 3/1599 (<1%) were called as different genotypes in the two attempts 
for rs7412 (changing from CT to CC).    
 
Table 6.5 shows the distribution of genotypes that were called identically in 
both attempts.  There were 1061/1599 (66%) samples that were called the 
same in both genotyping rounds, for both SNPs. 
 
The allelic discrimination plots (see figures 6.9 and 6.10) show the same 
problems of large Rn ranges and overlapping clusters that were observed on 
the first genotyping attempt.  This may mean that the second attempt at 
normalisation was no more successful than the first or that there is still some 
other underlying issue. 
 
Table 6.5  Genotype call frequencies for SNPs rs429358 and rs7412 (with the 
corresponding epsilon genotypes) of the samples which were called identically for both 
SNPs, in both genotyping rounds. 
 
rs429358 TT TC CC subtotals 
rs7412 
CC 692   (ε3ε3) 171   (ε3ε4) 19     (ε4ε4) 882 
CT 147   (ε3ε2) 23     (ε2ε4) - 170 
TT 9       (ε2ε2) - - 9 
subtotals 848 194 19 1061 
 



















Figure 6.9  Allelic discrimination plots for assay c904973 (rs7412) from the 2nd round of 
APOE genotyping in the Edinburgh Stroke Study 
 




















Figure 6.10  Allelic discrimination plots for assay c3084793 (rs429358) from the 2nd 
round of APOE genotyping in the Edinburgh Stroke Study. 
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6.3.5.1 Testing if genotyped plates are at 10ng/μl 
Figure 6.11 shows the distribution of the nanodrop concentrations from 92 of 
the samples (one 96-well ‘normalised’ plate).  All of the concentrations were 
>10ng/μl.  The range was 11 to 504ng/μl and the median and IQR were 
24ng/μl (16 to 35).  These are better than seen in the first round, but are still 
far too variable, suggesting normalisation was unsuccessful again. 
 
 
Figure 6.11  Nanodrop estimations of the concentrations of 92 of the Edinburgh Stroke 
Study ‘normalised’ samples.  Samples should be normalised to 10ng/µl 
Chapter 6 – ESS APOE Genotyping Study 
230 
6.3.5.2 Determining if samples are in solution 
The concentrations of 135 samples from the second 384-deep well stock 
plates (B) were estimated using PicoGreen® on two consecutive days, to test 
whether the samples were in solution.  Figure 6.12a shows the correlation 
between these two estimates.  The two estimates do not appear to give 
similar results (and neither is similar to the original B concentration estimates 
- data not shown).  Figure 6.12b shows the Bland-Altman plot for the 
comparison of the results from consecutive dates.  The limit of agreement is  -
163 to 183%.  This shows that when estimating the concentration of the same 
samples using the same method on two consecutive days, they appear to 
give very different results, suggesting that they are still not in solution.  It 
may be that the robotic mixing method was not enough to get the samples 
into solution.  If this is the case then none of the concentration estimates are 
reliable and attempting to get the samples into solution should be a matter of 
priority. 
 
6.3.6 Impurity of Samples 
DNA quantification may be difficult if there are protein (or other) impurities 
in the sample.  Nanodrop UV light absorption data can be used to investigate 
the purity of DNA samples (Thermo Scientific, T009 Technical Bulletin). The 
peak of UV light absorption for DNA is at 260nm and the peak for proteins 
(and some other contaminants) is at 280nm.  Therefore, the ratio of 
absorbance at 260nm and 280nm (A260/280) can be used to assess the purity of 
DNA.  A ratio of 1.8 is considered to indicate pure DNA, and any ratio 
between 1.7 and 1.9 is generally considered acceptable.   






















Figure 6.12  Comparison of PicoGreen® concentration estimates from the same samples 
from two consecutive days.  A. The two concentrations plotted against each other, the line 
represents day1 = day 2.  B. A Bland-Altman plot of % difference against average estimate 
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Figure 6.13 shows the A260/280 ratios from 322 of the ESS samples (four 96-well 
plates).  Only 36% (116) of the samples were within the acceptable range.  
Most (200, 62%) were below 1.7, suggesting contamination with proteins.  If 
DNA samples are impure, successful genotyping may be impossible.  It may 
be worthwhile limiting the genotype calling to those samples with acceptable 
A260/280 ratios.  This would require access to the raw Rn data and attempting to 
re-cluster only the ‘acceptable’ samples.  As I do not have access to the raw 
Rn data this is not something I could test and because so few samples are 




Figure 6.13  A260/280 ratios of 322 samples from the Edinburgh Stroke Study.  The acceptable 
range for DNA (1.7 to 1.9) is represented by the red bars. 
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The lab staff have subsequently suggested that DNA extraction problems 
may be due to the small quantities of blood collected.  Contamination with 
proteins or other impurities may be more likely if the quantity of blood 
collected is small.  According to the Tepnel Nucleon® Genomic DNA 
Extraction Kit Manual, this technology has been designed for between 3 and 
10ml.  ESS blood samples sent for DNA extraction were 2ml or less. 
 
6.3.7 Validity of Assay 
To check whether there was a specific problem with the ESS samples, or 
whether this assay did not work for other samples too, I wanted to check the 
assay use on a separate sample set.  The WTCRF laboratory had previously 
genotyped the two APOE SNPs using the same assays in a Scottish 
population.  The cluster plots produced from these samples are shown in 
figure 6.14.  These plots show much tighter clusters and smaller Rn ranges 
compared to our data.  However they still observed some spreading out of 
the clusters resulting in some samples being called as ‘undetermined’. 
 
6.3.8 Investigation of Mutation in the Primer or Probe Regions 
As the primers and probes used in these assays are commercially owned I 
was unable to obtain the exact locations and sequences or the primers and 
probes.  However, the probes will be within the ±25bp ‘context sequences’ 
that ABI provide.  The ± 40bp region for both assays is shown in figure 6.15 
along with all SNPs in this region.  For the rs7412 SNP the closest SNPs were 
at +39 and -39 and so may not affect the c904973 assay probes.  However, for 
the rs429358 SNP, two SNPs were very close to the SNP of interest and might 
be likely to affect the efficacy of the c3084793 assay probes:  rs11542041 at 
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Figure 6.15  The ±40bp regions around the two SNPs typed in this study. The red letter denotes the SNP of interest, the X’s denote other SNPs in the 
surrounding region.  NV= non-validated SNP, V= validated SNP. 
rs7412.  50103869-50103969  
GCGTAAGCGGCTCCTCCGCGATGCCGATGACCTGCAGAAGCGCCTGGCAGTGTACCAGGCCGGGGCCCGCGAGGGCGCCGA
X                                                            X
rs769455                                                        rs11542032
V                                                               NV 
rs429358.  50103731-50103831  
GGCGGCGCAGGCCCGGCTGGGCGCGGACATGGAGGACGTGTGCGGCCGCCTGGTGCAGTACCGCGGCGAGGTGCAGGCCAT 
X                             X                              X        X                                       X
rs28931577         rs11542037                                   rs11542041   rs11542035            rs11542039 
NV*                     NV                                      NV                 NV  NV
* NV = non-validated SNP, V = validated SNP.
50 4  - 50103821 
50103879  50103959 
CHR 19 
Chapter 6 – ESS APOE Genotyping Study 
236 
+6bp from the investigated SNP and rs11542035 at +12bp from the 
investigated SNP.  Both of these are missense mutations but have not been 
extensively studied and no allele frequencies are reported in the Single 
Nucleotide Polymorphism database (dbSNP).  There are three further SNPs 
within the surrounding 80bp region which may affect the efficacy of the 
primers used in the assay. 
 
The previous example of assay use that the WTCRF provided me with for 
use as a comparison shows possible evidence of a SNP in the probe region 
(see cluster drifts in figure 6.14a).  This drifting of clusters due to a SNP could 
explain some of the overlap of clusters seen for the ESS samples. 
 
A similar data pattern has previously been observed when genotyping the 
Ile655Val variant of the ERBB2 gene [Benusiglio et al., 2005].  The cluster plot 
produced from their genotyping is reproduced in figure 6.16.  They observed 
a group of heterozygote samples that are shifted to the left (circled in the 
figure).  They concluded that an Ile654Val variant close to the Ile655Val 
variant interferes with the correct binding of the probe, resulting in a cluster  
plot with more than 3 clusters.  This kind of scenario leaves the investigator 
with a dilemma of what to do with these extra clusters.  If they are classified 
as undetermined (as in the case of our data and the ERBB2 data), this could 
introduce bias, as a systematic group of samples are unclassified.  The shift to 
the left in the heterozygotes results in unclassified samples, whilst a similar 
shift in the homozygotes may result in the homozygote genotype still being 
called.  By systematically removing particular individuals (heterozygotes) 
from the analysis, bias is introduced.   
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To test whether these SNPs might affect the assay efficacy in this population 
one could genotype these SNPs within our sample, or more ideally sequence 
the region of interest to identify any potential assay-affecting SNPs in the 
region.   
 
 
6.3.9 Discussion of Genotyping Problems 
It is clear that there is a problem with the ESS samples, due to the poor 
results when genotyping using a ‘good’ assay, the large Rn ranges and the 
poor concentration estimation reproducibility.  There may also be a 
contamination problem. 
 
It also seems as though there may be a problem with the assays (particularly 
c3084793) as even in the genotyping of these SNPs in another studies samples 
there appears to be extra clusters.  If continuing on this work further I would 
want to sequence this region in a subset of the ESS samples to rule out any 
assay problem.   
 
6.3.10 Future Directions 
The lab have now combined the A and B 384-well stock plate samples and 
have robotically mixed these combined samples twice in an attempt to get 
the samples into solution.  Preliminary indications from the lab are that they 
are getting repeatable PicoGreen® concentration estimates from the samples 




Figure 6.16  All lic discrimination plot from a study [Benusiglio et al., 2005] that reported an 
underlying SNP in the probe region as seen by the circled samples that have drifted to the left 
of the heterozygote cluster. 
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It has been agreed between the lab staff and ESS investigators that although 
there may be sample problems, some samples will probably genotype ok.  
There are potentially some issues with the APOE assays, and so deciding 
which samples may genotype is difficult from the results of these assays, so 
other assays must be used to select the ‘good quality’ samples for future 
genotyping.  A panel of 14 SNPs that have previously genotyped well (>93% 
call rate) in a Scottish population is going to be used to select the usable ESS 
samples. 
 
6.4 Impact on Future Work and Other Studies 
The ABI assays are designed and tested using a small specific population.  It 
is quite likely that these may not work well in other populations.  It may be 
sensible to design assays specifically for the study population, taking into 
account nearby SNPs.  Although high through-put genotyping has its uses, 
this shows that it may not always be appropriate. 
 
For future genotyping in the ESS, the samples need to be good quality 
(properly normalised and without contamination) and poor quality samples 
should be excluded.  To increase the genotyping success rate in future 
studies it may be sensible to collect larger quantities of blood (between 3 and 
10ml), to improve the DNA extraction step. 
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6.5 Conclusion 
I have not carried out my planned analysis of the association between APOE 
genotype and stroke subtype because of the poor quality of the samples (and 
possibly also the problematic assays).  The accuracy of the genotyping (even 
for those where calls were the same in both) is in question.  This is reflected 
in the poor allelic discrimination plots and departure from Hardy-Weinberg 
equilibrium.  These serve as an alert that there have been problems in the 
genotyping and further quality control checks need to be carried out on these 
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Step 1 – Meta-ANOVA 
Have data in long format: 
 
study  genotype  n mean  sd 
1  0   x x  x 
1  1   x x  x 
1  2   x x  x 
 
Derive SE using: 
 




xi: regress mean i.genotype i.study [aweight=1/se^2] 
testparm_Igenotype* 
 
Gives the p-value for genotype in the ANOVA model. 
 
 
Step 2 – Determine genetic model 
 
Have data in wide format: 
 
study  n11 x11 s11 n12 x12 s12 n22 x22 s22 
xxxx  x x x x x x x x x 
 
Carry out MD1 and MD2 meta-analyses saving the _ES and _seES variables generated: 
 
metan n12 x12 s12 n11 x11 s11, random nostandard 
gen MD1 = _ES 
gen se1 = _seES 
 
metan n22 x22 s22 n11 x11 s11, random nostandard 
gen MD2 = _ES 
gen se2 = _seES 
 
Calculate the average of the standard errors to get a study-wide estimate: 
gen se = (se1 + se2) / 2 
 
Finally carry out the weighted linear regression: 
 






Step 3 – Calculating the mean difference using the appropriate genetic model 
Based on the regression coefficient estimated from step 2, the appropriate genetic model was 
chosen. 0= recessive, 0.5=co-dominant, 1=dominant. 
 
The data should be in wide format as for step 2. 
 
The following gametan* commands are used to estimate the appropriate mean difference: 
 
gametan n22 x22 s22 n12 x12 s12 n11 x11 s11, codominant 
Or 
gametan n22 x22 s22 n12 x12 s12 n11 x11 s11, recessive 
Or 
gametan n22 x22 s22 n12 x12 s12 n11 x11 s11, dominant 
 
 
*gametan is a STATA program written by Julian Higgins to carry out genetic association 






Appendix 2.  Terms used in CIMT gene-specific searches 
 
Gene Medline terms Embase terms 








((apolipoprotein$ adj e) or 
(apoprotein$ adj e) or apo-e or 
apo e or apoe).tw. 
apolipoprotein/ or 
apolipoprotein e/ or 
apolipoprotein e2/ or 
apolipoprotein e3/ or 
apolipoprotein e4/ or 
apolipoprotein e5/ or 
apolipoprotein e7/ 
 
((apolipoprotein$ adj e) or 
(apoprotein$ adj e) or apo-e or 
apoe or apo e).tw. 










enzyme or ace or peptidyl-
dipeptidase).tw. 
MTHFR exp "Methylenetetrahydrofolate 
Reductase (NADPH2)"/ge 
[Genetics] 
    
(MTHFR or c677t or nadph2 or 





   
(MTHFR or c677t or nadph2 or 
meythlene tetrahydrofolate or 
methylenetetrahydrofolate).tw. 
NOS3 exp Nitric Oxide/ or exp Nitric 
Oxide Synthase/ 
   
 
(eNOS or ecNOS or NOS or 
NOS3 or nitric oxide synthase 
or T-786C or T786C or 
Glu298Asp or NO synthase or 
G894T).tw. 
exp Endothelial Nitric Oxide 
Synthase/ or exp Nitric Oxide 
Synthase/ 
   
(eNOS or ecNOS or NOS or 
NOS3 or nitric oxide synthase 
or T-786C or T786C or 




(adducin$ or add1 or add-1 or 




(adducin$ or add1 or add-1 or 
addA or add-A or alpha-
adducin).tw. 
PON1 (paraoxonase or paraoxon 
esterase or PON1).tw. 
(paraoxonase or paraoxon 
esterase or PON1).tw. 
IL6 exp Interleukin-6/ge [Genetics] 
exp Interferon-beta/ge 
[Genetics] 
exp Interleukin 6/ 
exp Beta Interferon/ 
   
Appendices 
283 
   
(interleukin 6 or interferon beta 
2 or IL6 or IL-6 or IL 6 or 
interleukin-6 or interferon beta-
2 or BSF-2 or B-cell simulatory 
factor 2 or CDF or hybridoma 
growth factor or CTL 
differentiation factor).tw. 
 
(interleukin 6 or interferon beta 
2 or IL6 or IL-6 or IL 6 or 
interleukin-6 or interferon beta-
2 or BSF-2 or B-cell simulatory 
factor 2 or CDF or hybridoma 
growth factor or CTL 
differentiation factor).tw.   
IGF1 exp Insulin-Like Growth Factor 
I/ge [Genetics] 
   
(insulin-like growth factor I or 




(insulin-like growth factor I or 
IGF-I or IGF-1).tw. 
ADRB2 exp Receptors, Adrenergic, 
beta-2/ge [Genetics] 
   
(ADRB2 or beta 2 adrenergic 
receptor or ADRB2R or 
ADRBR or B2AR or BAR or 
BETA2AR or beta 2 
adrenoceptor or catecholamine 
receptor).tw. 




(ADRB2 or beta 2 adrenergic 
receptor or ADRB2R or 
ADRBR or B2AR or BAR or 
BETA2AR or beta 2 
adrenoceptor or catecholamine 
receptor).tw. 
CRP exp C-Reactive Protein/ge 
[Genetics] 
   
(CRP or reactive protein).tw. 
exp C Reactive Protein/ 
   
 
(crp or reactive protein).tw. 
FGG/FGA (fibrinogen or FGG or FGA).tw. (fibrinogen or FGG or FGA).tw. 
AGT exp Angiotensinogen/ge 
[Genetics] 
exp Receptors, Angiotensin/ge 
[Genetics] 
   
(agt$ or angiotensin$).tw. 
exp angiotensin derivative/ or 
angiotensinogen/ 
exp Angiotensin 1 Receptor/ or 
exp Angiotensin Receptor/ 
 
(agt$ or angiotensin$).tw. 
FV exp Factor V/ge [Genetics] 
   
(facV or factor V or FVL or 
Leiden or factor 5).tw. 
exp Blood Clotting Factor 5/ 
   
(facV or factor V or FVL or 
Leiden or factor 5).tw. 
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Appendix 3.  Data transformations of CIMT papers. 
Often it was necessary to transform the data presented in a paper in order to get the data in 
the required format for analysis (i.e.. number of subjects, mean and standard deviation of 
CIMT).  
 
3.1 Example of combining groups  




























 E2 E3 E4 
 n x  SD n x  SD n x  SD 
Men 169 0.77 0.17 874 0.78 0.20 272 0.77 0.20 
Women 204 0.70 0.14 908 0.71 0.16 296 0.72 0.19 
All* 373 0.73 0.16 1782 0.74 0.18 568 0.74 0.20 
 
* means and SDs to be used in the analysis, calculated using the above formulas. 
 
3.2 Combining data from left and right CCA 
Some papers had reported the mean CIMT per genotype separately for left and right CCAs. 
The ideal measurement was the mean of the right and left, so this was calculated. 
 
Note, this sort of combination of data (where the resulting sample size is the same as in the 
individual groups), is different to that described above (where there is a combination of data 
across individuals). 
 
Example, Bilici 2006: 
 
 DD ID II 
 n x  SD n x  SD n x  SD 
Left 28 1.27 0.32 28 1.32 0.35 8 1.30 0.22 
Right 28 1.31 0.27 28 1.25 0.30 8 1.33 0.36 
Mean 28 1.29 0.30 28 1.29 0.33 8 1.32 0.29 
 
 
3.3 Example of estimating numbers of subjects 
 
Linnebank 2006: 
In this paper the sample sizes per genotype were not reported.  Instead the genotype 
proportions were reported.  As the overall sample size is known it is possible to calculate the 
sample size per genotype.  However, the total must equal the overall sample size and there 
Appendices 
285 
are several genotype sample sizes possible.  Here I report the possible values and show 
which were selected: 
 
 Genotype proportions Total Mean     Possible sample sizes 
TT 0.48 714 343     340   341   342   343   344   345   346  
CT 0.44 714 314     311   312   313   314   315   316  317 
CC 0.07 714 50     47     48     49     50     51     52     53 
Total 0.99  707                                                 714 
 
 
3.4 Bleil 2006 
There was no SD data per genotype group in this paper.  However, the overall SD was 
reported to be 0.16mm, so the SD of the three genotypes were assumed to be equal and 0.16 
was used as the SD for each genotype. 
 
 
3.5 Cattin 1997 
This paper reports CIMT as the sum of the right and left CCAs.  As other papers report 
either only one CCA, or the mean of both I transformed the data to be more similar to these.  
I divided the mean for each genotype by 2, to represent the average CCA CIMT.  To estimate 
the standard deviation of this measurement I used the following formula: 
 
Var (X) = Var (2X) / 4 
 
The presented and transformed data are shown below: 
 
 n Mean (sum R&L) SD Mean (avg R&L) Var (2X)/4 SD (avg R&L) 
E2 32 3.6 0.2 1.80 0.01 0.10 
E3 177 3.7 0.3 1.84 0.0225 0.15 
E4 45 3.9 0.9 1.95 0.2025 0.45 
 
 
3.6 Slooter 2001 
The CIMT (per genotype) data were reported as the mean difference from the reference 
group (ε3ε3), with 95%CIs, as shown in the table below.  In the text, the median of ε3ε3 was 
reported to be 0.77mm (10th centile: 0.63; 90th centile: 1.00 mm).  I therefore took the mean for 
ε3ε3 to be 0.77mm and calculated the standard deviation as if the data were normally 
distributed (i.e.  (1.00 - 0.63)/ 2.564 = 0.14).  From the estimated ε3ε3 mean, I could calculate 
the mean of all the other genotypes.  Using the formula escribed above I converted each of 
the CIs to SDs.  The before and after data are shown in the table below: 
 
 ε2ε2 ε2ε3 ε3ε3 ε3ε4 ε4ε4 
mean difference -0.04 -0.02 0 0.00 0.01 
CI -0.08 to 0.00 -0.03 to -0.01 - -0.01 to 0.01 -0.01 to 0.04 
n 46 704 3122 1258 134 
mean 0.73 0.75 0.77 0.77 0.78 







3.7 Yazdanpanah 2006 
There were no data in the text or the tables relating to CIMT per genotype.  However the 
mean and standard error data were presented in a graph.  I therefore, estimated the means 
and standard deviations from the graph: 
 
Using the scale on the graph: 1mm (on graph) = 0.0043 
 
 *data estimated from graph, † standard deviation 
 calculated from standard error and n. 
 
 
3.8 Mannami  2001 
There were no data in the text or the tables relating to CIMT per genotype.  However the 
mean and standard error data was presented in a graph.  I therefore, estimated the means 

















*data estimated from graph, † standard deviation calculated from standard error and n. 
Genotype n Mean* se* sd
†
 
GG 3170 0.77 0.00645 0.36 
GT 1668 0.78 0.01075 0.44 
TT 245 0.76 0.02365 0.37 
Gender Genotype n Mean* SE* SD
†
 
Men DD 215 0.89 0.01 0.158 
DI 791 0.90 0.01 0.281 
II 694 0.90 0.01 0.263 
Women DD 262 0.85 0.02 0.324 
DI 849 0.85 0.01 0.291 




3.9 Balkestein 2002 
There were no data in the text or the tables relating to CIMT per genotype.  However the 
mean and standard error data was presented in a graph.  I therefore, estimated the means 




1mm = 0.95 
 
 
*data estimated from graph, † standard 







3.10 Spoto 2005 
There were no data in the text or the tables relating to CIMT per genotype.  However the 
mean and standard deviation data was presented in a graph. 
 
 
*data estimated from graph 
Genotype n Mean* se* sd
†
 
II 116 555 15 0.16 
ID 180 585 17 0.23 
DD 84 582 19 0.17 
Genotype n Mean* SD
*
 
GG 59 0.98 0.10 
GT 56 1.07 0.23 
TT 16 1.16 0.36 
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Appendix 4.  Example of data collection  letter – 
including letter and forms. 
 
 
Division of Clinical Neuroscience 




Tel. +44 131 537 2546 
Fax. +44 131 332 5150 
 
Dr Jan Staessen 
Study Coordinating Centre, 
Laboratory of Hypertension, 






07 October 2009 
 
Dear Dr Staessen, 
 
Re: Systematic review and meta-analyses of the association of commonly studied 
genes with carotid intima-media thickness. 
 
We are carrying out a systematic review and series of meta-analyses of the association 
between genotype and carotid intima-media thickness, focusing on those genes studied in 
large numbers of subjects. 
 
We have identified you as a principal investigator for the following study: 
 
Balkestein EJ, Wang JG, Struijker-Boudier HAJ, Barlassina C, Bianchi G, Birkenhäger 
WH, Brand E, Den Hond E, Fagard R, Herrmann S-M, Van Bortel LM, Staessen JA. 
2002. Carotid and femoral intima-media thickness in relation to three candidate genes 
in a Caucasian population. J. Hypertension 20:1551-61. 
 
This study seems very relevant to our review, and so we would be most grateful if you could 
help us by providing some basic information about it. Attached is a short data collection 
form, on which we have noted as much information as possible. It would be very helpful if 
you could check the information in the boxes (making any necessary changes) and complete 
any boxes that remain blank The easiest and quickest way to do this is probably to complete 
the form, save it to your PC, and then email it back to us as an attachment. If you prefer, 
however, you could print it out, complete it and then fax or post it to us. We intend to carry 
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out the analyses in June and would therefore be most grateful if you could return the form to 
us before the end of May. 
 
We very much appreciate your help with this. The review will be much more reliable if we 
are able to include data from all relevant studies identified. We will of course send you a 
copy of the results once we have completed the analyses and will acknowledge your 
contribution in publications arising from this work. 
 
If you have any questions or comments, please do not hesitate to contact us by email, phone, 
post or fax. 
 








Lavinia Paternoster   Dr Cathie Sudlow 
PhD Student    Clinical Senior Lecturer, Wellcome Trust Clinician
     Scientist and Honorary Consultant Neurologist 
 
Please return this form to Lavinia Paternoster preferably by email, 
L.Paternoster@sms.ed.ac.uk, or by post or fax. 
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CIMT measurement method 
 
Please tell us how the CIMT values in the analysis were obtained. If you have 
analysis data relating to more than one type of CIMT measurement, we 
would prefer to have data relating to only the mean CIMT from the both the 
right and left, far walls of the common carotid artery (or close to this ideal). 
 
Segment measured   Side measured  Wall measured 
(cross all that apply) 
 
Common carotid   Right    Near  
Bifurcation    Left    Far  
Internal carotid   Both    Both  
External carotid  
 
Value used in analysis 
 
Mean     Maximum    
 
Briefly describe how many measurements were taken and how they were 
combined to create the final value used in the analysis (eg. the mean of the 
maximum from the right and the maximum from the left artery, 3 
measurements taken from each side)  
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CIMT mean and standard deviation results per ADD1 genotype 
 
Please complete the boxes. 
 
Genotype Number of subjects 
with ACE and 







GG                   
GT                   
TT                   
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Appendix 5. Full table of studies identified in CIMT genetic search. 
Gene Total Subjects 
Number of 
publications Largest Study 
APOE 37493 47 12491 
ACE 23935 51 5321 
MTHFR 14205 33 3247 
NOS3 9434 19 2448 
PON1 8921 27 1786 
ADD1 8535 5 6471 
AGT 7515 19 737 
IL6 7190 10 2421 
CRP 6603 3 4641 
CD14 5943 7 1110 
FAC V 5828 5 3750 
TLR4 5638 6 2955 
APOA1/C3 5363 8 2265 
HFE 5288 4 2932 
ADRB2 5249 1 5249 
AGTR1 5117 14 737 
CETP 4387 7 2632 
FGG / 
FGA 4274 1 4274 
IGF1 4239 2 3769 
LPL 4178 10 2445 
ADIPOQ 4035 4 1745 
APOB 3386 7 326 
LIPC 3181 4 2268 
TLR2 3000 2 2955 
PPARA 2991 2 2301 
PPARG 2963 2 1379 
TNFR1 2737 1 2737 
MMP3 2531 5 1111 
MCP1 2490 7 610 
APOA5 2430 2 157 
HGF 2412 1 2412 
GJA4 2290 2 1440 
APOA4 2276 2 2057 
PTPN22 2268 1 2268 
GSTM1 2228 4 1394 
FABP2 2224 3 1621 
FAC VII 2178 4 810 
IL1 2142 3 1000 
MTTP 2138 1 2138 
GSTT1 2039 3 1394 
CX3CR1 2038 3 1256 
CYBA 2038 3 1361 
MMP9 2005 4 1000 
CYP7B1 1980 1 1980 
APOA1 1950 3 1856 
ABCA1 1817 4 969 
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Gene Total Subjects 
Number of 
publications Largest Study 
FGB 1804 1 1804 
LTA 1778 2 1088 
GP2B 1693 2 1292 
CCR5 1691 3 380 
PDE4D 1670 1 1670 
APOA 1634 5 826 
ADRB3 1488 2 731 
LEP 1428 1 1428 
PAI1 1378 3 218 
UCP2 1334 1 1334 
EDN1 1320 3 690 
TGFB1 1312 4 80 
FAC II  1307 4 407 
CYB11B2 1270 3 420 
FUT3 1238 1 1238 
MMP1 1224 2 1000 
ADH3 1181 1 1181 
ITGB2 1160 1 1160 
MPO 1160 1 1160 
NPY 1152 2 966 
MT-ND2 1148 1 1148 
IL3 1109 1 1109 
ECE1 1100 3 630 
TNF  1036 4 332 
ICAM1 1022 2 332 
IRS1 1018 1 1018 
OAZ1 1001 1 1001 
IL5 1000 1 1000 
MMP2 1000 1 1000 
TIMP2 1000 1 1000 
TIMP3 1000 1 1000 
SOD2 989 1 989 
ARG1 963 1 963 
MT-TL1 935 2 673 
GNB3 932 1 932 
IL10 883 3 121 
CCR2 850 2 531 
THBD 803 2 333 
ITGB3 792 3 161 
SELE 788 4 332 
PTGDS 782 1 782 
ESR1 778 2 88 
HTR2A 757 2 690 
PON2 734 3 310 
LTC4S 732 1 732 
NRG1 706 1 706 
BDKRB1 690 1 690 
GDLM 690 1 690 
GLUT1 690 1 690 
IL18 690 1 690 
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Gene Total Subjects 
Number of 
publications Largest Study 
MGP 690 1 690 
MARS 690 1 690 
THPO 690 1 690 
VEGF 690 1 690 
VWF 690 1 690 
GSTP1 645 2 605 
CD40 620 1 620 
TP53 605 1 605 
PTPN1 590 1 590 
ITGA2 537 1 537 
APOC3 530 2 369 
CLU 525 1 525 
MT2A 506 1 506 
SREBF2 497 1 497 
VDR 471 1 471 
ALOX5 470 1 470 
CAV3 470 1 470 
CD31 470 1 470 
CD36 470 1 470 
CTSG 470 1 470 
FAC III 470 1 470 
FAC VIII 470 1 470 
NPPA 470 1 470 
SPP1 470 1 470 
P2RY1 470 1 470 
PTAFR 470 1 470 
PROC 470 1 470 
SELL 470 1 470 
SELPLG 470 1 470 
TLR9 384 1 384 
INS 331 1 331 
PAFAH 330 2 190 
CBS 322 2 161 
ALDH2 304 1 304 
OPG 234 2 175 
COX2 220 1 220 
SREBP1A 204 1 204 
GPX1 184 1 184 
SDF1 183 1 183 
GP1B 158 1 158 
GP1A 157 1 157 
HPA1 156 1 156 
PCK2 150 1 150 
ADRA2B 148 1 148 
LDLR 113 2 82 
LCAT 105 1 105 
HLA 86 1 86 
GR 46 1 46 
MMP4 42 1 42 
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Appendix 6.  Terms used in the WMH gene-specific searches. 
 
Gene Medline terms Embase terms 






((apolipoprotein$ adj e) or 
(apoprotein$ adj e) or apo-e or apo e 
or apoe).tw. 
apolipoprotein/ or apolipoprotein e/ or 
apolipoprotein e2/ or apolipoprotein 
e3/ or apolipoprotein e4/ or 
apolipoprotein e5/ or apolipoprotein 
e7/ 
 
((apolipoprotein$ adj e) or 
(apoprotein$ adj e) or apo-e or apoe 
or apo e).tw. 
ACE exp Peptidyl-Dipeptidase A/ge 
[Genetics] 
 
(angiotensin converting enzyme or 
ace or peptidyl-dipeptidase).tw. 
exp Dipeptidyl Carboxypeptidase/ 
 
 
(angiotensin converting enzyme or 
ace or peptidyl-dipeptidase).tw. 
MTHFR exp "Methylenetetrahydrofolate 
Reductase (NADPH2)"/ge [Genetics] 
    
(MTHFR or c677t or nadph2 or 
methylene tetrahydrofolate or 
methylenetetrahydrofolate).tw. 
exp "5,10 methylenetetrahydrofolate 
reductase (fadh2)"/ 
   
(MTHFR or c677t or nadph2 or 
meythlene tetrahydrofolate or 
methylenetetrahydrofolate).tw. 
AGT exp Angiotensinogen/ge [Genetics] 
exp Receptors, Angiotensin/ge 
[Genetics] 
   
 
(agt$ or angiotensin$).tw. 
exp angiotensin derivative/ or 
angiotensinogen/ 
exp Angiotensin 1 Receptor/ or exp 
Angiotensin Receptor/ 
 





Reviewer initials LEUKOARAIOSIS DATA EXTRACTION FORM
Inclusion/Exclusion
Gene APOE MTHFR ACE
Polymorphism epsilon 677 I/D
other: other: other:
Leukoaraiosis leukoaraiosis White matter hyperintensities (W MH) grade:
WM lesions WM changes volume
other: other:
Study Design cohort case/control family-based
other:
Included Excluded
type? mean volume dichotomized grading
Reasons
Data Extraction
cases Number of cases: case population:









controls Number of controls: ca-co matching: control population:









Cohort Size of cohort: total genotyped: cohort populat ion:










Study or group nameFirst author and year










RFLP: secondary: HWE detected not stated
other: not detected
blinding scanning staff perhaps LD yes not stated
genotyping staff not stated no which?
leukoariosis MRI periventricular not stated other info?
scanning CT subcortical other:
volume or grade? volume normalized grade YES NO




associated with genotype?  
associated with phenotype?
genetic model dominant recessive codominant not stated














(N above and 
below cutoff or N 









Appendix 8.  WMH data transformations. 
Transformations similar to those carried out for CIMT were performed, such as combining 
data from two genotype groups, calculating sample size from proportions and calculating 
standard deviations from standard errors or confidence intervals.  For examples of these 
types of transformations see appendix 5 and section 3.2.5 of the main text. 
 
Some other specific transformations were required and are detailed below: 
 
8.1  Bornebroek 1997 
This paper reported the mean and range of WMH scores per genotype.  As sample sizes 
were quite small it was possible for some genotypes to determine the actual individual 
values by using the range to provide two values and then determining which combination of 
values gave the reported means, so that standard deviations could be estimated: 
 
genotype n mean range Individual values SD 
ε2ε2 1 22.0  22.0 - 
ε3ε3 12 19.7 14 to 24 14.0; ? ; ? ; ? ; ? ; ? ; ? ; ? ; ? ; ? ; ? ; 24.0 ? 
ε2ε4 2 20 19 to 21 19.0; 21.0 1.4 
ε3ε4 7 20 15 to 24 15.0; ? ; ? ; ? ; ? ; ?;  24.0 ? 
ε4ε4 3 20.7 14 to 24 14.0; 24.0; 24.0 5.8 
 
For ε3ε3 and ε3ε4, this was not possible, so these SDs were estimated by treating the range 
as a 99 percentile as using the following formula to calculate the SD: 
SD  =  (upper  -  lower) / 2  x  2.576 
The SDs for ε3ε3 and ε3ε4 were estimated to be 1.94 and 1.75, respectively. 
 
8.2  Van Rijn 2007 
This paper reports the sample sizes and the mean WMH lesion volume, per genotype in the 
text.  However, does not report the SDs in the text.  A graph is displayed showing the CIs, 





1mm = 0.09 
 
  *data estimated from graph,  





Genotype n Mean CI ± * sd
†
 
MM 385 1.09 0.27 2.7 
MT 501 1.45 0.23 2.7 




8.3  Hassan 2004 
This paper did not report the genotype frequencies for WMH patients. It only reported two 
Odds Ratios, neither were the Odds Ratio of interest: 
  
 OR1= (WMH & lacunar infarct patients) vs. controls 2.79 (1.36 to 5.7) 
 OR2= (lacunar infarct patients) vs. controls  1.79 (0.72 to 4.5) 
 
Control genotype frequencies were reported as follows: TT= 16; TC&CC= 154. 
The WMH & lacunar infarct group contained 90 patients.  Using trial-and-error, I 
apportioned these 90 patients to genotype groups to get the OR as close to 2.79 as possible: 
 
 
 OR= 2.75 (1.34 to 5.62) 
 
 
The lacunar infarct only group contained 52 patients.  Using trial-and-error, I apportioned 
these 52 patients to genotype groups to get the OR as close to 1.79 as possible. 
 
 










 TC & CC TT Total 
WMH & lacunar infarcts 70 20 90 
 Controls 154 16 170 
 TC & CC TT Total 
lacunar infarcts 44 8 52 
 Controls 154 16 170 
 TC & CC TT Total 
WMH+ 70 20 90 
 WMH- 44 8 52 
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Appendix 9.  ESS data collection forms 
 9.A. Inpatient data collection form, pages 301-302 
























LACI = lacunar infarction; PACI = partial anterior circulation infarction; TACI = total anterior circulation infarction; POCI = posterior circulation infarction; 





+/- relevant lesion  
on brain imaging 
(final syndrome=LACI) 
>/= 70% ICA stenosis  Multiple aetiologies 
Cardioembolic source  
Yes 
No 
SMALL VESSEL DISEASE 
Clinical signs of cerebral cortical impairment or 
cerebellar or brainstem signs+/-  
relevant lesion on brain imaging 
(Final syndrome = PACI, TACI or POCI) 
No 
>/= 70% ICA stenosis 






Cardioembolic source  
















or no vertebral 
stenosis  
reported 
